Page last updated: 2024-09-04

ezetimibe and Elevated Cholesterol

ezetimibe has been researched along with Elevated Cholesterol in 625 studies

Research

Studies (625)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	274 (43.84)	29.6817
2010's	281 (44.96)	24.3611
2020's	70 (11.20)	2.80

Authors

Authors	Studies
Song, Z; Wang, X; Xing, D; Xue, J; Zhang, R	1
Jiang, H; Liu, W; Meng, J; Wang, J; Xing, D; Zeng, J; Zhang, R	1
Baratzadeh, F; Jamialahmadi, T; Reiner, Ž; Sahebkar, A; Santos, RD; Simental-Mendía, LE; Susekov, AV; Xu, S	1
Blumenthal, RS; Braun, LT; Grundy, SM; Heidenreich, PA; Lloyd-Jones, D; Orringer, CE; Saseen, JJ; Smith, SC; Sperling, LS; Stone, NJ; Virani, SS	1
Bacchin, ASF; Bianco, HT; Caixeta, A; Damasceno, NRT; Fonseca, FA; França, CN; Izar, MCO; Mello, APQ; Moreira, FT; Neto, AMF; Pinto, LCS; Póvoa, RMS	1
Haidermota, S; Hoffmann, AP; Honigberg, MC; Natarajan, P; Newton, SL; Yu, Z	1
Catapano, AL; Pirillo, A	1
Adamson, SS; Biddinger, SB; Bullock, K; Chahar, S; Clish, CB; Crooke, RM; de Ferranti, SD; Gearing, ME; Graham, MJ; Hagey, LR; Kidambi, S; Krawczyk, J; Levenson, AE; Ling, AV; Miao, J; Semova, I; Shin, DJ; Vicent, D; Williams, KA	1
Papachristou, S; Papanas, N; Popovic, DS; Stokic, E	1
Burnett, H; Cichewicz, A; Di Domenico, M; Durand, A; Fahrbach, K; Jindal, R; Reichelt, A; Tarpey, J; Viljoen, A	1
Joung, KH; Kang, SM; Kim, HJ; Kim, JM; Ku, BJ; Lee, JC	2
Hamasaki, A; Hasebe, M; Honjo, S; Iwasaki, K; Iwasaki, Y; Keidai, Y	1
Calabrò, P; De Ferrari, GM; Filardi, PP; Indolfi, C; Romeo, F	1
Chao, TH; Chen, CP; Chou, MT; Hsieh, CH; Huang, CY; Jong, GP; Lee, IT; Lu, CH; McGirr, A; Sheu, WH	1
Chen, J; Ding, C; Ge, J; Li, Z; Liu, Y; Qian, J; Ren, X; Shi, M; Yang, P; Zhang, X	1
Chang, J; Han, N; Hu, X; Li, H; Li, J; Liang, B; Liu, W; Lu, C; Meng, J; Shi, L; Wang, C; Wang, X; Xing, D; Yang, S; Zeng, J; Zhang, R	1
Ahn, JC; Cha, DH; Cho, EJ; Cho, JM; Choi, CU; Choi, SY; Gwon, HC; Han, KH; Han, KR; Hong, SJ; Hong, YJ; Jeong, HS; Jeong, YH; Jo, SH; Kang, HJ; Kim, BK; Kim, SH; Kim, WS; Lee, SY; Park, TH; Woo, SI	1
Hu, YX; Jing, Q; Li, FF; Liang, C; Liang, YL; Qin, YW; You, HM; Zhao, XX; Zhu, RF	1
Baum, SJ; Bilitou, A; Gillard, KK; Louie, MJ; McQueen, RB; Nash, B; Ray, KK; Sasiela, WJ; Shah, H	1
Baum, SJ; Gaudet, D; Gencer, B; Kassahun, H; Knusel, B; Kuder, JF; Lepor, NE; López, JAG; Murphy, SA; O'Donoghue, ML; Ran, X; Rosenson, RS; Sabatine, MS; Stout, E; Wang, H; Wu, Y	1
Ju, SH; Ku, BJ	1
Campuzano Ruiz, R; Cosín-Sales, J; Díaz Díaz, JL; Escobar Cervantes, C; Fernández Olmo, MR; Gómez-Doblas, JJ; Mostaza, JM; Pedro-Botet, J; Plana Gil, N; Valdivielso, P	1
Lin, Z; Yang, C; Zhong, Z	1
Aker, A; Naoum, I; Saliba, W; Zafrir, B	1
Landmesser, U; Sinning, D	1
Garon, G; Liu, Y; Lv, Q; Ma, C; Mei, S; Su, Q; Wang, M; Wu, Y; Xu, L; Zhang, G	1
Cho, JM; Choi, JY; Chun, SW; Chung, JW; Hong, SJ; Hong, YJ; Kim, BJ; Kim, CS; Kim, DH; Kim, HS; Kim, KS; Kim, SH; Kim, TN; Lee, CW; Lee, SA; Lee, SH; Lee, SR; Park, HC; Sung, JH; Yoon, SB	1
Kim, HS; Kim, NH; Kim, SG; Kim, SS; Ko, SH; Lee, BK; Lee, I; Lee, JH; Moon, JS; Park, IR; Won, KC	1
Leong, D; Wu, PE	1
Kang, LN; Lan, RF; Wang, L; Xu, B; Xu, W; Zhang, XL; Zhang, XW	1
Barge-Caballero, E; Barge-Caballero, G; Couto-Mallón, D; Crespo-Leiro, MG; Del Castillo-García, S; Groba-Marco, MDV	1
Ahn, Y; Chae, IH; Han, KR; Hong, SJ; Hong, TJ; Jeon, DW; Jeon, HK; Kim, HS; Kim, HY; Kim, KJ; Kim, SH; Kim, W; Kwak, CH; Lee, N; Moon, KW; Nam, CW; Park, S; Park, TH; Rha, SW; Rhee, MY; Yoon, YW	1
Cyrille, M; Inomata, H; Inoue, I; Kajinami, K; Koba, S; Lu, C; Shimauchi, J	1
Pedro-Botet, J; Pintó, X	1
Suzuki, H; Takada, T; Toyoda, Y; Yamanashi, Y	1
Kong, Q; Li, M; Liang, C; Wang, Y; Yu, M	1
Kawashiri, MA; Nomura, A; Okada, H; Tada, H; Takamura, M	1
Lütjohann, D; Sijbrands, EJG; Weingärtner, O	1
Almeida, JT; Esteves, AL; Martins, F; Palma, I	1
Ahmed, ST; Akeroyd, JM; Ballantyne, CM; Dixon, DL; Gluckman, TJ; Jia, X; Nambi, V; Petersen, LA; Ramsey, DJ; Rifai, MA; Stone, NJ; Virani, SS	1
Cicero, AFG; Fogacci, F; Strilchuk, L; Tocci, G	1
Blom, DJ; Bouharati, C; Chilton, R; Ebrahim, IO; Karamchand, S; Leisegang, RF; Musa, MG; Naidoo, P; Raal, FJ; Rambiritch, V; Ranjith, N; Shunmoogam, N; Tonder, AV	1
Choksi, RR; Goldfaden, RF; Lewis, T; Niman, S; Rana, K; Reid, J; Sheikh-Ali, M	1
Scheen, AJ; Wallemacq, C	1
Cho, L	1
Bacalbasa, N; Bratu, OG; Crismaru, I; Diaconu, CC; Gaman, MA; Pantea Stoian, A; Stanescu, AMA	1
Abdel-Salam, S; Al-Asaad, H; Aronson, R; Bajaj, HS; Brown, RE; Jiandani, D; Khandwala, H; Steen, O; Venn, K	1
Huerín, M; Lobo, M; Masson, G; Masson, W; Molinero, G; Nogueira, JP; Siniawski, D	1
Corsini, A; Ferri, N	1
Dateki, S; Ikeda, K; Kashimada, K; Komiya, C; Mishima, H; Nakano, Y; Ogawa, Y; Shiba, K; Shimizu, H; Tsujimoto, K; Yamada, T; Yoshiura, KI	1
Lamb, YN	1
Hirano, S; Kawashiri, MA; Nomura, A; Tada, H; Takenaga, M; Tanaka, H; Watanabe, Y	1
Chan, P; Lam, CWK; Tomlinson, B; Zhang, Y	1
Khan, SA; Naz, A; Qamar Masood, M; Shah, R	1
Dornstauder, E; Fraas, U; Katzmann, JL; Laufs, U; Smieszek, T; Sorio-Vilela, F; Zappacosta, S	1
Cho, JH; Kim, H; Kim, HS; Kim, JH; Lee, H; Lee, J; Lee, SH; Yim, HW; Yoon, KH	1
Fabiszak, T; Kasprzak, M; Krintus, M; Kubica, J; Obońska, K; Tymosiak, K	1
Al Matrooshi, NO; Bhagavathula, AS; Clark, CCT; Rahmani, J	2
Banach, M; Penson, PE	1
Hanselman, JC; MacDougall, DE; Nicholls, SJ; Rubino, J; Sterling, LR	1
Bea, AM; Benaiges, D; Blanco-Vaca, F; Brea-Hernando, Á; Climent, E; Pedro-Botet, J; Perea, V; Pintó, X; Plana, N; Suárez-Tembra, M	1
Casula, M; Catapano, AL; Pirillo, A; Tokgözoğlu, L	1
Suadoni, MT	1
Diaconu, CC; Furtunescu, F; Iorga, RA; Katsiki, N; Rizzo, M; Stoian, AP	1
Lekuona, I; Pintó, X	1
Barrios, V; Escobar, C	2
Amarenco, P; Bruckert, E; Charles, H; Giroud, M; Kim, JS; Labreuche, J; Lavallée, PC; Lee, BC; Mahagne, MH; Meseguer, E; Nighoghossian, N; Steg, PG; Vicaut, É	1
Athyros, VG; Boutari, C; Karagiannis, A	1
Kyselák, O; Soška, V	1
Kamisako, T; Tanaka, Y	1
Bastos, RT; Cruz, ECS; Derogis, PBMC; Dos Santos Ferreira, CE; Faccio, AT; Fonseca, FAH; Fontoura, SC; Izar, MC; Klassen, A; Lopes, AS; Neto, AMF; Picossi, CRC; Sussulini, A; Tavares, MFM	1
Ahn, Y; Chae, IH; Cho, JM; Hong, SJ; Hong, TJ; Kang, TS; Kim, BJ; Kim, BS; Kim, JS; Kim, MH; Kim, SY; Kim, W; Lee, CW; Lee, SA; Rhee, MY; Shin, JH	1
Jones, PJH; Mymin, D; Myrie, SB; Othman, RA; Roullet, JB; Steiner, RD	1
Blanco-Vaca, F; Cedó, L; Escolà-Gil, JC	1
Bergeron, J; Catapano, AL; Krempf, M; Lee, LV; Louie, MJ; Thompson, D	1
Filipiak, KJ; Kapłon-Cieślicka, A; Kołtowski, Ł; Michalak, M	1
Korman, M; Wisløff, T	1
Ballantyne, CM; Baum, SJ; Howard, WB; Karayan, L; Knowles, JW; Myers, KD; Wilemon, KA	1
Bartuli, A; Bertolini, S; Bruzzi, P; Buonuomo, PS; Calandra, S; Cortese, C; Iughetti, L; Papadia, F; Pisciotta, L; Rabacchi, C; Tummolo, A	1
DeBarber, AE; Jones, PJH; Mymin, D; Myrie, SB; Othman, RA; Roullet, JB; Steiner, RD	1
Bastida, JM; Benito, R; Díez-Campelo, M; Girós, M; González-Porras, JR; Hernández-Rivas, JM; Hernández-Sánchez, JM; Hortal, A; Janusz, K; Lozano, ML; Marcellini, S; Rivera, J	1
Goździkiewicz, N; Kasprzak, M; Krintus, M; Kubica, J; Obońska, E; Obońska, K; Racki, K; Sikora, J	1
Dent, R; Descamps, OS; Fraass, U; Gouni-Berthold, I; März, W	1
Blom, DJ; Cannon, CP; Cariou, B; Chaudhari, U; Colhoun, HM; El Shahawy, M; Lecorps, G; McKenney, JM; Pordy, R	1
Lloyd-Jones, DM	1
Giugliano, RP; Sabatine, MS	1
Cannon, CP; Khan, I; Klimchak, AC; Reynolds, MR; Sanchez, RJ; Sasiela, WJ	1
Aoyama, K; Ichikawa, T; Kobayashi, K; Nakane, T; Sugita, K; Toda, T; Yagasaki, H	1
Nozue, T	1
Barthelmes, J; Sudano, I	1
Wójcik, C	1
Ballantyne, CM; Birtcher, KK; Daly, DD; DePalma, SM; Lloyd-Jones, DM; Minissian, MB; Morris, PB; Orringer, CE; Smith, SC	1
Lin, XL; Liu, MH	1
Frikke-Schmidt, R; Kobberø Lauridsen, B; Nordestgaard, BG; Stender, S; Tybjærg-Hansen, A	1
Farnier, M	2
Campos, AM; de Carvalho, LSF; Sposito, AC	1
Battaggia, A; Donzelli, A; Scalisi, A	1
Dembinski, T; Hatch, GM; Mymin, D; Salen, G; Triggs-Raine, B; Waggoner, DJ	1
Awad, K; Banach, M; Katsiki, N; Mikhailidis, DP; Muntner, P	1
Ahn, JC; Bae, JH; Cha, DH; Cho, SK; Chung, WS; Han, KR; Hong, SJ; Hyon, MS; Jeon, DW; Jeong, HS; Kim, HS; Kim, SY; Kim, W; Kwan, J; Lee, HC; Rha, SW; Rhee, MY; Shin, JH; Sung, KC; Won, KH; Yoo, BS; Yoo, KD	1
Boklage, SH; Elassal, J; Ghannam, AF; Gupta, R; Karalis, DG; Mallya, UG	1
Ahangari, N; Ghayour Mobarhan, M; Pasdar, A; Sahebkar, A	1
Korman, MJ; Kristiansen, IS; Retterstøl, K; Wisløff, T	1
Bae, JW; Han, SH; Hong, BK; Hong, SJ; Hwang, GS; Hyon, MS; Kim, JY; Kim, MK; Kim, SH; Kim, SW; Kim, W; Lee, SE; Park, CG; Park, JH; Rhee, MY; Shin, JH; Shin, SH; Son, JW; Sung, KC; Yoon, YE	1
Firnhaber, JM	1
Ballantyne, CM; Banach, M; Hanselman, JC; Leiter, LA; Lepor, NE; Mancini, GBJ; Zhao, X	1
Alegre Del Rey, EJ; Gimeno Ballester, V; González-Outón, J; Matas Hoces, A; Olry de Labry Lima, A; Sierra Sánchez, JF	1
Fukumoto, Y	1
Bajnok, L	1
Adam, S; Durrington, PN; Soran, H	1
Ambegaonkar, B; Baxter, CA; Davies, G; Jansen, J; Lorenzi, M; Zoratti, MJ	1
Ai, C; He, Q; Shi, J; Zhang, S	1
Bessac, L; Cannon, CP; Davidson, MH; Eckel, RH; Ginsberg, HN; Lee, LV; Letierce, A; Pordy, R; Ray, KK; Vallejo-Vaz, AJ	1
Bailey, AL; Beam, C; Birtcher, KK; Blumenthal, RS; Braun, LT; de Ferranti, S; Faiella-Tommasino, J; Forman, DE; Goldberg, R; Grundy, SM; Heidenreich, PA; Hlatky, MA; Jones, DW; Lloyd-Jones, D; Lopez-Pajares, N; Ndumele, CE; Orringer, CE; Peralta, CA; Saseen, JJ; Smith, SC; Sperling, L; Stone, NJ; Virani, SS; Yeboah, J	2
Barrett, HPR; Chan, DC; Ma, L; Ooi, EMM; Parhofer, KG; Waldmann, E; Watts, GF	1
Crump, B	1
He, F; Li, T; Li, Z; Liu, X; Su, J; Wu, W; Xu, R; Yan, Y; Zhao, M	1
Al-Rasadi, K; Atkin, SL; Banach, M; Pirro, M; Sahebkar, A; Simental-Mendía, LE; Sirtori, C; Watts, GF	1
Amornlerdpison, D; Duangjai, A; Muanprasat, C; Ontawong, A; Pasachan, T; Pongchaidecha, A; Srimaroeng, C	1
Fazio, S; Weitz, JI	1
Ding, S; Du, S; Luo, P; Shen, S; Wang, G; Wang, L; Zhao, Z	1
Li, Y; Pan, R; Zhou, H	1
Blé-Castillo, JL; Díaz-Zagoya, JC; Juárez-Rojop, IE; Marín-Medina, A; Ruíz-Hidalgo, G; Zamora, RM; Zetina-Esquivel, AM	1
Chan, P; Liu, Z; Ma, YB; Tomlinson, B; Zhang, Y	1
Bang, LE; Gislason, GH; Høfsten, DE; Jensen, JS; Køber, LV; Pallisgaard, J; Ripa, MS; Schjerning, AM; Theilade, JE; Weeke, PE	1
Al Rifai, M; Birnbaum, Y; Jia, X; Smith, SC; Virani, SS	1
Blumenthal, RS; Chuzi, S; Grundy, SM; Lloyd-Jones, DM; Pfenniger, A; Smith, SC; Stone, NJ; Virani, SS	1
Damonte, J; Halsband, A; Masson, W; Pizarro, R; Rossi, E; Siniawski, D	1
Hovingh, GK; Ray, KK; Reeskamp, LF	1
Khan, SU; Michos, ED	1
Feingold, KR	1
Ballantyne, CM; Bays, HE; Catapano, AL; Goldberg, AC; Laufs, U; Leiter, LA; MacDougall, D; Ray, KK; Stroes, ES; Zhao, X	1
Behm, MO; Fujimoto, K; Furihata, K; Matsumoto, Y; Nishida, C; Shirakawa, M; Wrishko, RE	1
Brath, H; Kästenbauer, T; Toplak, H; Wascher, TC	1
Boden, WE; Hartigan, PM; Maron, DJ; Neff, DR; Weintraub, WS	1
Chen, MH; Ibrahim, JG; Kim, S; Lin, J; Shah, AK	1
Brudi, P; Farnier, M; Guyton, JR; Jensen, E; Johnson-Levonas, AO; Polis, AB	1
Fukushima, Y; Higuchi, K; Hirayama, S; Inoue, M; Kamimura, Y; Miida, T; Nakagawa, S; Nishioka, E; Ohmura, H; Seino, U; Soda, S; Ueno, T; Yamato, S	1
Adler, C; Bögl, K; Drexel, H; Eber, B; Fauer, C; Föchterle, J; Föger, B; Gansch, K; Grafinger, P; Lautsch, D; Lechleitner, M; Ludvik, B; Maurer, G; Mörz, R; Paulweber, B; Pfeiffer, KP; Pichler, M; Prager, R; Stark, G; Toplak, H; Traindl, O; Weitgasser, R	1
Amber, V; Hall, GC; Jameson, K; O'Regan, C	1
Arao, T; Hajime, M; Inokuchi, N; Kurozumi, A; Matsuoka, H; Mori, H; Narisawa, M; Okada, Y; Tanaka, K; Tanaka, Y; Torimoto, K; Yamamoto, S	1
Averna, M; Bays, HE; Brudi, P; De Pellegrin, A; Farnier, M; Giezek, H; Lee, R; Lowe, RS; Majul, C; Muller-Wieland, D; Triscari, J	1
Hirano, T; Iijima, R; Inazawa, T; Kawamura, M; Kitazawa, T; Kohro, T; Mori, Y; Sakamoto, K; Shiba, T; Tagami, M; Tanaka, A; Yamazaki, T	1
Elisaf, MS; Liberopoulos, EN; Milionis, HJ; Moutzouri, E; Tellis, CC; Tselepis, AD	1
Sano, M	1
Jones, PJ; Myrie, SB; Othman, RA	1
Braamskamp, MJ; Hutten, BA; Kastelein, JJ; Wiegman, A	1
Bandyopadhyay, S; Katare, OP; Singh, B	2
Ballantyne, CM; Cain, VA; Hoogeveen, RC; Karlson, BW; Palmer, MK; Raya, JL	1
Ben-Yehuda, O; Constance, C; Hanson, ME; Lin, J; Lowe, RS; Tershakovec, AM; Wenger, NK; Zieve, F	1
Baumgartner, I; März, W; Silbernagel, G; Wanner, C	1
Alsabbagh, WM; Blackburn, DF; Dagenais, J; Lix, LM; Lu, X; Shevchuk, Y; Teare, GF; Yan, L	1
Cho, L; Colquhoun, D; Dent, R; Rocco, M; Rosenson, RS; Scott, R; Stroes, E; Sullivan, D; Wasserman, SM; Xue, A	2
Fialkow, J; Legg, JC; Nedergaard, BS; Nelson, P; Neutel, JM; Ramstad, D; Robinson, JG; Rogers, WJ; Scott, R; Somaratne, R; Wasserman, SM; Weiss, R	2
Chelladurai, Y; Gudzune, KA; Monroe, AK; Ranasinghe, PD; Robinson, KA; Sharma, R	1
Li, JJ; Li, S; Liu, J; Sun, J; Xu, RX; Zhang, Y	1
Gürsel, T; Kaya, Z; Niu, DM; Tekin, A; Yorulmaz, A	1
Chang, WT; Huang, SK; Liau, I; Yang, YC	1
Mitka, M	2
Berthold, HK; Gouni-Berthold, I; Krone, W; Montalto, G; Rizzo, M; Spenrath, N	1
Pan, XD; Sun, LY; Wang, LY; Wu, WF; Yang, SW	1
Du, S; Han, YG; Li, L; Luo, P; Wang, GG; Wang, LX; Wu, SL; Zhu, HH	1
Jackevicius, CA; Ko, DT; Krumholz, HM; Lu, L; Ross, JS; Tu, JV	1
Huang, W; Qian, H; Sun, L	1
Machnik, G; Okopień, B; Suchy, D; Łabuzek, K	1
Blanco-Vaca, F; Cedó, L; Escolà-Gil, JC; Julve, J; Martín-Campos, JM; Quesada, H	1
Krysiak, R; Okopień, B; Żmuda, W	4
Coticchia, CM; Curatolo, AS; Moses, MA; Pelton, K; Schaffner, CP; Solomon, KR; Zurakowski, D	1
Reiner, Z	1
Baccara-Dinet, MT; Colhoun, HM; Ginsberg, HN; Kastelein, JJ; Merlet, L; Pordy, R; Robinson, JG; Roth, EM; Taskinen, MR	1
Frazee, SG; Garavaglia, SB; Jackevicius, CA; Krumholz, HM; Levin, R; Novshadian, H; Ross, JS; Stettin, G	1
Levesque, MC; Liang, KP; Mock, GD; Modi, SR; Ruiz, XD	1
Bays, H; Li, Y; Louder, A; Mallick, R; Schwab, P	1
Krysiak, R; Marek, B; Okopień, B; Zmuda, W	3
Krysiak, R; Okopien, B	2
Gaciong, Z; Lewandowski, J; Puchalska, L; Siński, M; Symonides, B	1
Bays, HE; Chen, E; McPeters, G; Polis, AB; Tomassini, JE; Triscari, J	1
Jones, PJ; Merkens, LS; Mymin, D; Myrie, SB; Othman, RA; Roullet, JB; Steiner, RD	1
Cui, CJ; Li, JJ; Li, S	1
Lee, TC; McDonald, EG; Saleh, RR	1
Ambegaonkar, BM; Polis, AB; Tershakovec, AM; Tipping, D; Tomassini, JE	1
Adachi, H; Bekki, H; Honma, T; Nakano, H; Nakata, M; Nohara, M; Yamamoto, K; Yoshiyama, H	1
Caamaño, J; Lanas, F; Saavedra, N; Salazar, LA; Zambrano, T	1
Ferenci, T; Simonyi, G	1
McKenney, JM; Roth, EM	1
Einecke, D	2
Parhofer, K	1
Ambegaonkar, BM; Cao, X; Ejzykowicz, F; Mavros, P; Ramey, DR; Sajjan, S; Tunceli, K	1
Angeli, V; Khoo, LH; Soh, SY; Thiam, CH	1
Huang, W; Luo, L; Ren, F; Tang, L; Yuan, X; Zheng, Y; Zhu, H	1
Blom, D; Cannon, CP; Cariou, B; Chaudhari, U; Colhoun, HM; Lorenzato, C; McKenney, JM; Pordy, R	1
Civeira, F; Masana, L; Pedro-Botet, J	1
Emery, M; Langslet, G; Wasserman, SM	1
Caceres, M; Coll, M; Cuffie, C; Gagné, C; Jacobson, MS; Kastelein, JJ; Kusters, DM; Kwiterovich, PO; Lee, R; Lowe, RS; Massaad, R; McCrindle, BW; Musliner, TA; Triscari, J	1
Frikke-Schmidt, R; Lauridsen, BK; Nordestgaard, BG; Stender, S; Tybjærg-Hansen, A	1
Doi, M; Ito, H; Miyoshi, T; Nakamura, K	1
Alves, C; Cerda, A; Dorea, EL; Fajardo, CM; Genvigir, FD; Gusukuma, MC; Hirata, MH; Hirata, RD; Pinto, GA; Rodrigues, AC	1
Brudi, P; Descamps, O; Hanson, ME; Lin, J; Polis, AB; Shah, A; Tershakovec, AM; Tomassini, JE	1
Deckers, JW; Simoons, ML	2
Azuma, K; Hanson, ME; Kakikawa, T; Oshima, N; Saito, I; Tershakovec, AM	1
Tsimikas, S; Witztum, JL; Yeang, C	1
Brudi, P; Farnier, M; Giezek, H; Krempf, M; Lee, R; Ramey, DR; Simpson, RJ; Tomassini, JE	1
Signy, J; Signy, M	1
Poli, A	1
Balakrishnan, A; Cassis, LA; Daugherty, A; Howatt, DA; Liu, J; Lu, H; Moorleghen, JJ; Sorci-Thomas, M	1
Han, SH; Hayashi, T; Kim, EY; Koh, KK; Lee, Y; Oh, PC; Park, YM; Sakuma, I; Shin, EK	1
Hansen, EH; Wallach-Kildemoes, H	1
Elisaf, MS; Filippatos, TD	2
Makris, T; Michalopoulou, H; Skalis, G; Thomopoulos, C; Tsioufis, C	1
Stiefelhagen, P	1
Erdmann, E	2
Ballantyne, CM; Hsueh, WA; Lin, J; Lowe, RS; Rosen, JB; Shah, AK; Tershakovec, AM	1
Koh, KK; Oh, PC; Sakuma, I	1
Averna, M; Colhoun, HM; Donahue, S; Du, Y; Farnier, M; Hanotin, C; Jones, P; Severance, R; Steinhagen-Thiessen, E	1
Goldstein, MR; Mascitelli, L	2
Ibarretxe, D; Masana, L; Plana, N	1
Hayward, RA; Hofer, TP; Sussman, JB	1
Alvarez, A; Bañuls, C; de Pablo, C; Diaz-Morales, N; Escribano-Lopez, I; Hernandez-Mijares, A; Rocha, M; Rovira-Llopis, S; Veses, S; Victor, VM	1
Elisaf, MS; Filippatos, TD; Kei, AA	1
Ballantyne, CM; Catapano, A; Dent-Acosta, RE; Gouni-Berthold, I; Mancini, GB; Nissen, SE; Preiss, D; Rosenson, RS; Sattar, N; Scott, R; Stein, EA; Stroes, E; Thompson, PD; Wasserman, SM; Xue, A	1
Scheen, AJ	2
Ajufo, E; Rader, DJ	1
Bangalore, S; Hsue, PY; Waters, DD	1
Ballantyne, CM; Brennan, DM; Bruckert, E; Ceška, R; Dent-Acosta, RE; Elliott, M; Gouni-Berthold, I; Lehman, SJ; Lepor, N; Nissen, SE; Preiss, D; Rosenson, RS; Sattar, N; Scott, R; Somaratne, R; Stein, EA; Stroes, E; Wasserman, SM	1
Torjesen, I	1
Johnson, TA; Pfeffer, SR	1
Banach, M; Nikolic, D; Rizzo, M; Toth, PP	1
Bridges, I; Dent, R; Djedjos, CS; Jacobson, TA; Miller, M; Preiss, D; Rosenson, RS	1
Brunet, A; Cannon, CP; DiCioccio, AT; Hanotin, C; Paehler, T; Pinquier, JL; Poitiers, F; Rey, J; Sasiela, WJ; Surks, HK	1
Abrignani, MG; Arca, M; Colivicchi, F; Gulizia, MM; Mureddu, GF; Nardi, F; Perna, GP; Riccio, C	1
Blazing, MA; Braunwald, E; Cannon, CP; Giugliano, RP; Murphy, SA; Tershakovec, AM	1
Ahn, Y; Chae, IH; Han, KR; Hong, SJ; Hong, TJ; Jeon, DW; Jeon, HK; Kim, HS; Kim, KJ; Kim, SH; Kim, W; Kwak, CH; Lee, N; Moon, KW; Nam, CW; Park, S; Park, TH; Rha, SW; Rhee, MY; Yoon, YW	1
Groves, C; Ramachandran, S; Shetty, C; Strange, RC; Waldron, J	1
Mark, L; Paragh, G; Ray, KK	1
Baccara-Dinet, MT; Civeira, F; Farnier, M; Gaudet, D; Guyton, JR; Lecorps, G; Lepor, N; Manvelian, G; Stroes, E; Watts, GF	1
Ballantyne, CM; Bilen, O	1
Bays, HE; Chaudhari, U; Jones, PH; Lorenzato, C; Miller, K; Pordy, R; Robinson, JG	1
Catapano, AL; Farnier, M; Foody, J; Hanson, ME; Jensen, E; Musliner, TA; Polis, AB; Tershakovec, AM; Tomassini, JE; Toth, PP	1
Edelberg, J; Gaudet, D; Louie, MJ; Minini, P; Raal, FJ; Robinson, JG; Sasiela, WJ; Watts, GF	1
Angeli, V; Faveeuw, C; Khoo, LH; Lim, HY; Lim, SY; Ng, JX; Soh, SY; Thiam, CH; Yeo, KP	1
James, DE; Krueger, KA; Shen, T	1
David, MC; Hollingworth, SA; Martin, JH; Ostino, R; Tett, SE	1
Collins, PD; Sattar, N	1
Ashraf, TB; Ballantyne, CM; Cressman, MD; Gill, GG; Hunter, JA; Johnson-Levonas, AO; Kher, U; Mitchel, YB; Shah, S	1
Ahn, Y; Bae, JH; Cho, HJ; Cho, JM; Cho, KI; Cho, YK; Chun, WJ; Jang, Y; Jin, DK; Jin, HY; Kim, BJ; Kim, BS; Kim, MA; Kim, SY; Koh, KK; Lee, B; Lee, BK; Lee, HC; Lee, J; Lee, N; Lee, SC; Lee, SG; Lee, SH; Oh, SJ; Park, C; Park, CG; Park, JI; Park, JS; Park, WJ; Ryu, JK; Suh, J; Yang, YJ	1
Lüscher, TF	1
Ann, SJ; Cheon, DH; Cheon, EJ; Choi, D; Choi, S; Kang, SM; Kim, KY; Lee, CJ; Lee, JE; Lee, SH; Noh, HM; Park, S	1
Basurto, L; Hernández-Valencia, M; Manuel-Apolinar, L; Saucedo, R; Zárate, A	1
Elisaf, MS; Filippatos, TD; Georgoula, M; Kiortsis, DN; Mikhailidis, DP; Nakou, ES; Tselepis, AD	1
Kevelaitiene, S; Slapikas, R	1
Blumenthal, RS; Musunuru, K	1
Gadarla, M; Kearns, AK; Thompson, PD	1
Catapano, AL; Grigore, L; Norata, GD	1
Dujovne, CA; Maccubbin, D; McCrary Sisk, C; Strony, J; Suresh, R; Veltri, E	1
Davidson, M; Robinson, JG	1
Kohalmy, K; Monostory, K; Pascussi, JM; Rozman, D; Sárváry, E	1
Miura, S; Saku, K	1
Dresner, J; Shani, M; Vinker, S	1
Davidson, MH	4
Taylor, AJ	1
Dixit, RP; Nagarsenker, MS	1
Fras, Z; Mikhailidis, DP	1
Dallinga-Thie, GM; Hajer, GR; Olijhoek, JK; van der Graaf, Y; Visseren, FL	1
Barho, C; Bode, C; Darius, H; Hildemann, SK; Karmann, B	1
Elsais, A; Kerty, E; Lund, C	1
Ariza, J; Castellote, J; Girbau, A; Rota, R; Xiol, X	1
Baigent, C; Califf, R; Clare, R; Collins, R; Emberson, J; Landray, M; Peto, R	1
Eron, JJ; Hsue, P; Keys, J; Napravnik, S; Richard, S; Schnell, A; Simpson, RJ; Waters, D; Wohl, DA	1
Bays, H; Capece, R; Liu, J; Sapre, A; Taggart, W; Tershakovec, A	1
Cox, A	1
Hamilton-Craig, IR	1
Ara, R; Chilcott, J; Duenas, A; Durrington, P; Paisley, S; Pandor, A; Tumur, I; Wilkinson, A; Williams, R	1
Wierzbicki, AS	2
Johnson-Levonas, AO; Lin, J; Lütjohann, D; Macdonell, G; Musliner, T; Sapre, A; Shah, A; Sirah, W; von Bergmann, K	1
Agarwal, S; Baruch, L; Eng, C; Gupta, B; Lieberman-Blum, SS	1
Hanson, ME; Strony, J; Veltri, EP; Yang, B	1
Seip, RL; Thompson, PD; Venero, CV; Venero, JV	1
Asghar, AK; Bower, M; Holmes, P; Isenman, HL; Nelson, M; Stebbing, J	1
Chan, J; Kushwaha, RS; Vandeberg, JF; Vandeberg, JL	1
Bays, HE; Bird, SR; Conard, SE; Leiter, LA; Lowe, RS; Rubino, J; Tershakovec, AM; Tomassini, JE	1
Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Rubino, J; Tershakovec, AM; Tomassini, JE	1
Fee, WH	1
Porat, G	1
Nissen, SE	2
Ara, RM; Chilcott, J; Duenas, A; Durrington, PN; Paisley, S; Pandor, A; Tumur, I; Wilkinson, AJ	1
Ara, R; Chilcott, J; Duenas, A; Durrington, P; Paisley, S; Pandor, A; Rees, A; Tumur, I; Wilkinson, A; Williams, R	1
Ballantyne, CM; Bird, S; Lin, J; Pearson, TA; Rosenberg, E; Shah, A; Tershakovec, AM; Veltri, E	1
Hanson, M; Hoffman, R; Strony, J; Veltri, E	1
Averna, M; Brudi, P; Farnier, M; Johnson-Levonas, AO; Massaad, R; Missault, L; Vandormael, K; Vaverkova, H; Viigimaa, M	1
Abramsky, O; Boimel, M; Grigoriadis, N; Lourbopoulos, A; Rosenmann, D; Rosenmann, H; Touloumi, O	1
Clauss, S; Kavey, RE; Kuehl, K; Wai, KM	1
Almazan, F; Choi, SH; Crosier, P; Fang, L; Hall, C; Hansen, LF; Hartvigsen, K; Juliano, J; Klemke, RL; Miller, ER; Miller, YI; Pattison, J; Stoletov, K; Witztum, JL	1
Chen, CW; Hsueh, CH; Hwang, JJ; Lai, LP; Shen, MJ; Su, YN; Tsai, CT	1
Gibbons, P; Lütjohann, D; Musliner, T; Reber, M; Sapre, A; Sudhop, T; Taggart, W; Tribble, D; von Bergmann, K	1
Almutairi, F; Alwayn, I; Molinari, M; Peltekian, KM; Peterson, TC; Walsh, MJ	1
Ashikaga, H; Blumenthal, RS; Jones, SR	1
Jeon, TI; Osborne, TF; Seo, YK; Zhu, B	1
Goldberg, RB; Guyton, JR; Jensen, E; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS	1
Adewale, AJ; Ballantyne, CM; Grundy, SM; Hsueh, WA; Parving, HH; Polis, AB; Robinson, JG; Rosen, JB; Tershakovec, AM; Tomassini, JE	1
Chhabria, MT; Mahajan, BM	1
Blazing, MA; Califf, RM; Harrington, RA	1
Iughetti, L	1
Albisu, MA; Carrascosa, A; Chacón, P; Clemente, M; Gussinyé, M; Yeste, D	1
Alexopoulos, D; Efthimiadis, A; Migdalis, I; Mikhailidis, DP; Pappas, S; Vlasserou, F	1
Andersen, J; Busti, A; Chen, H; Chow, D; Glesby, MJ; Kohrs, S; Koletar, SL; Souza, S; Wu, J	1
Abdalla, DS; Araujo, DB; Bertolami, MC; Bricharello, LP; Faludi, AA; Ferreira, WP; Nakamura, Y	1
Aoyama, N; Hatakeyama, Y; Izumi, T; Kosugi, R; Machida, Y; Masuda, T; Tojo, T; Yamaoka-Tojo, M; Yoshida, Y	1
Kanazawa, I; Sugimoto, T; Yamaguchi, T; Yamauchi, M	1
Bass, A; Hinderliter, AL; Lee, CR	1
Abel, T; Dinya, E; Eldin, MG; Fehér, J; Kovács, A	1
Cheng, SJ; Ma, Q; Xu, FX; Yan, HB	1
Mach, F; Montecucco, F; Quercioli, A	1
Ayter, M; Ersoy, U; Gultekin Tirtil, F; Kucukkaya, B; Sertbas, Y	1
Anagnostopoulou, K; Christopoulou-Cokkinou, V; Cokkinos, DV; Galea, V; Kolovou, G; Kostakou, P; Mihas, C; Theodoridis, T	1
Aihara, K; Akaike, M; Dagvasumberel, M; Hirata, Y; Ishikawa, K; Iwase, T; Koshiba, K; Kusunose, K; Matsumoto, T; Niki, T; Sata, M; Soeki, T; Sumitomo-Ueda, Y; Taketani, Y; Tomita, N; Wakatsuki, T; Yagi, S; Yamada, H; Yamaguchi, K; Yoshida, S	1
Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Lin, J; Shah, A; Tershakovec, AM	1
Ahmed, MH	1
Awata, T; Inoue, I; Katayama, S	1
Allgar, V; Chipperfield, R; Gaunt, R; Harvey, P; McCormack, T; Robinson, P	1
Drakopoulou, M; Skoumas, I; Stefanadis, C; Toutouzas, K	1
Gupta, A; Guyomard, V; Myint, PK; Rehman, HU; Zaman, MJ	1
Averna, M; Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Missault, L; Shah, A; Vaverkova, H; Viigimaa, M	2
Ishibashi, S; Kotani, K; Miyamoto, M; Nagasaka, S; Okada, K; Osuga, J; Yagyu, H	1
Lee, T	1
Bays, HE; Bird, SR; Conard, SE; Leiter, LA; Lowe, RS; Tershakovec, AM	1
Montgomery, BD	1
Arazi, SS; Bernik, MM; Cerda, A; Curi, R; Dorea, EL; Genvigir, FD; Hirata, MH; Hirata, RD; Oliveira, R; Rodrigues, AC; Willrich, MA	1
Bays, H; Conard, S; Hanson, ME; Leiter, LA; Lin, J; Shah, A; Tershakovec, AM	1
Ali, J; Ali, M; Bali, V	1
Breuer, HW	1
Adewale, AJ; Brown, WV; Flaim, D; Foody, JM; Jones-Burton, C; Lowe, RS; Tershakovec, AM; Zieve, F	1
Ishibashi, T; Takeishi, Y	1
Izumi, T; Masuda, T; Takahira, N; Tojo, T; Yamaoka-Tojo, M	1
Ikeda, S; Maemura, K	1
Averna, M; Brudi, P; Dong, Q; Farnier, M; Hanson, ME; Missault, L; Shah, A; Vaverkova, H; Viigimaa, M	1
Krumholz, HM	1
Ishida, S; Maeyama, T; Miyake, I; Saito, F; Saito, H; Shimizu, N; Shirotani, K; Takata, K; Ueda, S; Yamagishi, S; Yonemitsu, K	1
Hessen, SE; Karalis, DG; Liu, L; Subramanya, RD; Victor, MF	1
Ason, B; Bartz, SR; Davis, HR; Dubinina, N; Flanagan, WM; Galinski, B; Hubbard, B; Kuklin, NA; Ranalletta, M; Sachs, AB; Soriano, F; Stefanni, A; Strack, A; Tadin-Strapps, M; Tep, S; Tetzloff, G; Wong, KK; Xu, Y; Zhu, L	1
Elisaf, MS; Florentin, M; Liberopoulos, EN; Moutzouri, E; Rizos, CV; Tselepis, AD	1
Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP	1
Doggrell, SA	2
Choi, D; Chung, N; Jang, Y; Kang, SM; Lee, SH; Park, S	1
Betteridge, DJ; Brudi, P; Farnier, M; Guyton, JR; Johnson-Levonas, AO; Leiter, LA; Lin, J; Shah, A	1
Campos, AH; Cavalcanti, AB; de Lemos, JA; Fernandes, JL; Maranhão, RC; Martins, HS; Nicolau, JC; Pesaro, AE; Serrano, CV; Souza, HP	1
Cao, G; Konrad, RJ; Troutt, JS	1
Elisaf, M; Gazi, IF; Kostapanos, MS; Liberopoulos, EN; Spyrou, AT; Tellis, CC; Tselepis, AD	1
Kishimoto, M; Noda, M; Okamoto, M; Osame, K; Sugiyama, T; Takarabe, D	1
Davies, GM; Lawson, RW; McCormick, AL; Mikhailidis, DP; Sibbring, GC; Tershakovec, AM; Tunceli, K	1
Arazi, SS; Bernik, MM; Cerda, Á; Dorea, EL; Genvigir, FD; Hirata, MH; Hirata, RD; Oliveira, Rd; Rodrigues, AC; Willrich, MA	1
Pasutharnchat, N; Phanthumchinda, K	1
Bays, HE; Davidson, MH; Flaim, D; Jones-Burton, C; Lowe, RS; Massaad, R; Tershakovec, AM	1
Cariou, B; Costet, P; Le May, C	1
Chen, ZC; Huang, JC; Kwok, CF; Lee, TY; Lin, CM; Liou, MJ; Liu, RT; Pei, D	1
Parhofer, KG	1
Aoki, I; Bakalova, R; Hadjidekov, G; Ishii, I; Kitada, M; Saga, T; Tomizawa, A; Zhelev, Z	1
De Sutter, J; Descamps, OS; Guillaume, M; Missault, L	1
Hu, FB	1
Lefevre, M; Lin, X; Ma, L; Ostlund, RE; Racette, SB; Spearie, CA; Steger-May, K	1
Borges, NC; Fonseca, FA; Helfenstein, T; Izar, MC; Kasmas, SH; Moreira, FT; Moreno, RA; Ramos, SC; Rezende, VM; Silva, FC	1
Bae, JW; Choi, CI; Jang, CG; Kim, MJ; Lee, SY; Lee, YH	1
Elisaf, M; Kei, AA; Kostapanos, MS; Liberopoulos, E; Mikhailidis, DP; Milionis, H; Moutzouri, E	1
Aihara, K; Akaike, M; Fujimoto, E; Higashida, M; Hirata, Y; Kanbara, T; Kinoshita, H; Kitagawa, T; Kitaichi, T; Kurobe, A; Kurobe, H; Matsumoto, T; Matsuoka, Y; Nakayama, T; Nishiya, M; Sata, M; Sugano, M; Sugasawa, N	1
Davis, HR; Musliner, T; Tershakovec, AM; Tomassini, JE	1
Caccavello, R; Gugliucci, A; Kotani, K; Miyamoto, M; Sakane, N	1
Lyseng-Williamson, KA	1
Carru, C; Deiana, L; Loriga, G; Satta, AE; Sotgia, S; Zinellu, A	1
Civeira, F; Dan, AG; De Tilleghem, Cle B; Hanson, ME; Hing Ling, PK; Massaad, R; Milardo, C; Triscari, J	1
Baulmann, J; Schunkert, H	1
Desta, Z; Hubeny, A; Jia, J; Keiser, M; Kroemer, HK; Lütjohann, D; Marinova, M; Meyer zu Schwabedissen, HE; Modess, C; Mostertz, J; Nassif, A; Ogburn, ET; Oswald, S; Runge, D; Siegmund, W; Ulrich, A	1
Morinaga, Y; Nakazato, M; Shiiya, T; Tamaki, N; Ueno, H	1
Okopień, B; Stadnicki, A; Suchy, D; Łabuzek, K	1
Hanson, ME; Lin, J; Lowe, RS; Morrone, D; Shah, AK; Tershakovec, AM; Toth, PP; Weintraub, WS	1
Arca, M; Budal, S; Degli Esposti, E; Degli Esposti, L; Sangiorgi, D; Vigna, GB	1
Amaha, M; Inoue, H; Kawagoe, Y; Maeda, S; Nakamura, T; Sato, E; Yamagishi, SI	1
Hanson, ME; Hwang, JJ; Lai, HJ; Lai, WT; Lin, TH; Lu, CH; Shih, KC; Yu, CC	1
Biro, S; Hata, S; Kono, S; Oshima, Y; Otonari, T; Saikawa, T; Sasaki, J; Sawayama, Y	1
Chechetkin, AV; Filippov, AE; Kozobova, AI; Popova, NN; Vashchenko, TN; Vashchenko, VI; Vil'ianinov, VN	1
Guo, L; Tian, Z; Ye, Y; Zhai, G; Zhang, S; Zhao, X	1
Catapano, AL; Garlaschelli, K; Grigore, L; Norata, GD; Pirillo, A; Raselli, S; Redaelli, L	1
Funae, O; Kadonosono, K; Miyamoto, K; Morita, S; Shigematsu, E; Shigematsu, H; Taguri, M; Takatuka, Y; Terauchi, Y; Tokui, M; Yamakawa, T	1
Borges, NC; Figueiredo-Neto, AM; Fonseca, FA; França, CN; Helfenstein, T; Izar, MC; Kasmas, SH; Moreira, FT; Moreno, RA; Ramos, SC	1
Chen, MH; Ibrahim, JG; Lin, J; Shah, AK; Yao, H	1
Bellocchio, A; Bertolini, S; Pisciotta, L	1
Dohi, Y; Goto, Y; Hashimoto, T; Kimura, G; Okado, T; Takase, H	1
Lin, J; Lowe, RS; Schaefer, EJ; Shah, AK; Tershakovec, AM; Thongtang, N; Tomassini, JE	1
Gu, P; Jiang, S; Lu, B; Shao, J; Wang, J; Zhong, Y	1
Tonkin, AM; Watts, GF	1
Abrahamsen, TE; Desai, NR; Giugliano, RP; Hoffman, EB; Huang, F; Kohli, P; Liu, T; McDonald, ST; Mohanavelu, S; Rogers, WJ; Sabatine, MS; Scott, R; Somaratne, R; Wasserman, SM	1
Bokuda, K; Ichihara, A; Itoh, H; Kinouchi, K; Morimoto, S	1
Bianchi, S; Gaspardone, A	1
Heinzl, S	2
Igel, M; Kodal, A; Lütjohann, D; Perevozskaya, I; Shah, S; Sudhop, T; Tribble, DL; von Bergmann, K	1
Sudhop, T; von Bergmann, K	2
Bays, HE; Cho, M; Gagné, C; Gumbiner, B; Mata, P; Melino, M; Musliner, TA; Quinto, K; Weiss, SR	1
Dujovne, CA; Ettinger, MP; LeBeaut, AP; Lipka, LJ; McNeer, JF; Suresh, R; Veltri, EP; Yang, B	1
Bays, H	1
Evans, M; Rees, A; Roberts, A	1
Brown, AJ	1
Gylling, H; Miettinen, TA; Vanhanen, H	1
Bettis, R; Davidson, MH; LeBeaut, AP; Lipka, LJ; McGarry, T; Melani, L; Sun, S; Suresh, R; Veltri, EP	1
Corbelli, J; Kerzner, B; LeBeaut, A; Lipka, LJ; Melani, L; Mukhopadhyay, P; Sharp, S; Suresh, R; Veltri, EP	1
Ambrosi, P; Andréjak, M; Gayet, JL	1
Shepherd, J	1
Hassman, D; LeBeaut, A; Lipetz, R; Lipka, L; Melani, L; Mills, R; Mukhopadhyay, P; Suresh, R; Veltri, E	1
Bays, H; Gitter, H; Knopp, RH; LeBeaut, AP; Lipka, LJ; Manion, CV; Suresh, R; Truitt, T; Veltri, EP; Yang, B	1
Ballantyne, CM; Houri, J; LeBeaut, AP; Lipka, LJ; Melani, L; Notarbartolo, A; Sager, PT; Sun, S; Suresh, R; Veltri, EP	1
Compton, DS; Davis, HR; Farley, C; Hoos, LM; Smith-Torhan, A; van Heek, M	1
Brown, WV; Davis, W; Harris, M	1
SoRelle, R	2
Mauro, VF; Tuckerman, CE	1
Bruckert, E; Giral, P; Tellier, P	1
Dujovne, CA; Knopp, RH; Le Beaut, A; Lipka, LJ; Suresh, R; Veltri, EP	1
Weston, C	1
Cheng, AY; Leiter, LA	1
Lavoie, MA	1
Morris, S; Tiller, R	1
Cheng, JW; Jeu, L	1
Nutescu, EA; Shapiro, NL	1
Jialal, I; Kappagoda, T	1
Schunack, W	1
Lehmann, R; Ramsey, LA	1
Lipka, LJ	1
Lipka, L; Melani, L; Sager, PT; Strony, J; Suresh, R; Veltri, E; Yang, B	1
Darkes, MJ; Goa, KL; Poole, RM	1
Jurado, J; Seip, R; Thompson, PD	1
Farmer, JA; Manhas, A	1
Kane, JP; Malloy, MJ; Pullinger, CR	1
Hendriksz, CJ; Humphries, SE; Norbury, G; Tabrah, S; Taylor, A	1
Catapano, AL; Norata, GD	1
Tellier, P	1
Simon, HB	1
Capece, R; Goldberg, AC; Liu, J; Mitchel, YB; Sapre, A	1
Davies, S; Evans, M; Rees, A; Roberts, A	1
Czine, Z; Márk, L; Paragh, G	1
Cho, M; Feldman, T; Insull, W; Koren, M; Kush, D; Lewin, A; McKenney, J; Mitchel, Y; Schrott, H; Shah, S; Sidisin, M	1
Ballantyne, CM; Blazing, MA; Brady, WE; King, TR; Palmisano, J	1
Heller, JG	1
Naoumova, RP; Soutar, AK; Thompson, GR	1
Alizadeh, J; Ballantyne, CM; Lipka, LJ; Sager, PT; Strony, J; Suresh, R; Veltri, EP	1
Boutros, T; Cutler, DL; Kosoglou, T; Maxwell, SE; Statkevich, P; Suresh, R; Tiessen, R; Yang, B; Zhu, Y	1
Cutler, DL; Fruchart, JC; Guillaume, M; Kosoglou, T; Maxwell, SE; Pember, LJ; Reyderman, L; Statkevich, P; Veltri, EP	1
Ballantyne, CM; Davidson, MH; Kerzner, B; Lipka, L; Melani, L; Sager, PT; Strony, J; Suresh, R; Veltri, E	1
Ballantyne, CM; Chiou, P; Guyton, JR; Jones, PH; Stein, JL; Xydakis, AM	1
Gumbiner, B; Lee, M; Maccubbin, D; Masana, L; Shah, A; Simons, L; Tonkon, M	1
Kroemer, HK; Meyer Zu Schwabedissen, H	1
Lipka, L; Maccubbin, D; Mata, P; Melani, L; Ponsonnet, D; Sager, P; Stein, E; Stender, S; Suresh, R; Veltri, E	1
Diz-Lois, F	1
Patel, SB	1
Kvapil, M	1
Murdoch, D; Scott, LJ	1
Batta, AK; Bollineni, JS; Salen, G; Shefer, S; Xu, G	1
Charlotte, N; Sani, M	1
Lipka, L; Sager, P; Strony, J; Suresh, R; Veltri, E; Yang, B	1
Bays, HE; Donahue, SR; Fraser, N; Johnson-Levonas, AO; Ose, L; Quinto, K; Reyes, R; Sapre, A; Tribble, DL	1
Bennett, S; Lipka, L; Melani, L; Sager, P; Suresh, R; Veltri, E	1
Alemao, E; Cook, JR; Drummond, M; Yin, D	1
Alemao, E; Badia, X; Cook, JR; Davies, G; Krobot, KJ; Lipka, L; Veltri, E; Yin, D	1
Sawicki, PT; Weizel, A	1
Haghfelt, T	1
Capece, R; Lipka, L; Mitchel, Y; Sager, PT; Strony, J; Suresh, R; Veltri, E; Yang, B	1
Cho, M; Gagné, C; Gumbiner, B; Johnson-Levonas, AO; Masana, L; Mata, P; Meehan, A; Sirah, W; Troxell, JK	1
Geiss, HC; Hund-Wissner, E; Otto, C; Parhofer, KG	1
Keough-Ryan, T; Kiberd, BA; Kiberd, M; Lawen, J; Puthenparumpil, JJ	1
Taéron, C	1
Abate, N; Ballantyne, CM; King, TR; Palmisano, J; Yuan, Z	1
Hurley, DL; Isley, WL	1
Battisti, WP; Brady, WE; Denke, MA; McBride, PE; Palmisano, J; Pearson, TA	1
Alings, AM; Allen, C; Banai, S; Brohet, C; Davies, MJ; Massaad, R	1
Adgey, J; Allen, C; Bedarida, GV; Cruz-Fernández, JM; Johnson-Levonas, AO; Massaad, R	1
Chandrasekar, D; Diwan, PV; Kashyap, YV; Sistla, R; Tata, VS	1
Chacón, P; Fonollosa, V; Lima, J	1
Al-Saady, N; Daskalopoulou, SS; Griffiths, H; Hamilton, G; Mikhailidis, DP; Monkman, D; Patel, V; Pittard, J; Schachter, M; Wierzbicki, AS	1
Allen, C; Davies, MJ; Farnier, M; Massaad, R; Volpe, M	1
Lütjohann, D; Sudhop, T; von Bergmann, K	1
Brady, WE; Catapano, A; King, TR; Palmisano, J	1
Cole, P; Rabasseda, X	1
Cutler, DL; Kosoglou, T; Maxwell, S; Reyderman, L; Statkevich, P	1
Ban, MR; Guy, J; Hegele, RA; Wang, J	1
van Heyningen, C	1
Sármán, B	1
Chandalia, M; Jialal, I	1
Allen, C; Amabile, N; Barrios, V; Chen, JW; Johnson-Levonas, AO; Massaad, R; Paganelli, F; Vandormael, K	1
Araújo, RG; Casella Filho, A; Chagas, AC	1
Heemann, U; Kohnle, M; Kribben, A; Philipp, T; Pietruck, F; Witzke, O	1
Fisher, EA; Schwartzbard, A; Yatskar, L	1
Cohn, JS; Couture, P; Hogue, JC; Lamarche, B; Tremblay, AJ	1
Chuang, P; Langone, AJ	1
Daskalopoulou, SS; Mikhailidis, DP	1
Geiss, HC; Otto, C; Parhofer, KG	1
Holland, RC; Lopez, D; Ness, GC	1
Benecke, H; Bestehorn, K; Karmann, B; Renner, H; Völler, H; Wegscheider, K	1
Davies, MJ; Maccubbin, D; Mitchel, Y; Ose, L; Rotonda, J; Shah, A; Tribble, D; Veltri, E	1
Kerzner, B; Rodney, RA; Strony, J; Sugimoto, D; Suresh, R; Veltri, E; Wagman, B; Yang, B; Zieve, F	1
Becx, MC; Kuypers, KC; Seldenrijk, CA; Stolk, MF	1
Arteaga Ll, A; Maiz G, A; Rigotti R, A	1
Capps, N	1
Davidson, M; Feldman, T; Maccubbin, D; Meehan, A; Mitchel, Y; Shah, A; Tribble, D; Veltri, E; Zakson, M	1
Hughes, EA; Patel, JV	1
Alemao, E; Attard, C; Bourgault, C; Cook, J; Huse, D; Kohli, M; Lam, A; Marentette, M; Yin, D	1
Davidson, MH; Robinson, JG	1
Czuriga, I; Edes, I	1
Battisti, WP; Brady, WE; Denke, MA; Gazzara, RA; McBride, PE; Palmisano, J; Pearson, TA	1
Bissonnette, S; Boukas, S; Habib, R; Sampalis, F; Sampalis, JS	1
Burnett, JR; Huff, MW	1
Abby, S; Bays, H; Jones, M; Lai, YL; Rhyne, J	1
Gazi, IF; Mikhailidis, DP	1
Anderson, S; Fish, B; Knopp, RH; Nguyen, H; Nguyen, T; Retzlaff, BM; Tsunehara, C	1
Edwards, P; Goldberg, RB; Guyton, JR; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS	1
Bitzur, R; Cohen, H; Harats, D	1
Pasierski, T; Pikto-Pietkiewicz, W	1
Katz, U; Shoenfeld, Y; Szyper-Kravitz, M; Zimlichman, E	1
Ballantyne, CM; Duffield, E; Eber, B; Moccetti, T; Sosef, F; Vogt, A; Weiss, R	1
Ambrose, MS; Cote, H; DeNofrio, D; Duffy, GA; Patel, AR	1
Shechter, M	1
Fischer, S; Jaster, M; Martus, P; Morguet, AJ; Piorkowski, M; Rauch, U; Schultheiss, HP; Stellbaum, C	1
Abinader, EG	1
Márk, L; Paragh, G	1
Alonso K, R; Arteaga Ll, A; Castillo, S; Cuevas M, A; González, F; Mata L, P; Rigotti R, A	1
Blagden, MD; Chipperfield, R	1
Blaimont, M; Chenot, F; de Meester, A; Descamps, OS; Marcovitch, O; Montant, PF	1
Johnson, RR; Sweeney, ME	1
Dani, G; Fazekas, O; Katona, A; Kovacs, H; Mark, L; Szüle, O	1
Angelin, B; Gälman, C; Matasconi, M; Parini, P; Persson, L; Rudling, M	1
Davis, HR; Veltri, EP	1
Devaraj, S; Jialal, I	1
Johnson-Levonas, A; Lin, J; Musliner, T; Ose, L; Reyes, R; Shah, A; Tribble, D	1
Ballantyne, CM; Catapano, AL; Davies, GM; Mikhailidis, DP; Sibbring, GC	1
Bissonnette, S; Boukas, S; Habib, R; Sampalis, JS	1
Daskalopoulou, SS; Gazi, IF; Mikhailidis, DP; Nair, DR	1
Carlson, HE; John-Kalarickal, J; Pearlman, G	1
Spener, F	1
Heemann, U; Kohnle, M; Kribben, A; Nürnberger, J; Philipp, T; Türk, TR; Voropaeva, E; Witzke, O	1
Berthold, J; Krone, W	1
Catapano, AL	1
Assmann, G; Gutkin, SW; Kannenberg, F; Musliner, TA; Ramey, DR; Veltri, EP	1
Acton, S; Braun, A; Broschat, KO; Krieger, M; Krul, ES; Napawan, N; Stagliano, N; Yesilaltay, A	1
Berthold, HK; Gouni-Berthold, I; Gylling, H; Krone, W; Laaksonen, R; Lehtimäki, T	1
Johnson-Levonas, AO; Musliner, T; Ose, L; Reyes, R; Sapre, A; Tribble, DL	1
Elisaf, MS; Florentin, M; Liberopoulos, EN	1
Hussein, O; Itzkovich, Y; Minasian, L; Shestatski, K; Solomon, L; Zidan, J	1
Allen, C; Brudi, P; Henry, P; Johnson-Levonas, AO; Lim, ST; Lis, K; Massaad, R; Pomykaj, T; Reckless, JP; Vandormael, K	1
Athyros, VG; Kakafika, AI; Karagiannis, A; Koumaras, H; Mikhailidis, DP; Tziomalos, K	1
Viljoen, A; Wierzbicki, AS	1
Alvarez-Sala, LA; Cachofeiro, V; Gambus, G; Lahera, V; Masana, L; Moreno, MA; Pinilla, B; Pintó, X; Plana, N; Suarez, C; Trias, F	1
Antoniades, C; Chrysohoou, C; Giotsas, N; Masoura, C; Metalinos, G; Papadimitriou, L; Pitsavos, C; Skoumas, I; Stefanadis, C; Tousoulis, D; Toutouza, M	1
Thompson, CA	1
Jackevicius, CA; Ko, DT; Krumholz, HM; Ross, JS; Tu, JV	1
Angelin, B; Bonde, Y; Gälman, C; Matasconi, M; Rudling, M	1
Lindsley, CW	1
Bays, HE; Neff, D; Tershakovec, AM; Tomassini, JE	1
Barnett, D; Charles, Z; Pugh, E	1
Armitage, J	1
Barho, C; Bode, C; Darius, H; Hildemann, S; Karmann, B; Pittrow, D	1
Gaughan, JP; Klibanov, OM; Tedaldi, EM; van den Berg-Wolf, M	1
Bauersachs, J; Ertl, G; Hu, K; Huang, PL; Kuhlencordt, PJ; Padmapriya, P; Rützel, S; Schäfer, A; Schödel, J	1
Ara, R; Chilcott, J; Duenas, A; Paisley, S; Pandor, A; Tumur, I; Wilkinson, A; Williams, R	1
Bheemreddy, S; Foody, JM; Kashani, A; Mann, DL; Sallam, T; Wang, Y	1
Bloedon, LT; McKenney, J; Rader, DJ; Samaha, FF; Sasiela, WJ	1
Compton, DS; Davis, HR; van Heek, M	1
Brown, WV	2
Austin, TM; Cook, JA; Davis, HR; Farley, C; Tetzloff, GG; van Heek, M	1
Batra, V; Ezzet, F; Kosoglou, T; Lipka, L; Mellars, L; Patrick, J; Statkevich, P; Veltri, E; Wexler, D	1
Bays, HE; Cuffie-Jackson, C; Drehobl, MA; Dujovne, CA; Knopp, RH; Lebeaut, AP; Lipka, LJ; Mellars, LE; Moore, PB; Rosenblatt, S; Toth, PD; Veltri, EP; Yang, B	1
Meng, CQ	1
Alton, KB; Burrier, RE; Davis, HR; Pula, KK; Watkins, RW	1
Aumiller, J	1
Miettinen, TA	1
Stein, EA	1
Leitersdorf, E	1

Reviews

149 review(s) available for ezetimibe and Elevated Cholesterol

Article	Year
Niemann-Pick C1-Like 1 inhibitors for reducing cholesterol absorption. European journal of medicinal chemistry, 2022, Feb-15, Volume: 230 Topics: Anticholesteremic Agents; Biological Transport; Cholesterol; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Absorption; Membrane Transport Proteins	2022
The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Mediators of inflammation, 2021, Volume: 2021 Topics: Atherosclerosis; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Oxygen; Randomized Controlled Trials as Topic; Regression Analysis; Risk Factors; Treatment Outcome	2021
High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clinic proceedings, 2021, Volume: 96, Issue:10 Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Primary Prevention; Secondary Prevention	2021
New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia. Current opinion in endocrinology, diabetes, and obesity, 2022, 04-01, Volume: 29, Issue:2 Topics: Anticholesteremic Agents; Cholesterol, LDL; Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Randomized Controlled Trials as Topic; Treatment Outcome	2022
Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis. Current medical research and opinion, 2022, Volume: 38, Issue:5 Topics: Anticholesteremic Agents; Bayes Theorem; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Network Meta-Analysis; Risk Factors; Treatment Outcome	2022
[From statin revolution to gene silencing therapy: 50 years of evolution in the treatment of hypercholesterolemia]. Giornale italiano di cardiologia (2006), 2022, Volume: 23, Issue:7 Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Gene Silencing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Proprotein Convertase 9	2022
Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 2019, 08-20, Volume: 8, Issue:16 Topics: Anticholesteremic Agents; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Myocardial Revascularization; Stroke; Treatment Outcome	2019
LDL-cholesterol: The lower the better. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis, 2019, Volume: 31 Suppl 2 Topics: Anion Exchange Resins; Antibodies, Monoclonal; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Risk	2019
Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature. Lipids in health and disease, 2020, Jan-04, Volume: 19, Issue:1 Topics: Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged	2020
[Approach to Patients with Statin Intolerance: Evidence-Based Review]. Acta medica portuguesa, 2020, Jan-03, Volume: 33, Issue:1 Topics: Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Meta-Analysis as Topic; Practice Guidelines as Topic; Systematic Reviews as Topic	2020
An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:5 Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Drug Synergism; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Rosuvastatin Calcium; Treatment Outcome; Triglycerides	2020
PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility. Endocrine, metabolic & immune disorders drug targets, 2020, Volume: 20, Issue:6 Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; PCSK9 Inhibitors	2020
A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2020, Volume: 20, Issue:6 Topics: Anticholesteremic Agents; Cholesterol, LDL; Dicarboxylic Acids; Drug Combinations; Dyslipidemias; Ezetimibe; Fatty Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Randomized Controlled Trials as Topic; Receptors, LDL	2020
Low-density lipoprotein cholesterol lowering treatment: the current approach. Lipids in health and disease, 2020, May-06, Volume: 19, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Benzimidazoles; Bile Acids and Salts; Carrier Proteins; Cholesterol, LDL; Dicarboxylic Acids; Europe; Ezetimibe; Fatty Acids; Gene Expression; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Proprotein Convertase 9; RNA, Small Interfering	2020
Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression. Lipids in health and disease, 2020, May-27, Volume: 19, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Treatment Outcome; Ultrasonography	2020
Clinical Pharmacology of Statins: an Update. Current atherosclerosis reports, 2020, 06-03, Volume: 22, Issue:7 Topics: Adolescent; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Atherosclerosis; Child; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Primary Prevention; RNA, Small Interfering; Treatment Outcome	2020
Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2020, Volume: 20, Issue:4 Topics: Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Rosuvastatin Calcium	2020
Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:17 Topics: Antibodies, Monoclonal, Humanized; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Treatment Outcome	2020
Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia. The American journal of cardiology, 2020, 11-01, Volume: 134 Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Anticholesteremic Agents; Apolipoproteins B; Aspartate Aminotransferases; Bilirubin; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Injection Site Reaction; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; RNA, Small Interfering; Stroke	2020
Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III trials. Clinical drug investigation, 2021, Volume: 41, Issue:1 Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dicarboxylic Acids; Drug Combinations; Ezetimibe; Fatty Acids; Humans; Hypercholesterolemia; Randomized Controlled Trials as Topic; Triglycerides	2021
Statin intolerance: new data and further options for treatment. Current opinion in cardiology, 2021, 07-01, Volume: 36, Issue:4 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Proprotein Convertase 9	2021
Clinical development of bempedoic acid: phase 2 and phase 3 clinical trials. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis, 2021, Volume: 33 Suppl 1 Topics: Cholesterol, LDL; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dicarboxylic Acids; Drug Development; Drug Therapy, Combination; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Inflammation	2021
Fixed-dose combination of rosuvastatin and ezetimibe: treating hypercholesteremia according to cardiovascular risk. Expert review of clinical pharmacology, 2021, Volume: 14, Issue:7 Topics: Anticholesteremic Agents; Cholesterol, LDL; Drug Combinations; Ezetimibe; Heart Disease Risk Factors; Humans; Hypercholesterolemia; Medication Adherence; Rosuvastatin Calcium	2021
Two novel variants of the ABCG5 gene cause xanthelasmas and macrothrombocytopenia: a brief review of hematologic abnormalities of sitosterolemia. Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:9 Topics: Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 5; DNA Mutational Analysis; Ezetimibe; Female; Genetic Predisposition to Disease; High-Throughput Nucleotide Sequencing; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Lipoproteins; Middle Aged; Mutation; Phenotype; Phytosterols; Sitosterols; Spain; Thrombocytopenia; Xanthomatosis	2017
Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care. International journal of clinical practice, 2017, Volume: 71, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Primary Health Care; Proprotein Convertase 9	2017
Lipid Lowering Therapy and Circulating PCSK9 Concentration. Journal of atherosclerosis and thrombosis, 2017, Sep-01, Volume: 24, Issue:9 Topics: Antibodies, Monoclonal; Biomarkers; Cholesterol, LDL; Ezetimibe; Fibric Acids; Gene Silencing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipid Metabolism; Niacin; PCSK9 Inhibitors; Proprotein Convertase 9	2017
Praxis, 2017, Volume: 106, Issue:17 Topics: Cholesterol, LDL; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Secondary Prevention	2017
Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. Postgraduate medicine, 2017, Volume: 129, Issue:8 Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Practice Guidelines as Topic; Proprotein Convertase 9	2017
Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review. Expert review of cardiovascular therapy, 2017, Volume: 15, Issue:12 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; PCSK9 Inhibitors; Treatment Outcome	2017
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes care, 2018, Volume: 41, Issue:2 Topics: Blood Glucose; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Randomized Controlled Trials as Topic	2018
The systematic review of randomized controlled trials of PCSK9 antibodies challenges their "efficacy breakthrough" and the "lower, the better" theory. Current medical research and opinion, 2018, Volume: 34, Issue:10 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Treatment Outcome	2018
Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Drugs, 2018, Volume: 78, Issue:4 Topics: Anticholesteremic Agents; Cholesterol, LDL; Databases, Pharmaceutical; Dose-Response Relationship, Drug; Ezetimibe; Hypercholesterolemia; Lipoprotein(a); Randomized Controlled Trials as Topic; Treatment Outcome; Triglycerides	2018
Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes. Annals of medicine, 2018, Volume: 50, Issue:4 Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Anticholesteremic Agents; Atherosclerosis; Bile Acids and Salts; Cholesterol, LDL; Disease Progression; Ezetimibe; Genetic Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Intestinal Mucosa; MicroRNAs; Mutation; PCSK9 Inhibitors; Proprotein Convertase 9; Receptors, LDL; RNA, Small Interfering; Sequestering Agents	2018
Are PCSK9 Inhibitors Cost Effective? PharmacoEconomics, 2018, Volume: 36, Issue:9 Topics: Anticholesteremic Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Enzyme Inhibitors; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Quality-Adjusted Life Years	2018
Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk. Atherosclerosis, 2018, Volume: 278 Topics: Anticholesteremic Agents; Atorvastatin; Cardiology; Cardiovascular Diseases; Cholesterol, LDL; Europe; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Oxazolidinones; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; United Kingdom; United States	2018
Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy. Clinical research in cardiology : official journal of the German Cardiac Society, 2019, Volume: 108, Issue:5 Topics: Anticholesteremic Agents; Bayes Theorem; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Global Health; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Risk Factors	2019
Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse. Lipids in health and disease, 2018, Oct-17, Volume: 17, Issue:1 Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Triglycerides	2018
Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Scientific reports, 2018, 12-14, Volume: 8, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein(a); Male; Middle Aged; Placebos; Plasma; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult	2018
Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis. Medicine, 2019, Volume: 98, Issue:6 Topics: Adult; Aged; Comparative Effectiveness Research; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Network Meta-Analysis; PCSK9 Inhibitors; Treatment Outcome	2019
Efficacy and safety of different doses of alirocumab in reducing low-density lipoprotein cholesterol levels: a network meta-analysis. Die Pharmazie, 2019, 01-01, Volume: 74, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, LDL; Dose-Response Relationship, Drug; Ezetimibe; Humans; Hypercholesterolemia; Network Meta-Analysis; PCSK9 Inhibitors	2019
Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:8 Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Risk Factors; Simvastatin	2019
The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know. Current atherosclerosis reports, 2019, 04-02, Volume: 21, Issue:6 Topics: Aged; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; PCSK9 Inhibitors; Secondary Prevention	2019
Maximizing the benefits of cholesterol-lowering drugs. Current opinion in lipidology, 2019, Volume: 30, Issue:5 Topics: Antibodies, Monoclonal; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Proprotein Convertase 9	2019
Liptruzet: a combination of ezetimibe and atorvastatin. The Medical letter on drugs and therapeutics, 2013, Jun-24, Volume: 55, Issue:1419 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Combinations; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome	2013
Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia. Atherosclerosis, 2013, Volume: 229, Issue:2 Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Linear Models; Male; Middle Aged; Predictive Value of Tests; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides	2013
[An inhibitor of intestinal cholesterol transporter]. Nihon rinsho. Japanese journal of clinical medicine, 2013, Volume: 71, Issue:9 Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Ezetimibe; Humans; Hypercholesterolemia; Insulin Resistance; Intestinal Absorption	2013
Non-cholesterol sterols and cholesterol metabolism in sitosterolemia. Atherosclerosis, 2013, Volume: 231, Issue:2 Topics: Absorption; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G; ATP-Binding Cassette Transporters; Azetidines; Cholesterol; Disease Progression; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Diseases; Kinetics; Lipid Metabolism, Inborn Errors; Membrane Proteins; Membrane Transport Proteins; Phytosterols; Sitosterols; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Sterols; Xanthomatosis	2013
Management of hypercholesterolemia in children. Paediatric drugs, 2014, Volume: 16, Issue:2 Topics: Age Factors; Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Child; Cholesterol; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Style; Mass Screening; Risk Factors	2014
Toward individualized cholesterol-lowering treatment in end-stage renal disease. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2014, Volume: 24, Issue:2 Topics: Azetidines; Cardiovascular Diseases; Cholesterol, Dietary; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Kidney Failure, Chronic; Phytosterols; Polyamines; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Sevelamer	2014
Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review. Annals of internal medicine, 2014, Apr-01, Volume: 160, Issue:7 Topics: Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Omega-3; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Medication Adherence; Niacin; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome	2014
Virtual screening for cholesterol absorption inhibitors. Medicinal chemistry (Shariqah (United Arab Emirates)), 2014, Volume: 11, Issue:1 Topics: Animals; Anticholesteremic Agents; Azetidines; Biological Transport; Cholesterol; Coronary Disease; Ezetimibe; Gene Expression; High-Throughput Screening Assays; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Membrane Proteins; Membrane Transport Proteins; Structure-Activity Relationship; User-Computer Interface	2014
Sitosterolemia: diagnosis, investigation, and management. Current atherosclerosis reports, 2014, Volume: 16, Issue:7 Topics: Anemia, Hemolytic; Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Mice; Phytosterols; Thrombocytopenia; Xanthomatosis	2014
Resistance and intolerance to statins. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2014, Volume: 24, Issue:10 Topics: Anticholesteremic Agents; Azetidines; Benzimidazoles; Bile Acids and Salts; Cholesterol, LDL; Drug Resistance; Drug Therapy, Combination; Drug Tolerance; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Multidrug Resistance-Associated Protein 2; Pharmacogenetics; Polymorphism, Genetic	2014
PCSK9 and its modulation. Clinica chimica acta; international journal of clinical chemistry, 2015, Feb-02, Volume: 440 Topics: Age Factors; Atherosclerosis; Azetidines; Cholesterol; Circadian Rhythm; Diet; Drugs, Chinese Herbal; Exercise; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Kidney Diseases; Liver Regeneration; Molecular Targeted Therapy; Proprotein Convertase 9; Proprotein Convertases; Risk Factors; Serine Endopeptidases	2015
Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta-analysis. Internal medicine journal, 2015, Volume: 45, Issue:5 Topics: Anticholesteremic Agents; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Risk Factors; Treatment Outcome	2015
'LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. Current opinion in lipidology, 2015, Volume: 26, Issue:3 Topics: Animals; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein(a); Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases; Treatment Outcome	2015
The IMPROVE-IT study and ezetimibe. British journal of community nursing, 2015, Volume: 20, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin	2015
Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials. Clinical cardiology, 2015, Volume: 38, Issue:12 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Incidence; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome	2015
The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. Expert opinion on drug safety, 2016, Volume: 15, Issue:4 Topics: Animals; Anticholesteremic Agents; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Safety; Simvastatin	2016
Recent advances in the pharmacological management of hypercholesterolaemia. The lancet. Diabetes & endocrinology, 2016, Volume: 4, Issue:5 Topics: Anticholesteremic Agents; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; PCSK9 Inhibitors	2016
IMPROVE-IT: what have we learned? Current opinion in cardiology, 2016, Volume: 31, Issue:4 Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin; Treatment Outcome	2016
Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. Current atherosclerosis reports, 2016, Volume: 18, Issue:10 Topics: Anticholesteremic Agents; ATP Citrate (pro-S)-Lyase; Cholesterol, LDL; Dicarboxylic Acids; Drug Therapy, Combination; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia	2016
Glycaemic Effects of Non-statin Lipid-Lowering Therapies. Current cardiology reports, 2016, Volume: 18, Issue:12 Topics: Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipid Metabolism; Meta-Analysis as Topic; Niacin; PCSK9 Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome	2016
Hypercholesterolemia As a Risk Factor for Cardiovascular Disease: Current Controversial Therapeutic Management. Archives of medical research, 2016, Volume: 47, Issue:7 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Biological Transport; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Receptors, LDL; Risk Factors	2016
[A new approach to the treatment of dyslipidemia]. Medicina (Kaunas, Lithuania), 2008, Volume: 44, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Middle Aged; Practice Guidelines as Topic; Prognosis; Pyrroles; Risk Factors	2008
Combination therapy in cholesterol reduction: focus on ezetimibe and statins. Vascular health and risk management, 2008, Volume: 4, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Liver; Practice Guidelines as Topic; Treatment Outcome	2008
[Crosstalk between cholesterol homeostasis and drug metabolism]. Orvosi hetilap, 2008, Jul-06, Volume: 149, Issue:27 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; Bile; Cardiovascular Diseases; Cholesterol; Cholesterol, Dietary; Cytochrome P-450 Enzyme System; Ezetimibe; Feedback, Physiological; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Pharmaceutical Preparations; Receptor Cross-Talk; Receptors, Cytoplasmic and Nuclear	2008
Ezetimibe, a selective inhibitor of the transport of cholesterol. Internal medicine (Tokyo, Japan), 2008, Volume: 47, Issue:13 Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Membrane Proteins; Membrane Transport Proteins; Mice; Protein Structure, Secondary	2008
Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Current atherosclerosis reports, 2009, Volume: 11, Issue:1 Topics: Animals; Anticholesteremic Agents; Azetidines; Benzimidazoles; Carrier Proteins; Cholesterol, LDL; Ezetimibe; Farnesyl-Diphosphate Farnesyltransferase; Humans; Hypercholesterolemia; Indoles; Oligonucleotides; Oxazepines; Piperidines; Proprotein Convertase 9; Proprotein Convertases; Pyridines; Serine Endopeptidases; Serine Proteinase Inhibitors	2009
Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. Journal of internal medicine, 2009, Volume: 265, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Randomized Controlled Trials as Topic; Treatment Outcome; Triglycerides	2009
Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2008, Volume: 8, Issue:6 Topics: Age Factors; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Contraindications; Cost-Benefit Analysis; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Markov Chains; Middle Aged; Models, Economic; Quality-Adjusted Life Years; United Kingdom	2008
Update on patented cholesterol absorption inhibitors. Expert opinion on therapeutic patents, 2009, Volume: 19, Issue:8 Topics: Absorption; Animals; Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Biological Transport; Blood Proteins; Cholesterol; Ezetimibe; Heterocyclic Compounds; Humans; Hypercholesterolemia; Patents as Topic; Sterol Esterase; Sterol O-Acyltransferase	2009
The impact of ezetimibe on endothelial function and other markers of cardiovascular risk. The Annals of pharmacotherapy, 2009, Volume: 43, Issue:12 Topics: Animals; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Endothelium, Vascular; Ezetimibe; Humans; Hypercholesterolemia; Risk Factors	2009
Ezetimibe/simvastatin. Expert opinion on drug safety, 2009, Volume: 8, Issue:6 Topics: Animals; Anticholesteremic Agents; Azetidines; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin	2009
Advancing therapy for hypercholesterolemia. Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:10 Topics: Azetidines; Bile Acids and Salts; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Ezetimibe; Farnesyl-Diphosphate Farnesyltransferase; Fatty Acids, Omega-3; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Niacin	2010
Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. Advances in therapy, 2010, Volume: 27, Issue:6 Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Drug Therapy, Combination; Evidence-Based Practice; Ezetimibe; Fatty Acids, Omega-3; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Patient Selection; Phytosterols; Practice Guidelines as Topic; Primary Prevention; Risk Assessment; Risk Factors; Risk Reduction Behavior; Secondary Prevention; Treatment Outcome	2010
Attainment of Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin. International journal of clinical practice, 2010, Volume: 64, Issue:13 Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Triglycerides	2010
Ezetimibe and vascular inflammation. Current vascular pharmacology, 2011, Volume: 9, Issue:1 Topics: Animals; Anticholesteremic Agents; Arteritis; Atherosclerosis; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Meta-Analysis as Topic	2011
Ezetimibe and reactive oxygen species. Current vascular pharmacology, 2011, Volume: 9, Issue:1 Topics: Animals; Atherosclerosis; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Oxidative Stress; Reactive Oxygen Species	2011
Ezetimibe and vascular endothelial function. Current vascular pharmacology, 2011, Volume: 9, Issue:1 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Endothelium, Vascular; Ezetimibe; Humans; Hypercholesterolemia	2011
Lowering LDL cholesterol with margarine containing plant stanol/sterol esters: is it still relevant in 2011? Complementary therapies in medicine, 2011, Volume: 19, Issue:1 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Margarine; Micronutrients; Niacin; Phytosterols; Sitosterols; Triglycerides	2011
Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Current medical research and opinion, 2011, Volume: 27, Issue:6 Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia	2011
Clinical aspects of PCSK9. Atherosclerosis, 2011, Volume: 216, Issue:2 Topics: Adolescent; Animals; Azetidines; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fibric Acids; Genes, Dominant; Humans; Hypercholesterolemia; Lipid Metabolism; Male; Mice; Mutation; Nutritional Status; Phenotype; Proprotein Convertase 9; Proprotein Convertases; Protease Inhibitors; Receptors, LDL; Serine Endopeptidases	2011
Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today? Atherosclerosis, 2011, Volume: 217, Issue:2 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol; Evidence-Based Medicine; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Intestinal Mucosa; Intestines; Liver; Treatment Outcome	2011
Intestinal sterol transporters and cholesterol absorption inhibition. Current opinion in lipidology, 2011, Volume: 22, Issue:6 Topics: Animals; Anticholesteremic Agents; Azetidines; Biological Transport; Cholesterol; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Randomized Controlled Trials as Topic; Sterol O-Acyltransferase	2011
Ezetimibe/simvastatin: a guide to its clinical use in hypercholesterolemia. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Feb-01, Volume: 12, Issue:1 Topics: Animals; Anticholesteremic Agents; Azetidines; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Practice Guidelines as Topic; Simvastatin	2012
Ezetimibe--a new approach in hypercholesterolemia management. Pharmacological reports : PR, 2011, Volume: 63, Issue:6 Topics: Animals; Anticholesteremic Agents; Azetidines; Disease Management; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Absorption	2011
Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis, 2012, Volume: 223, Issue:2 Topics: Aged; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Treatment Outcome	2012
Effect of high-dose statin versus low-dose statin plus ezetimibe on endothelial function: a meta-analysis of randomized trials. Journal of cardiovascular pharmacology and therapeutics, 2012, Volume: 17, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, Dietary; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Gastrointestinal Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Randomized Controlled Trials as Topic; Vasodilation	2012
The ezetimibe controversy - can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together? Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:10 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin	2012
Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs, 2002, Volume: 62, Issue:16 Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Clinical Trials as Topic; Drug Synergism; Ezetimibe; Humans; Hypercholesterolemia; Phytosterols; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Structure-Activity Relationship	2002
Ezetimibe. Expert opinion on investigational drugs, 2002, Volume: 11, Issue:11 Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia	2002
The future direction of cholesterol-lowering therapy. Current opinion in lipidology, 2002, Volume: 13, Issue:6 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Forecasting; Humans; Hypercholesterolemia; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2002
[Combination therapy of hypercholesterolemia]. Duodecim; laaketieteellinen aikakauskirja, 2002, Volume: 118, Issue:19 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Cholestyramine Resin; Combined Modality Therapy; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Margarine; Phytosterols	2002
[The best of clinical pharmacology in 2002]. Archives des maladies du coeur et des vaisseaux, 2003, Volume: 96 Spec No 1 Topics: Anticholesteremic Agents; Antihypertensive Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; Hormone Replacement Therapy; Humans; Hydrazones; Hypercholesterolemia; Losartan; Myocardial Infarction; Natriuretic Agents; Natriuretic Peptide, Brain; Neovascularization, Physiologic; Nicorandil; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Vasodilator Agents	2003
Ezetimibe. Drugs of today (Barcelona, Spain : 1998), 2003, Volume: 39, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia	2003
Ezetimibe for management of hypercholesterolemia. The Annals of pharmacotherapy, 2003, Volume: 37, Issue:6 Topics: Animals; Azetidines; Clinical Trials as Topic; Disease Management; Ezetimibe; Humans; Hypercholesterolemia	2003
Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation, 2003, Jul-01, Volume: 107, Issue:25 Topics: Adolescent; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Male; Middle Aged; Myocardial Infarction; Treatment Outcome	2003
The place of ezetimibe in clinical practice. Hospital medicine (London, England : 1998), 2003, Volume: 64, Issue:8 Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II	2003
Clinical use of ezetimibe. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2003,Winter, Volume: 10 Suppl A Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Practice Guidelines as Topic; Randomized Controlled Trials as Topic	2003
Ezetimibe and cholesterol absorption. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2003,Winter, Volume: 10 Suppl A Topics: Anticholesteremic Agents; Azetidines; Cholesterol, Dietary; Chylomicrons; Ezetimibe; Homeostasis; Humans; Hypercholesterolemia; Intestinal Absorption	2003
Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clinical therapeutics, 2003, Volume: 25, Issue:9 Topics: Animals; Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Lipoproteins	2003
Ezetimibe: a selective cholesterol absorption inhibitor. Pharmacotherapy, 2003, Volume: 23, Issue:11 Topics: Animals; Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Absorption	2003
[Cardiovascular risk factor reduction. Cholesterol absorption inhibitors: a new action principle]. Pharmazie in unserer Zeit, 2003, Volume: 32, Issue:6 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, Dietary; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Absorption; Risk Factors	2003
Cholesterol absorption inhibitors: a closer look. Advance for nurse practitioners, 2003, Volume: 11, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Patient Selection; Phytosterols; Treatment Outcome	2003
Ezetimibe: a first-in-class, novel cholesterol absorption inhibitor. Cardiovascular drug reviews, 2003,Winter, Volume: 21, Issue:4 Topics: Animals; Anticholesteremic Agents; Azetidines; Biological Availability; Ezetimibe; Half-Life; Humans; Hypercholesterolemia; Intestinal Absorption; Randomized Controlled Trials as Topic; Species Specificity	2003
Ezetimibe. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2003, Volume: 3, Issue:1 Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia	2003
Hypolipidemic therapy and cholesterol absorption. Current atherosclerosis reports, 2004, Volume: 6, Issue:2 Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol; Colesevelam Hydrochloride; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Absorption	2004
Ezetimibe: a novel option for lowering cholesterol. Expert review of cardiovascular therapy, 2003, Volume: 1, Issue:1 Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Randomized Controlled Trials as Topic	2003
Primary hypercholesterolemia: genetic causes and treatment of five monogenic disorders. Expert review of cardiovascular therapy, 2003, Volume: 1, Issue:1 Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Diet, Fat-Restricted; Ezetimibe; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Receptors, LDL	2003
Lipid lowering activity of drugs affecting cholesterol absorption. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2004, Volume: 14, Issue:1 Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, Dietary; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Absorption; Molecular Biology; Sterols	2004
[Ezetimibe: from pharmacology to clinical trials]. Annales d'endocrinologie, 2003, Volume: 64, Issue:6 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Depression, Chemical; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Intestinal Absorption; Liver; Lovastatin; Pravastatin; Pyrroles; Safety; Simvastatin; Treatment Outcome	2003
Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Drugs, 2004, Volume: 64, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Ezetimibe; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome	2004
[New treatment option for decreasing blood cholesterol level--clinical significance of inhibition of both, cholesterol absorption and synthesis]. Orvosi hetilap, 2004, Apr-11, Volume: 145, Issue:15 Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Drug Tolerance; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Liver	2004
Current management of severe homozygous hypercholesterolaemias. Current opinion in lipidology, 2004, Volume: 15, Issue:4 Topics: Adolescent; Adult; Apolipoproteins B; Azetidines; Blood Component Removal; Child; Cholesterol; Coronary Disease; Ezetimibe; Female; Genes, Recessive; Genetic Therapy; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Liver Transplantation; Male; Models, Genetic; Mutation; Pregnancy; Time Factors	2004
[Ezetimib]. Deutsche medizinische Wochenschrift (1946), 2004, Sep-24, Volume: 129, Issue:39 Topics: Anticholesteremic Agents; Arteriosclerosis; Azetidines; Coronary Disease; Ezetimibe; Humans; Hypercholesterolemia; Hyperlipoproteinemias	2004
[The role of intestinal absorption blockade in hypercholesterolemia treatment]. Revista clinica espanola, 2004, Volume: 204, Issue:10 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Intestinal Obstruction; Pyrroles	2004
Ezetimibe: a novel cholesterol-lowering agent that highlights novel physiologic pathways. Current cardiology reports, 2004, Volume: 6, Issue:6 Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, Dietary; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption	2004
Ezetimibe/Simvastatin: a review of its use in the management of hypercholesterolemia. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2004, Volume: 4, Issue:6 Topics: Animals; Anticholesteremic Agents; Azetidines; Cost-Benefit Analysis; Drug Combinations; Drug Interactions; Ezetimibe; Humans; Hypercholesterolemia; Randomized Controlled Trials as Topic; Simvastatin	2004
[Selective cholesterol absorption inhibition as a new prospect in treatment of hypercholesterolemia]. Medicina clinica, 2005, Jun-04, Volume: 125, Issue:1 Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Ezetimibe; Humans; Hypercholesterolemia	2005
Cholesterol and plant sterol absorption: recent insights. The American journal of cardiology, 2005, Jul-04, Volume: 96, Issue:1A Topics: Absorption; Anticholesteremic Agents; ATP-Binding Cassette Transporters; Azetidines; Cholesterol; Diet; Ezetimibe; Humans; Hypercholesterolemia; Membrane Proteins; Membrane Transport Proteins; Microvilli; Phytosterols; Proteins	2005
Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Current medical research and opinion, 2005, Volume: 21, Issue:7 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hypercholesterolemia; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2005
Enhanced hypercholesterolemia therapy: the ezetimibe/simvastatin tablet. Drugs of today (Barcelona, Spain : 1998), 2005, Volume: 41, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Drug Combinations; Ezetimibe; Humans; Hypercholesterolemia; Randomized Controlled Trials as Topic; Simvastatin	2005
[New results in the management of hypercholesterolemia]. Orvosi hetilap, 2005, Sep-25, Volume: 146, Issue:39 Topics: Anticholesteremic Agents; Azetidines; C-Reactive Protein; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Enzyme Inhibitors; Evidence-Based Medicine; Ezetimibe; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Practice Guidelines as Topic; Sterol O-Acyltransferase	2005
Ezetimibe: rationale and role in the management of hypercholesterolemia. Clinical cardiology, 2006, Volume: 29, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Absorption	2006
Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Current medical research and opinion, 2006, Volume: 22, Issue:3 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin	2006
Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. Current medical research and opinion, 2006, Volume: 22, Issue:5 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Azetidines; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Retrospective Studies; Risk Factors; Sex Factors; Simvastatin; Treatment Outcome	2006
[Intensive cholesterol lowering therapy to reduce cardiovascular risk]. Revista medica de Chile, 2006, Volume: 134, Issue:5 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clofibric Acid; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles	2006
Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. Clinical therapeutics, 2006, Volume: 28, Issue:6 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin	2006
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert review of cardiovascular therapy, 2006, Volume: 4, Issue:4 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Lipoproteins, LDL; Phytosterols; Pravastatin; Pyrroles; Simvastatin	2006
[Lowering cholesterol: how low is low enough?]. Orvosi hetilap, 2006, Jul-23, Volume: 147, Issue:29 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia	2006
Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:11 Topics: Acetyl-CoA C-Acyltransferase; Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; Bile Acids and Salts; Carrier Proteins; Cholesterol, Dietary; Drugs, Investigational; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Absorption; Phytosterols	2006
Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. Expert opinion on therapeutic targets, 2006, Volume: 10, Issue:6 Topics: Azetidines; Ezetimibe; Humans; Hypercholesterolemia; Hypolipidemic Agents	2006
[Cholesterol absorption as a target for the treatment of hypercholesterolemia]. Harefuah, 2006, Volume: 145, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, Dietary; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption	2006
[Ezetimibe--intestinal cholesterol absorbtion inhibitor]. Kardiologia polska, 2006, Volume: 64, Issue:12 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Drug Interactions; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Intestinal Mucosa; Intestines; Liver	2006
[Change in the cholesterol metabolism associated with the combined inhibition of synthesis and absorption]. Orvosi hetilap, 2007, Apr-08, Volume: 148, Issue:14 Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Cholestanol; Cholesterol; Cholesterol, Dietary; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Phytosterols; Sitosterols	2007
Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert opinion on drug metabolism & toxicology, 2007, Volume: 3, Issue:3 Topics: Anticholesteremic Agents; Area Under Curve; Azetidines; Cholesterol; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Molecular Structure; Treatment Outcome	2007
Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. Journal of atherosclerosis and thrombosis, 2007, Volume: 14, Issue:3 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Hyperlipidemias; Intestinal Absorption; Intestinal Mucosa; Intestines; Membrane Proteins; Membrane Transport Proteins; Niemann-Pick Diseases	2007
Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Current medical research and opinion, 2007, Volume: 23, Issue:8 Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Placebos; Randomized Controlled Trials as Topic; Triglycerides	2007
The pharmacologic elegance of inhibiting cholesterol absorption and synthesis while providing a homeostatic balance. Fundamental & clinical pharmacology, 2007, Volume: 21 Suppl 2 Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Ezetimibe; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Liver	2007
Ezetimibe-associated adverse effects: what the clinician needs to know. International journal of clinical practice, 2008, Volume: 62, Issue:1 Topics: Anticholesteremic Agents; Azetidines; Chemical and Drug Induced Liver Injury; Drug Interactions; Ezetimibe; Humans; Hypercholesterolemia; Muscular Diseases; Treatment Outcome	2008
Ezetimibe: cholesterol lowering and beyond. Expert review of cardiovascular therapy, 2008, Volume: 6, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Controlled Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia	2008
Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2008, Volume: 12, Issue:21 Topics: Anticholesteremic Agents; Azetidines; Cost-Benefit Analysis; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic	2008
Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. The American journal of cardiology, 2008, Jun-01, Volume: 101, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Gastrointestinal Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Lipids; Muscular Diseases; Randomized Controlled Trials as Topic; Risk Factors	2008
Novel approaches to lipid lowering: what is on the horizon? The American journal of cardiology, 2001, Mar-08, Volume: 87, Issue:5A Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Evaluation; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Prognosis	2001
Therapies on the horizon for cholesterol reduction. Clinical cardiology, 2001, Volume: 24, Issue:8 Suppl Topics: Acetamides; Acetates; Anticholesteremic Agents; Azetidines; Carrier Proteins; Cholestyramine Resin; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxysteroid Dehydrogenases; Hypercholesterolemia; Membrane Glycoproteins; Pyrimidines; Rosuvastatin Calcium; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids	2001
Cholesterol absorption inhibition: a strategy for cholesterol-lowering therapy. International journal of clinical practice, 2001, Volume: 55, Issue:10 Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Disease; Ezetimibe; Humans; Hypercholesterolemia	2001
An investigative look: selective cholesterol absorption inhibitors--embarking on a new standard of care. The American journal of managed care, 2002, Volume: 8, Issue:2 Suppl Topics: Anticholesteremic Agents; Azetidines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia	2002
Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management. International journal of clinical practice, 2002, Volume: 56, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Europe; Ezetimibe; Humans; Hypercholesterolemia; Practice Guidelines as Topic	2002

Trials

190 trial(s) available for ezetimibe and Elevated Cholesterol

Article	Year
Main differences between two highly effective lipid-lowering therapies in subclasses of lipoproteins in patients with acute myocardial infarction. Lipids in health and disease, 2021, Sep-29, Volume: 20, Issue:1 Topics: Aged; Atherosclerosis; Cholesterol; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Liver; Male; Middle Aged; Rosuvastatin Calcium; Simvastatin; ST Elevation Myocardial Infarction	2021
Insulin Prevents Hypercholesterolemia by Suppressing 12α-Hydroxylated Bile Acids. Circulation, 2022, 03-29, Volume: 145, Issue:13 Topics: Animals; Bile Acids and Salts; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 1; Ezetimibe; Humans; Hypercholesterolemia; Hyperlipidemias; Insulin; Liver; Mice; Receptor, Insulin; Simvastatin; Steroid 12-alpha-Hydroxylase	2022
Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia. The Journal of international medical research, 2022, Volume: 50, Issue:3 Topics: Adaptor Proteins, Signal Transducing; Anticholesteremic Agents; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Prospective Studies; Rosuvastatin Calcium; Tumor Suppressor Proteins	2022
Effect of 1PC111, a Fixed-dose Combination of Pitavastatin and Ezetimibe, Versus Pitavastatin or Ezetimibe Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia or Mixed Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase III Study. Clinical therapeutics, 2022, Volume: 44, Issue:10 Topics: Aged; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hypercholesterolemia	2022
Efficacy and Tolerability of Ezetimibe/Atorvastatin Fixed-dose Combination Versus Atorvastatin Monotherapy in Hypercholesterolemia: A Phase III, Randomized, Active-controlled Study in Chinese Patients. Clinical therapeutics, 2022, Volume: 44, Issue:10 Topics: Anticholesteremic Agents; Atorvastatin; China; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Treatment Outcome	2022
A Multicenter, Randomized, Double-blind, Active-controlled, Factorial Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hyp Clinical therapeutics, 2022, Volume: 44, Issue:10 Topics: Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Treatment Outcome	2022
Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2023, Volume: 23, Issue:1 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Quality of Life; Treatment Outcome	2023
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. The New England journal of medicine, 2022, 11-17, Volume: 387, Issue:20 Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein(a); Liver; PCSK9 Inhibitors; RNA, Small Interfering	2022
Effects of rosuvastatin/ezetimibe on senescence of CD8+ T-cell in type 2 diabetic patients with hypercholesterolemia: A study protocol. Medicine, 2022, Nov-25, Volume: 101, Issue:47 Topics: CD8-Positive T-Lymphocytes; Cholesterol, LDL; Cytokines; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Randomized Controlled Trials as Topic; Rosuvastatin Calcium	2022
Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Cli Advances in therapy, 2023, Volume: 40, Issue:12 Topics: Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Drug Combinations; East Asian People; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Rosuvastatin Calcium; Treatment Outcome	2023
Effectiveness of low-intensity atorvastatin 5 mg and ezetimibe 10 mg combination therapy compared with moderate-intensity atorvastatin 10 mg monotherapy: A randomized, double-blinded, multi-center, phase III study. Medicine, 2023, Nov-24, Volume: 102, Issue:47 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Treatment Outcome	2023
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Stu Diabetes & metabolism journal, 2023, Volume: 47, Issue:6 Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Rosuvastatin Calcium	2023
Ezetimibe and Rosuvastatin Combination Treatment Can Reduce the Dose of Rosuvastatin Without Compromising Its Lipid-lowering Efficacy. Clinical therapeutics, 2019, Volume: 41, Issue:12 Topics: Anticholesteremic Agents; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Lipids; Rosuvastatin Calcium; Treatment Outcome	2019
Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial. Journal of atherosclerosis and thrombosis, 2020, May-01, Volume: 27, Issue:5 Topics: Antibodies, Monoclonal, Humanized; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Outcome Assessment, Health Care	2020
Goal achievement of HbA1c and LDL-cholesterol in a randomized trial comparing colesevelam with ezetimibe: GOAL-RCT. Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:10 Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Glycated Hemoglobin; Goals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Treatment Outcome	2020
Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study - preliminary results. Cardiology journal, 2021, Volume: 28, Issue:1 Topics: Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Rosuvastatin Calcium; Treatment Outcome	2021
Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial. Atherosclerosis, 2021, Volume: 320 Topics: Anticholesteremic Agents; Atorvastatin; Dicarboxylic Acids; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Treatment Outcome	2021
Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction. Scientific reports, 2021, 08-05, Volume: 11, Issue:1 Topics: Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Lipids; Male; Middle Aged; Myocardial Infarction; Rosuvastatin Calcium; Simvastatin; ST Elevation Myocardial Infarction	2021
Effects of Fixed-dose Combination of Low-intensity Rosuvastatin and Ezetimibe Versus Moderate-intensity Rosuvastatin Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia: A Randomized, Double-blind, Multicenter, Phase III Study. Clinical therapeutics, 2021, Volume: 43, Issue:9 Topics: Anticholesteremic Agents; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Rosuvastatin Calcium; Treatment Outcome	2021
Thyroid Hormone Status in Sitosterolemia Is Modified by Ezetimibe. The Journal of pediatrics, 2017, Volume: 188 Topics: Adolescent; Adult; Anticholesteremic Agents; Cholestanol; Cholestenones; Cholesterol; Ezetimibe; Female; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Male; Middle Aged; Phytosterols; Sitosterols; Thyrotropin; Thyroxine; Triiodothyronine; Young Adult	2017
The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial. Trials, 2017, 07-11, Volume: 18, Issue:1 Topics: Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Clinical Protocols; Cross-Over Studies; Drug Administration Schedule; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Poland; Research Design; Rosuvastatin Calcium; Time Factors; Treatment Outcome	2017
Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). The American journal of cardiology, 2017, Sep-15, Volume: 120, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, LDL; Clinical Decision-Making; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Ezetimibe; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections, Subcutaneous; Male; Medication Adherence; Middle Aged; Time Factors; Treatment Outcome	2017
A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE Clinical therapeutics, 2018, Volume: 40, Issue:2 Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Republic of Korea; Rosuvastatin Calcium; Treatment Outcome	2018
Efficacy and Safety of Ezetimibe and Rosuvastatin Combination Therapy Versus Those of Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia. Clinical therapeutics, 2018, Volume: 40, Issue:6 Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Rosuvastatin Calcium; Treatment Outcome	2018
Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis, 2018, Volume: 277 Topics: Aged; Biomarkers; Canada; Cholesterol, LDL; Dicarboxylic Acids; Double-Blind Method; Down-Regulation; Drug Therapy, Combination; Europe; Ezetimibe; Fatty Acids; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Time Factors; Treatment Outcome; United States	2018
Cost-effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain. Revista espanola de cardiologia (English ed.), 2018, Volume: 71, Issue:12 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cost-Benefit Analysis; Drug Costs; Ezetimibe; Female; Follow-Up Studies; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Male; Middle Aged; Spain; Treatment Outcome	2018
Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. Journal of the American Heart Association, 2018, 09-18, Volume: 7, Issue:18 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Incidence; Male; Middle Aged; Sex Distribution; Sex Factors; Treatment Outcome; United Kingdom	2018
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. European journal of preventive cardiology, 2020, Volume: 27, Issue:6 Topics: Aged; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Dicarboxylic Acids; Double-Blind Method; Down-Regulation; Drug Combinations; Ezetimibe; Fatty Acids; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Time Factors; Treatment Outcome; United States	2020
The Bioequivalence and Effect of Food on the Pharmacokinetics of a Fixed-Dose Combination Tablet Containing Rosuvastatin and Ezetimibe in Healthy Japanese Subjects. Clinical and translational science, 2019, Volume: 12, Issue:6 Topics: Administration, Oral; Adult; Anticholesteremic Agents; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Fasting; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Hypercholesterolemia; Japan; Male; Middle Aged; Postprandial Period; Rosuvastatin Calcium; Tablets; Therapeutic Equivalency; Young Adult	2019
Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial). The American journal of cardiology, 2013, Jun-01, Volume: 111, Issue:11 Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Revascularization; Retrospective Studies; Secondary Prevention; Simvastatin; Treatment Outcome	2013
Are there differences in LDL-C target value attainment in Austrian federal states? Yes! Wiener medizinische Wochenschrift (1946), 2013, Volume: 163, Issue:23-24 Topics: Aged; Anticholesteremic Agents; Austria; Azetidines; Cholesterol, LDL; Cross-Sectional Studies; Drug Resistance; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Retreatment; Topography, Medical	2013
Observational study of ezetimibe discontinuation in primary care practices in the UK. Current medical research and opinion, 2013, Volume: 29, Issue:12 Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol; Databases, Factual; Drug Substitution; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Primary Health Care; Risk Factors; Time Factors; United Kingdom	2013
Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids in health and disease, 2013, Sep-22, Volume: 12 Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides	2013
Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. The American journal of cardiology, 2013, Dec-15, Volume: 112, Issue:12 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides	2013
RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese Lipids in health and disease, 2013, Oct-05, Volume: 12 Topics: Age Factors; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Glycated Hemoglobin; Humans; Hypercholesterolemia; Male; Middle Aged; Sex Factors; Simvastatin	2013
Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis, 2013, Volume: 231, Issue:1 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Azetidines; Cholesterol, LDL; Dinoprost; Drug Combinations; Ezetimibe; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2013
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis, 2014, Volume: 232, Issue:1 Topics: Absorption; Adult; Atherosclerosis; Azetidines; Biomarkers; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Male; Pyrimidines; Risk; Rosuvastatin Calcium; Simvastatin; Sitosterols; Sulfonamides; Treatment Outcome	2014
Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years. Lipids in health and disease, 2014, Jan-13, Volume: 13 Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Canada; Cholesterol, LDL; Double-Blind Method; Europe; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Treatment Outcome	2014
Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. Clinical cardiology, 2014, Volume: 37, Issue:3 Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Azetidines; Cholesterol; Cholesterol, LDL; Contraindications; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Injections, Subcutaneous; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases; Triglycerides	2014
Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. Clinical cardiology, 2014, Volume: 37, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Azetidines; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Treatment Outcome; Young Adult	2014
Effects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men-a randomized trial. PloS one, 2014, Volume: 9, Issue:3 Topics: Adipokines; Adult; Azetidines; Biomarkers; Drug Therapy, Combination; Ezetimibe; Glucose; Healthy Volunteers; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, HDL; Male; Simvastatin	2014
Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada. American heart journal, 2014, Volume: 167, Issue:5 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Canada; Cholesterol; Disease Progression; Dose-Response Relationship, Drug; Drug Costs; Drug Prescriptions; Ezetimibe; Follow-Up Studies; Humans; Hypercholesterolemia; Prevalence; Retrospective Studies; Time Factors; Treatment Outcome; United States	2014
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA, 2014, May-14, Volume: 311, Issue:18 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Azetidines; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2014
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. International journal of cardiology, 2014, Volume: 176, Issue:1 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Azetidines; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases	2014
Simvastatin but not ezetimibe reduces sympathetic activity despite similar reductions in cholesterol levels. Journal of the American Society of Hypertension : JASH, 2014, Volume: 8, Issue:10 Topics: Adult; Anticholesteremic Agents; Azetidines; Baroreflex; Cholesterol; Cholesterol, HDL; Double-Blind Method; Ezetimibe; Female; Heart Rate; Hemodynamics; Humans; Hypercholesterolemia; Male; Middle Aged; Muscle, Skeletal; Simvastatin; Sympathetic Nervous System	2014
Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response model. Fundamental & clinical pharmacology, 2015, Volume: 29, Issue:2 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged	2015
Ezetimibe reduces plant sterol accumulation and favorably increases platelet count in sitosterolemia. The Journal of pediatrics, 2015, Volume: 166, Issue:1 Topics: Adolescent; Adult; Anticholesteremic Agents; Azetidines; Canada; Cholesterol; Erythrocyte Count; Ezetimibe; Female; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Male; Middle Aged; Phytosterols; Pilot Projects; Platelet Count; Treatment Outcome; United States; Young Adult	2015
Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia. Lipids in health and disease, 2015, Jan-10, Volume: 14 Topics: Atherosclerosis; Biomarkers; Drug Therapy, Combination; Ezetimibe; Female; Hepatocyte Growth Factor; Humans; Hypercholesterolemia; Insulin Resistance; Lipids; Male; Middle Aged; Obesity	2015
ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. Future cardiology, 2015, Volume: 11, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Ezetimibe; Female; Humans; Hypercholesterolemia; Injections, Subcutaneous; Male; Middle Aged	2015
[IMPROVE-IT Study proves effectiveness of ezetimib. The Higgs particle of lipidologists]. MMW Fortschritte der Medizin, 2014, Dec-15, Volume: 156, Issue:21-22 Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Simvastatin	2014
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. European heart journal, 2015, May-14, Volume: 36, Issue:19 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Injections, Subcutaneous; Male; Maximum Tolerated Dose; Middle Aged; Treatment Outcome	2015
Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. The Journal of pediatrics, 2015, Volume: 166, Issue:6 Topics: Anticholesteremic Agents; Azetidines; Child; Double-Blind Method; Ezetimibe; Female; Heterozygote; Humans; Hypercholesterolemia; Male; Single-Blind Method; Treatment Outcome	2015
Modulation of adhesion molecules by cholesterol-lowering therapy in mononuclear cells from hypercholesterolemic patients. Cardiovascular therapeutics, 2015, Volume: 33, Issue:4 Topics: Aged; Atorvastatin; Biomarkers; Cell Adhesion Molecules; Cell Line; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Male; Middle Aged; RNA, Messenger; Simvastatin; Treatment Outcome	2015
A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia. Lipids in health and disease, 2015, May-01, Volume: 14 Topics: Anticholesteremic Agents; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Ezetimibe; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypercholesterolemia; Male; Middle Aged; Serum Albumin; Triglycerides	2015
Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. Lipids in health and disease, 2015, May-19, Volume: 14 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Patient Care Planning; Practice Patterns, Physicians'; Rosuvastatin Calcium; Surveys and Questionnaires	2015
[Even lower values are even better!]. MMW Fortschritte der Medizin, 2015, Aug-20, Volume: 157, Issue:14 Topics: Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Myocardial Infarction; Risk Factors; Simvastatin; Stroke	2015
[What is the use of even lower LDL cholesterol by combination therapy? A critical viewpoint]. Deutsche medizinische Wochenschrift (1946), 2015, Volume: 140, Issue:17 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Comorbidity; Drug Therapy, Combination; Evidence-Based Medicine; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Prevalence; Risk Factors; Stroke; Survival Rate; Treatment Outcome	2015
Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk. Lipids in health and disease, 2015, Sep-04, Volume: 14 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Blood Pressure; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Insulin Resistance; Lipoproteins, HDL; Male; Metabolic Syndrome; Middle Aged; Obesity, Abdominal; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides	2015
Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. Atherosclerosis, 2016, Volume: 244 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Injections, Subcutaneous; Retrospective Studies; Rosuvastatin Calcium; Time Factors; Treatment Outcome	2016
Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hypercholesterolemia. Atherosclerosis, 2016, Volume: 247 Topics: Aged; Anticholesteremic Agents; Biomarkers; Cell Adhesion; Cell Adhesion Molecules; Cells, Cultured; Cholesterol; Coculture Techniques; Endothelial Cells; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hypercholesterolemia; Leukocytes; Male; Membrane Potential, Mitochondrial; Middle Aged; Mitochondria; Oxidative Stress; Simvastatin; Spain; Time Factors; Treatment Outcome	2016
Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study. Cardiovascular drugs and therapy, 2016, Volume: 30, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscular Diseases; PCSK9 Inhibitors; Young Adult	2016
Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. Clinical cardiology, 2016, Volume: 39, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoprotein B-100; Biomarkers; Cholesterol, LDL; Clinical Protocols; Double-Blind Method; Ezetimibe; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; PCSK9 Inhibitors; Proprotein Convertase 9; Research Design; Time Factors; Treatment Outcome	2016
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA, 2016, Apr-19, Volume: 315, Issue:15 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol, LDL; Creatine Kinase; Cross-Over Studies; Double-Blind Method; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscular Diseases; Myalgia; Myositis; Rhabdomyolysis; Time Factors	2016
[Approval extension for statin plus ezetimib]. MMW Fortschritte der Medizin, 2016, Mar-31, Volume: 158, Issue:6 Topics: Acute Coronary Syndrome; Drug Approval; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin	2016
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. Cardiovascular drugs and therapy, 2016, Volume: 30, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins B; Cholesterol; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; PCSK9 Inhibitors; Treatment Outcome; Triglycerides; Young Adult	2016
Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies. Journal of the American Heart Association, 2016, 06-10, Volume: 5, Issue:6 Topics: Administration, Oral; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Proprotein Convertase 9; Young Adult	2016
Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovascular therapeutics, 2016, Volume: 34, Issue:5 Topics: Aged; Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Republic of Korea; Rosuvastatin Calcium; Time Factors; Treatment Outcome; Triglycerides	2016
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. Journal of the American Heart Association, 2016, 09-13, Volume: 5, Issue:9 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, LDL; Combined Modality Therapy; Diet Therapy; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hypercholesterolemia; Hypolipidemic Agents; Injection Site Reaction; Male; Middle Aged; PCSK9 Inhibitors; Treatment Outcome	2016
Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program). The American journal of cardiology, 2017, Jan-01, Volume: 119, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein(a); Male; Middle Aged; Treatment Outcome	2017
Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients. Pharmaceutical research, 2017, Volume: 34, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Anticholesteremic Agents; Ezetimibe; Female; Healthy Volunteers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunoglobulin G; Male; Middle Aged; Proprotein Convertase 9; Young Adult	2017
Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. The American journal of cardiology, 2017, Feb-01, Volume: 119, Issue:3 Topics: Aged; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Niacin; Oxazolidinones; Treatment Outcome	2017
Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk. Clinical therapeutics, 2017, Volume: 39, Issue:1 Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Risk Factors; Rosuvastatin Calcium; Treatment Outcome; Triglycerides	2017
Effect of two lipid-lowering strategies on high-density lipoprotein function and some HDL-related proteins: a randomized clinical trial. Lipids in health and disease, 2017, Feb-28, Volume: 16, Issue:1 Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Treatment Outcome; Vascular Cell Adhesion Molecule-1	2017
The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Current medical research and opinion, 2008, Volume: 24, Issue:7 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Anti-Obesity Agents; Anticholesteremic Agents; Azetidines; Body Mass Index; Caloric Restriction; Cholesterol, LDL; Diet, Fat-Restricted; Drug Therapy, Combination; Ezetimibe; Female; gamma-Glutamyltransferase; Homeostasis; Humans; Hypercholesterolemia; Lactones; Male; Middle Aged; Obesity; Orlistat; Overweight; Treatment Outcome; Uric Acid	2008
Safety and efficacy of ezetimibe monotherapy in 1624 primary hypercholesterolaemic patients for up to 2 years. International journal of clinical practice, 2008, Volume: 62, Issue:9 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Double-Blind Method; Ezetimibe; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged	2008
The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. Journal of cardiovascular pharmacology, 2008, Volume: 52, Issue:2 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Cross-Over Studies; Dietary Fats; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Postprandial Period; Prospective Studies; Simvastatin; Triglycerides	2008
Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice. Current medical research and opinion, 2008, Volume: 24, Issue:10 Topics: Administration, Oral; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Cohort Studies; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Professional Practice; Prospective Studies; Risk Factors; Simvastatin; Time Factors; Triglycerides	2008
Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Oct-15, Volume: 47, Issue:8 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Azetidines; Cholesterol, LDL; Ezetimibe; Female; HIV Infections; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos	2008
Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. Current medical research and opinion, 2008, Volume: 24, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Ezetimibe; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Time Factors	2008
Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2-year, open-label extension study. International journal of clinical practice, 2008, Volume: 62, Issue:10 Topics: Achilles Tendon; Adolescent; Adult; Aged; Anticholesteremic Agents; Azetidines; Child; Double-Blind Method; Ezetimibe; Female; Homozygote; Humans; Hypercholesterolemia; Male; Middle Aged; Sitosterols; Treatment Outcome; Young Adult	2008
Ezetimibe 5 and 10 mg for lowering LDL-C: potential billion-dollar savings with improved tolerability. The American journal of managed care, 2008, Volume: 14, Issue:10 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Ezetimibe; Female; Heptanoic Acids; Hospitals, Veterans; Humans; Hypercholesterolemia; Male; Pyrroles	2008
Long-term safety and tolerability of ezetimibe coadministered with simvastatin in hypercholesterolemic patients: a randomized, 12-month double-blind extension study. Current medical research and opinion, 2008, Volume: 24, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Azetidines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Simvastatin; Time Factors; Treatment Outcome	2008
Use of ezetimibe during HIV infection. The Journal of antimicrobial chemotherapy, 2009, Volume: 63, Issue:1 Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; HIV Infections; Humans; Hypercholesterolemia; Treatment Outcome	2009
Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. The American journal of cardiology, 2008, Dec-01, Volume: 102, Issue:11 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pyrroles; Risk Assessment; Risk Factors; Treatment Outcome	2008
Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. The American journal of cardiology, 2008, Dec-01, Volume: 102, Issue:11 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Assessment; Treatment Outcome	2008
Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients. Clinical therapeutics, 2008, Volume: 30, Issue:12 Topics: Adult; Aged; Anticholesteremic Agents; Arthralgia; Azetidines; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Headache; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Patient Dropouts; Pravastatin; Respiratory Tract Infections; Simvastatin; Sinusitis; Treatment Outcome; Triglycerides	2008
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. International journal of clinical practice, 2009, Volume: 63, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2009
Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. Journal of lipid research, 2009, Volume: 50, Issue:10 Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol; Double-Blind Method; Drug Combinations; Ezetimibe; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Young Adult	2009
Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:9 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Young Adult	2009
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). The American journal of cardiology, 2009, Jun-15, Volume: 103, Issue:12 Topics: Adolescent; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Young Adult	2009
Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents. Journal of pediatric endocrinology & metabolism : JPEM, 2009, Volume: 22, Issue:6 Topics: Adolescent; Anticholesteremic Agents; Azetidines; Child; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Female; Humans; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Male; Prospective Studies; Treatment Outcome; Triglycerides	2009
Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients. AIDS (London, England), 2009, Oct-23, Volume: 23, Issue:16 Topics: Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Azetidines; CD4 Lymphocyte Count; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged	2009
Pleiotropic effects with equivalent low-density lipoprotein cholesterol reduction: comparative study between simvastatin and simvastatin/ezetimibe coadministration. Journal of cardiovascular pharmacology, 2010, Volume: 55, Issue:1 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Azetidines; Brachial Artery; C-Reactive Protein; Cholesterol, LDL; Cross-Over Studies; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Ultrasonography; Vasodilation; Young Adult	2010
Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterol-lowering effect in patients with type 2 diabetes and hypercholesterolemia. Internal medicine (Tokyo, Japan), 2009, Volume: 48, Issue:21 Topics: Aged; Alkaline Phosphatase; Amino Acids; Azetidines; Bone and Bones; Cholesterol; Cholesterol, LDL; Collagen Type I; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Osteocalcin; Peptides; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2009
Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:12 Topics: Aged; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Azetidines; Cardiovascular Diseases; Cholesterol; Creatine Kinase; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Fatty Liver; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Metabolic Syndrome; Middle Aged; Retrospective Studies; Risk Factors; Simvastatin; Triglycerides	2009
Ezetimibe effect on bone mineral density and markers of bone formation and resorption. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2010, Volume: 58, Issue:2 Topics: Alkaline Phosphatase; Anticholesteremic Agents; Azetidines; Biomarkers; Bone Density; Bone Remodeling; Collagen Type I; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipids; Male; Peptide Fragments	2010
Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Canada; Coronary Artery Disease; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; United States; Young Adult	2010
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. International journal of clinical practice, 2010, Volume: 64, Issue:8 Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; General Practice; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Treatment Outcome	2010
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy. Cardiovascular therapeutics, 2012, Volume: 30, Issue:2 Topics: Anticholesteremic Agents; Apolipoproteins B; Azetidines; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Odds Ratio; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2012
Lipid-lowering effects of ezetimibe for hypercholesterolemic patients with and without type 2 diabetes mellitus. Endocrine journal, 2010, Volume: 57, Issue:10 Topics: Aged; Azetidines; Biomarkers; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Cholestanol; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Phytosterols; Sitosterols	2010
Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease. International journal of cardiology, 2011, Dec-01, Volume: 153, Issue:2 Topics: Adolescent; Adult; Age Factors; Aged; Atorvastatin; Azetidines; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Racial Groups; Risk Factors; Sex Factors; Treatment Outcome; Young Adult	2011
Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study). The American journal of cardiology, 2010, Nov-01, Volume: 106, Issue:9 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Logistic Models; Male; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome	2010
Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. Lipids in health and disease, 2010, Nov-04, Volume: 9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult	2010
The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Current medical research and opinion, 2011, Volume: 27, Issue:3 Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Combinations; Ezetimibe; Female; Follow-Up Studies; Greece; Humans; Hypercholesterolemia; Male; Middle Aged; Osmolar Concentration; Particle Size; Simvastatin	2011
The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia. Journal of cardiovascular pharmacology, 2011, Volume: 57, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Cytokines; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Monocytes; Risk Factors; Simvastatin; Time Factors	2011
The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A₂. Clinical cardiology, 2011, Volume: 34, Issue:2 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers, Pharmacological; Chemokine CCL2; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Male; Middle Aged; Pyrroles; Treatment Outcome; Young Adult	2011
Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. International journal of cardiology, 2012, Jul-26, Volume: 158, Issue:3 Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Synergism; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Platelet Aggregation; Simvastatin	2012
Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. Clinical biochemistry, 2011, Volume: 44, Issue:8-9 Topics: Aged; Apolipoproteins B; Azetidines; Cholesterol; Coronary Disease; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2011
Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress. Lipids, 2011, Volume: 46, Issue:4 Topics: Aged; Anticholesteremic Agents; Azetidines; Biomarkers; Dinoprost; Ezetimibe; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress	2011
Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes. The journal of medical investigation : JMI, 2011, Volume: 58, Issue:1-2 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged	2011
The effect of ezetimibe and simvastatin on hemostasis in patients with isolated hypercholesterolemia. Fundamental & clinical pharmacology, 2012, Volume: 26, Issue:3 Topics: Adult; Aged; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Hemostasis; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Treatment Outcome; Young Adult	2012
Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). The American journal of cardiology, 2011, Aug-15, Volume: 108, Issue:4 Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2011
The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels. Journal of internal medicine, 2012, Volume: 271, Issue:1 Topics: Anticholesteremic Agents; Azetidines; Cytokines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Inflammation; Lymphocytes; Male; Middle Aged; Prospective Studies; Simvastatin	2012
Begin with the real-world patients of non-goal-achieved hypercholesterolemia in taiwan through the ezetimibe/simvastatin tablet - The BRAVO Study. Current medical research and opinion, 2011, Volume: 27, Issue:8 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Taiwan; Time Factors; Triglycerides	2011
Combined effects of ezetimibe and phytosterols on cholesterol metabolism: a randomized, controlled feeding study in humans. Circulation, 2011, Aug-02, Volume: 124, Issue:5 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, Dietary; Cholesterol, LDL; Combined Modality Therapy; Drug Synergism; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipid Metabolism; Male; Middle Aged; Phytosterols; Young Adult	2011
The role of soluble fiber intake in patients under highly effective lipid-lowering therapy. Nutrition journal, 2011, Aug-02, Volume: 10 Topics: Azetidines; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dietary Fiber; Ezetimibe; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Male; Middle Aged; Phytosterols; Pyrimidines; Rosuvastatin Calcium; Sitosterols; Sulfonamides; Triglycerides	2011
Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. International journal of clinical practice, 2011, Volume: 65, Issue:11 Topics: Aged; Azetidines; Blood Glucose; Body Mass Index; Cholesterol, LDL; Drug Combinations; Ezetimibe; Fasting; Female; Fluorobenzenes; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Male; Medication Adherence; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2011
Influence of ezetimibe monotherapy on ischemia-modified albumin levels in hypercholesterolemic patients. Pharmacological reports : PR, 2011, Volume: 63, Issue:5 Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Cholesterol, LDL; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Oxidative Stress; Prospective Studies; Regression Analysis; Risk Factors; Serum Albumin; Serum Albumin, Human	2011
Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy. Amino acids, 2012, Volume: 43, Issue:4 Topics: Aged; Allantoin; Azetidines; Drug Administration Schedule; Drug Combinations; Ezetimibe; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Kidney; Kidney Failure, Chronic; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Simvastatin; Sulfhydryl Compounds; Superoxides; Taurine; Uric Acid	2012
Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study. Lipids in health and disease, 2012, Jan-31, Volume: 11 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome	2012
Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers. Clinical pharmacology and therapeutics, 2012, Volume: 91, Issue:3 Topics: Adult; Alkynes; Animals; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azetidines; Benzoxazines; Biological Transport; Cell Line; Cell Line, Transformed; Cyclopropanes; Cytochrome P-450 CYP3A; Dogs; Drug Interactions; Ezetimibe; Gene Expression; Glucuronosyltransferase; HEK293 Cells; HIV Infections; Humans; Hypercholesterolemia; Intestinal Absorption; Intestinal Mucosa; Intestines; Liver; Liver-Specific Organic Anion Transporter 1; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; RNA, Messenger; Young Adult	2012
Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial. BMC research notes, 2012, May-23, Volume: 5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intention to Treat Analysis; Lipids; Male; Middle Aged; Taiwan; Treatment Outcome; Young Adult	2012
Double-dose pravastatin versus add-on ezetimibe with low-dose pravastatin - effects on LDL cholesterol, cholesterol absorption, and cholesterol synthesis in Japanese patients with hypercholesterolemia (PEAS study). Journal of atherosclerosis and thrombosis, 2012, Volume: 19, Issue:5 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Middle Aged; Patient Compliance; Pravastatin	2012
Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia. European journal of clinical pharmacology, 2013, Volume: 69, Issue:3 Topics: Adult; Anticholesteremic Agents; Azetidines; Biomarkers; Brachial Artery; Cholesterol; Endothelium, Vascular; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Male; Middle Aged; Pravastatin; Severity of Illness Index; Treatment Outcome; Ultrasonography; Vasodilation	2013
Differences in synthesis and absorption of cholesterol of two effective lipid-lowering therapies. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2012, Volume: 45, Issue:11 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2012
Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. Lipids in health and disease, 2012, Sep-22, Volume: 11 Topics: Aged; Anticholesteremic Agents; Azetidines; Berberine; Biological Products; Cholesterol, LDL; Dietary Supplements; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Fatty Alcohols; Female; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Mutation; Receptors, LDL; Statistics, Nonparametric; Triglycerides	2012
Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study. European journal of clinical investigation, 2012, Volume: 42, Issue:12 Topics: Adiponectin; Aged; Anticholesteremic Agents; Azetidines; Ezetimibe; Female; Humans; Hypercholesterolemia; Intra-Abdominal Fat; Male; Metabolic Syndrome; Middle Aged; Tomography, X-Ray Computed	2012
Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients. Atherosclerosis, 2012, Volume: 225, Issue:2 Topics: Aged; Anticholesteremic Agents; Apolipoproteins; Azetidines; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Male; Middle Aged; Multivariate Analysis; Sitosterols; Time Factors; Treatment Outcome; United States	2012
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 stu Lancet (London, England), 2012, Dec-08, Volume: 380, Issue:9858 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunoglobulin G; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases; Treatment Outcome; Young Adult	2012
Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. Journal of atherosclerosis and thrombosis, 2013, Volume: 20, Issue:3 Topics: Adult; Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hypercholesterolemia; Indoles; Kidney Function Tests; Male; Middle Aged	2013
Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation, 2002, Oct-08, Volume: 106, Issue:15 Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol; Cross-Over Studies; Double-Blind Method; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Absorption; Lipoproteins; Male; Middle Aged; Sterols	2002
Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. The American journal of cardiology, 2002, Nov-15, Volume: 90, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Quebec; Treatment Outcome; Triglycerides; United States	2002
Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. The American journal of cardiology, 2002, Nov-15, Volume: 90, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, HDL3; Male; Middle Aged; Treatment Outcome; Triglycerides; United States	2002
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. Journal of the American College of Cardiology, 2002, Dec-18, Volume: 40, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Simvastatin; Treatment Outcome	2002
Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. The American journal of cardiology, 2003, Feb-15, Volume: 91, Issue:4 Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipoprotein(a); Lovastatin; Male; Middle Aged; Practice Guidelines as Topic; Safety; Treatment Outcome; Triglycerides	2003
Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. European heart journal, 2003, Volume: 24, Issue:8 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pravastatin; Treatment Outcome; Vitamins	2003
Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. European heart journal, 2003, Volume: 24, Issue:8 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Cosyntropin; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Single-Blind Method; Triglycerides; Vitamins	2003
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation, 2003, May-20, Volume: 107, Issue:19 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Digestive System; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Musculoskeletal Diseases; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides	2003
Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. International journal of clinical practice, 2003, Volume: 57, Issue:5 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diet Records; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Liver Function Tests; Male; Middle Aged; Patient Satisfaction; Single-Blind Method	2003
Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. The American journal of cardiology, 2003, Dec-15, Volume: 92, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Treatment Outcome; Triglycerides	2003
Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clinic proceedings, 2004, Volume: 79, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Treatment Outcome	2004
Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. The American journal of cardiology, 2004, Jun-15, Volume: 93, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Practice Guidelines as Topic; Risk Factors; Simvastatin; Treatment Outcome	2004
Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. The American journal of cardiology, 2004, Jun-15, Volume: 93, Issue:12 Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Azetidines; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome	2004
Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. International journal of clinical practice, 2004, Volume: 58, Issue:7 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Treatment Outcome	2004
Pharmacodynamic interaction between ezetimibe and rosuvastatin. Current medical research and opinion, 2004, Volume: 20, Issue:8 Topics: Adult; Anticholesteremic Agents; Azetidines; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pilot Projects; Pyrimidines; Rosuvastatin Calcium; Single-Blind Method; Sulfonamides; Treatment Outcome	2004
Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Current medical research and opinion, 2004, Volume: 20, Issue:8 Topics: Adult; Azetidines; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pilot Projects; Single-Blind Method; Treatment Outcome	2004
Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. International journal of clinical practice, 2004, Volume: 58, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Treatment Outcome	2004
Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Current medical research and opinion, 2004, Volume: 20, Issue:9 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Complications; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Metabolic Syndrome; Middle Aged	2004
Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. American heart journal, 2004, Volume: 148, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Triglycerides	2004
Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs & aging, 2004, Volume: 21, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Aging; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Azetidines; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Drug Interactions; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged	2004
A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary Clinical therapeutics, 2004, Volume: 26, Issue:11 Topics: Administration, Oral; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Azetidines; Cholesterol, LDL; Data Interpretation, Statistical; Double-Blind Method; Drug Combinations; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Tablets; Triglycerides	2004
Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis, 2005, Volume: 179, Issue:2 Topics: Aged; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Simvastatin	2005
Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Clinical therapeutics, 2005, Volume: 27, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Simvastatin; Time Factors	2005
Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins. Atherosclerosis, 2005, Volume: 180, Issue:1 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Combined Modality Therapy; Cross-Over Studies; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides	2005
Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplantation proceedings, 2005, Volume: 37, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Female; Humans; Hypercholesterolemia; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Postoperative Complications	2005
Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. American heart journal, 2005, Volume: 149, Issue:3 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin	2005
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clinic proceedings, 2005, Volume: 80, Issue:5 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Nephelometry and Turbidimetry; Practice Guidelines as Topic; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin	2005
LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Current medical research and opinion, 2005, Volume: 21, Issue:4 Topics: Administration, Oral; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Simvastatin; Treatment Outcome	2005
Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. International journal of clinical practice, 2005, Volume: 59, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Safety	2005
Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. International journal of cardiology, 2005, Jul-10, Volume: 102, Issue:2 Topics: Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; International Cooperation; Male; Middle Aged; Prospective Studies; Safety; Simvastatin; Treatment Outcome; Triglycerides	2005
The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe. Current medical research and opinion, 2005, Volume: 21, Issue:8 Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged	2005
Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. International journal of clinical practice, 2005, Volume: 59, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Europe; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Taiwan; Treatment Outcome	2005
Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2006, Volume: 6, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Cyclosporine; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Kidney Transplantation; Liver; Male; Middle Aged; Muscle, Skeletal; Pravastatin; Simvastatin; Tacrolimus	2006
Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins. Metabolism: clinical and experimental, 2006, Volume: 55, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Triglycerides	2006
Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia. Journal of the National Medical Association, 2006, Volume: 98, Issue:5 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Black or African American; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Safety; Simvastatin; Treatment Outcome	2006
Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia. International journal of clinical practice, 2006, Volume: 60, Issue:8 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Treatment Outcome	2006
Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness t Mayo Clinic proceedings, 2006, Volume: 81, Issue:9 Topics: Anticholesteremic Agents; Azetidines; Black or African American; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Hispanic or Latino; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; United States; White People	2006
Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study--the Ezetrol Add-On Study. The Canadian journal of cardiology, 2006, Volume: 22, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Canada; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Safety; Treatment Outcome	2006
Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Current medical research and opinion, 2006, Volume: 22, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Allylamine; Apolipoprotein A-I; Apolipoproteins B; Azetidines; Cholesterol; Colesevelam Hydrochloride; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Patient Compliance; Treatment Outcome	2006
Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. Metabolism: clinical and experimental, 2006, Volume: 55, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Colesevelam Hydrochloride; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Pilot Projects; Triglycerides	2006
Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clinic proceedings, 2006, Volume: 81, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin	2006
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). The American journal of cardiology, 2007, Mar-01, Volume: 99, Issue:5 Topics: Aged; Azetidines; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2007
Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? Journal of the American College of Cardiology, 2007, Mar-13, Volume: 49, Issue:10 Topics: Atorvastatin; Azetidines; Blood Chemical Analysis; Blood Platelets; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Probability; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome	2007
Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Current medical research and opinion, 2007, Volume: 23, Issue:4 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome	2007
Co-administration of ezetimibe and simvastatin in acute myocardial infarction. European journal of clinical investigation, 2007, Volume: 37, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Simvastatin; Triglycerides	2007
Effects of ezetimibe on lipids and lipoproteins in patients with hypercholesterolemia and different apolipoprotein E genotypes. Current medical research and opinion, 2007, Volume: 23, Issue:7 Topics: Alleles; Anticholesteremic Agents; Apolipoproteins E; Azetidines; Ezetimibe; Female; Genotype; Humans; Hungary; Hypercholesterolemia; Lipid Metabolism; Lipids; Lipoproteins; Male; Middle Aged	2007
A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet. International journal of clinical practice, 2007, Volume: 61, Issue:9 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Combinations; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Tablets; Treatment Outcome	2007
Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin. The Annals of pharmacotherapy, 2007, Volume: 41, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Metabolic Syndrome; Middle Aged; Risk	2007
New medications which decrease levothyroxine absorption. Thyroid : official journal of the American Thyroid Association, 2007, Volume: 17, Issue:8 Topics: Adult; Anticholesteremic Agents; Azetidines; Chelating Agents; Drug Interactions; Ezetimibe; Female; Humans; Hypercholesterolemia; Hypothyroidism; Intestinal Absorption; Iron Chelating Agents; Male; Picolinic Acids; Polyamines; Sevelamer; Thyroxine	2007
Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:1 Topics: Anticholesteremic Agents; Azetidines; Case-Control Studies; Ezetimibe; Female; Humans; Hypercholesterolemia; Kidney Transplantation; Male; Middle Aged; Pilot Projects; Postoperative Complications; Prospective Studies	2008
Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. Current medical research and opinion, 2008, Volume: 24, Issue:1 Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Phytosterols; Placebos; Simvastatin; Sitosterols; Sterols	2008
SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-absorption in response to ezetimibe treatment. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2008, Volume: 116, Issue:5 Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol; Ezetimibe; Gene Frequency; Genotype; Humans; Hypercholesterolemia; Intestinal Absorption; Male; Polymorphism, Single Nucleotide; Regression Analysis; Simvastatin; Sterol Regulatory Element Binding Protein 1	2008
Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clinical therapeutics, 2007, Volume: 29, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Method; Drug Combinations; Endpoint Determination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Particle Size; Simvastatin	2007
Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. International journal of clinical practice, 2008, Volume: 62, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Myocardial Infarction; Simvastatin; Treatment Outcome	2008
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. The American journal of cardiology, 2008, Feb-15, Volume: 101, Issue:4 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Creatinine; Diabetes Mellitus; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Peripheral Vascular Diseases; Prospective Studies; Pyrroles; Stroke	2008
Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-labe Clinical therapeutics, 2008, Volume: 30, Issue:1 Topics: Anticholesteremic Agents; Apolipoproteins B; Azetidines; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Interleukin-1beta; Male; Middle Aged; Triglycerides	2008
The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia. International journal of cardiology, 2009, May-15, Volume: 134, Issue:2 Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged	2009
Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5, Issue:8 Topics: Aged; Anticholesteremic Agents; Azetidines; Benzimidazoles; Carrier Proteins; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Microsomes; Middle Aged; Severity of Illness Index; Treatment Outcome	2008
The plasma concentration and LDL-C relationship in patients receiving ezetimibe. Journal of clinical pharmacology, 2001, Volume: 41, Issue:9 Topics: Adolescent; Adult; Aged; Algorithms; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Chromatography, Liquid; Dose-Response Relationship, Drug; Ezetimibe; Female; Humans; Hypercholesterolemia; Linear Models; Male; Mass Spectrometry; Middle Aged	2001
Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clinical therapeutics, 2001, Volume: 23, Issue:8 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged	2001

Other Studies

286 other study(ies) available for ezetimibe and Elevated Cholesterol

Article	Year
One-step modification to identify dual-inhibitors targeting both pancreatic triglyceride lipase and Niemann-Pick C1-like 1. European journal of medicinal chemistry, 2021, Apr-15, Volume: 216 Topics: Anticholesteremic Agents; Binding Sites; Cell Line, Tumor; Drug Design; Ezetimibe; Gene Expression Regulation; Humans; Hypercholesterolemia; Lipase; Membrane Transport Proteins; Molecular Docking Simulation; Molecular Dynamics Simulation; Orlistat; Pancreas	2021
Management of Severe and Moderate Hypercholesterolemia in Young Women and Men. JAMA cardiology, 2022, 02-01, Volume: 7, Issue:2 Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Disease Management; Ezetimibe; Female; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; PCSK9 Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Registries; Severity of Illness Index; Sex Factors; Young Adult	2022
Ezetimibe and Insulin Resistance. Current vascular pharmacology, 2022, Volume: 20, Issue:4 Topics: Anticholesteremic Agents; Ezetimibe; Humans; Hypercholesterolemia; Insulin Resistance	2022
Plant sterol hyperabsorption caused by uncontrolled diabetes in a patient with a heterozygous ABCG5 variant. Journal of diabetes investigation, 2022, Volume: 13, Issue:11 Topics: ATP Binding Cassette Transporter, Subfamily G, Member 5; Diabetes Mellitus; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Lipoproteins; Phytosterols	2022
Effect of cholesterol-lowering agents on soluble epidermal growth factor receptor level in type 2 diabetes and hypercholesterolemia. Medicine, 2022, Aug-26, Volume: 101, Issue:34 Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; ErbB Receptors; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Rosuvastatin Calcium; Treatment Outcome	2022
First Discovery of Cholesterol-Lowering Activity of Parthenolide as NPC1L1 Inhibitor. Molecules (Basel, Switzerland), 2022, Sep-23, Volume: 27, Issue:19 Topics: Anticholesteremic Agents; Cholesterol; Ezetimibe; Filipin; Humans; Hypercholesterolemia; Hyperlipidemias; Membrane Transport Proteins; Molecular Docking Simulation; Sesquiterpenes	2022
Establishment of a lipid metabolism disorder model in ApoEb mutant zebrafish. Atherosclerosis, 2022, Volume: 361 Topics: Animals; Apolipoproteins E; Atherosclerosis; Ezetimibe; Hypercholesterolemia; Hyperlipidemias; Lipid Metabolism; Mammals; Simvastatin; Zebrafish	2022
Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain. Atherosclerosis, 2023, Volume: 375 Topics: Anticholesteremic Agents; Cholesterol, LDL; Cross-Sectional Studies; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Perception; Proprotein Convertase 9; Spain; Treatment Outcome	2023
Sitosterolaemia presenting with consistent skin xanthomas in a pair of monozygotic twins who responded to ezetimibe treatment. Clinical and experimental dermatology, 2023, 10-25, Volume: 48, Issue:11 Topics: Ezetimibe; Humans; Hypercholesterolemia; Twins, Monozygotic; Xanthomatosis	2023
Guideline-Directed Low-Density Lipoprotein Cholesterol Management After Acute Ischemic Stroke: Findings from a National Health Care Service. The American journal of cardiology, 2023, 09-15, Volume: 203 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Delivery of Health Care; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Stroke; Stroke	2023
[Hypercholesterolemia and cardiovascular risk]. Deutsche medizinische Wochenschrift (1946), 2023, Volume: 148, Issue:16 Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Proprotein Convertase 9; Risk Factors	2023
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2019, 08-12, Volume: 191, Issue:32 Topics: Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors	2019
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain. Revista espanola de cardiologia (English ed.), 2019, Volume: 72, Issue:12 Topics: Aged; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Heart Transplantation; Humans; Hypercholesterolemia; Injections, Subcutaneous; Middle Aged; PCSK9 Inhibitors; Spain; Transplant Recipients; Treatment Outcome; Triglycerides	2019
Pathophysiological importance of bile cholesterol reabsorption: hepatic NPC1L1-exacerbated steatosis and decreasing VLDL-TG secretion in mice fed a high-fat diet. Lipids in health and disease, 2019, Dec-28, Volume: 18, Issue:1 Topics: Animals; Azetidines; Bile; Cholesterol, VLDL; Diet, High-Fat; Ezetimibe; Fatty Liver; Gene Expression Regulation; Humans; Hypercholesterolemia; Intestinal Reabsorption; Liver; Membrane Transport Proteins; Mice; Mice, Transgenic; Triglycerides	2019
Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene. Lipids in health and disease, 2020, Jan-04, Volume: 19, Issue:1 Topics: Aged; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; Cholesterol, LDL; Drug Combinations; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Mutation	2020
Optimizing Clinical Cardiovascular Outcomes by a Personalized Approach to Add Ezetimibe to a Statin. Journal of the American College of Cardiology, 2020, 01-07, Volume: 75, Issue:1 Topics: Anticholesteremic Agents; Biomarkers; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia	2020
Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). The American journal of cardiology, 2020, 03-15, Volume: 125, Issue:6 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Female; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Monitoring, Physiologic; Odds Ratio; Treatment Outcome; United States; Veterans Health Services	2020
[Ezetimibe-rosuvastatin fixed-dose combination (Myrosor®)]. Revue medicale de Liege, 2020, Volume: 75, Issue:4 Topics: Anticholesteremic Agents; Belgium; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Rosuvastatin Calcium; Treatment Outcome	2020
A practical approach to the cholesterol guidelines and ASCVD prevention. Cleveland Clinic journal of medicine, 2020, Volume: 87, Issue:5 suppl 1 Topics: Age Factors; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Autoimmune Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Practice Guidelines as Topic; Primary Prevention; Risk Assessment; Risk Reduction Behavior; Secondary Prevention; Vascular Calcification	2020
A case of ezetimibe-effective hypercholesterolemia with a novel heterozygous variant in ABCG5. Endocrine journal, 2020, Nov-28, Volume: 67, Issue:11 Topics: Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 5; Cholesterol; Cholesterol, LDL; Diagnostic Errors; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Lipoproteins; Loss of Function Mutation; Middle Aged; Phytosterols; Sitosterols; Treatment Failure	2020
Sitosterolemia Exhibiting Severe Hypercholesterolemia with Tendon Xanthomas Due to Compound Heterozygous ABCG5 Gene Mutations Treated with Ezetimibe and Alirocumab. Internal medicine (Tokyo, Japan), 2020, Dec-01, Volume: 59, Issue:23 Topics: Achilles Tendon; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 5; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Male; Middle Aged; Mutation; Phytosterols; Treatment Outcome; Xanthomatosis	2020
Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C. Clinical research in cardiology : official journal of the German Cardiac Society, 2022, Volume: 111, Issue:3 Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Cross-Sectional Studies; Drug Prescriptions; Drug Therapy, Combination; Ezetimibe; Female; General Practice; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Time Factors; Treatment Outcome	2022
Low-density lipoprotein cholesterol reduction and target achievement after switching from statin monotherapy to statin/ezetimibe combination therapy: Real-world evidence. Journal of clinical pharmacy and therapeutics, 2021, Volume: 46, Issue:1 Topics: Cholesterol, LDL; Drug Therapy, Combination; Electronic Health Records; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Republic of Korea; Retrospective Studies; Treatment Outcome	2021
Lipid-lowering therapies: Better together. Atherosclerosis, 2021, Volume: 320 Topics: Atorvastatin; Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hypercholesterolemia	2021
LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry. Cardiovascular drugs and therapy, 2022, Volume: 36, Issue:2 Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Registries; Rosuvastatin Calcium; Simvastatin	2022
Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk. Atherosclerosis. Supplements, 2020, Volume: 42 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Europe; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; PCSK9 Inhibitors; Practice Guidelines as Topic; Primary Prevention; Renal Insufficiency, Chronic; United States	2020
Comment on 'Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III trials'. Clinical drug investigation, 2021, Volume: 41, Issue:5 Topics: Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hypercholesterolemia	2021
Authors' Reply to 'Comment on: Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials'. Clinical drug investigation, 2021, Volume: 41, Issue:5 Topics: Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hypercholesterolemia	2021
Impact of Lower Versus Higher LDL Cholesterol Targets on Cardiovascular Events After Ischemic Stroke in Patients With Diabetes. Diabetes, 2021, Volume: 70, Issue:8 Topics: Aged; Cholesterol, LDL; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Stroke; Male; Middle Aged; Myocardial Infarction; Treatment Outcome	2021
Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia. Expert review of cardiovascular therapy, 2021, Volume: 19, Issue:7 Topics: Adult; Anticholesteremic Agents; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Rosuvastatin Calcium; Treatment Outcome	2021
Don't we forget about biological therapy of hypercholesterolemia with PCSK9-inhibitors? Vnitrni lekarstvi, 2021,Summer, Volume: 67, Issue:3 Topics: Anticholesteremic Agents; Biological Therapy; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Proprotein Convertase 9	2021
Regulation of the expression of cholesterol transporters by lipid-lowering drugs ezetimibe and pemafibrate in rat liver and intestine. Biochimica et biophysica acta. Molecular basis of disease, 2021, 11-01, Volume: 1867, Issue:11 Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; Benzoxazoles; Butyrates; Cholesterol; Ezetimibe; Hepatobiliary Elimination; Humans; Hypercholesterolemia; Hypolipidemic Agents; Intestinal Absorption; Intestinal Mucosa; Lipoproteins; Liver; Male; Membrane Transport Proteins; Rats; Scavenger Receptors, Class B	2021
Effect of ezetimibe on low- and high-density lipoprotein subclasses in sitosterolemia. Atherosclerosis, 2017, Volume: 260 Topics: Adolescent; Adult; Anticholesteremic Agents; Cholesterol, HDL; Electrophoresis, Polyacrylamide Gel; Ezetimibe; Female; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Lipoproteins, HDL; Lipoproteins, IDL; Lipoproteins, VLDL; Male; Middle Aged; Phytosterols; Treatment Outcome; Young Adult	2017
Antiatherogenic potential of ezetimibe in sitosterolemia: Beyond plant sterols lowering. Atherosclerosis, 2017, Volume: 260 Topics: Ezetimibe; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Lipoproteins, HDL; Phytosterols	2017
Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials. Scientific reports, 2017, 04-04, Volume: 7 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Proprotein Convertase 9; Rosuvastatin Calcium; Simvastatin	2017
How has the treatment of hypercholesterolemia in Poland changed over the last six years? Cardiology journal, 2017, Volume: 24, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Incidence; Lipoproteins, LDL; Male; Middle Aged; Patient Compliance; Poland; Registries; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Surveys and Questionnaires; Time Factors	2017
Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting. European heart journal. Cardiovascular pharmacotherapy, 2018, 01-01, Volume: 4, Issue:1 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Ezetimibe; Female; Humans; Hypercholesterolemia; Incidence; Middle Aged; Norway; PCSK9 Inhibitors; Risk Factors; Secondary Prevention	2018
Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease. Circulation, 2017, 05-30, Volume: 135, Issue:22 Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Databases, Factual; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; PCSK9 Inhibitors	2017
Timely diagnosis of sitosterolemia by next generation sequencing in two children with severe hypercholesterolemia. Atherosclerosis, 2017, Volume: 262 Topics: Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; Biomarkers; Child; Child, Preschool; Cholesterol, LDL; Codon, Nonsense; Diet, Fat-Restricted; DNA Mutational Analysis; Ezetimibe; Female; Genetic Predisposition to Disease; Heterozygote; High-Throughput Nucleotide Sequencing; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Lipoproteins; Male; Phenotype; Phytosterols; Predictive Value of Tests; Severity of Illness Index; Treatment Outcome; Up-Regulation	2017
Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand? JAMA cardiology, 2017, 09-01, Volume: 2, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Patient Selection; PCSK9 Inhibitors; Risk Reduction Behavior; RNA, Small Interfering	2017
Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target. JAMA cardiology, 2017, 09-01, Volume: 2, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Patient Care Planning; PCSK9 Inhibitors; Practice Guidelines as Topic; Primary Prevention; Risk Reduction Behavior; Secondary Prevention	2017
Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA cardiology, 2017, 09-01, Volume: 2, Issue:9 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Cohort Studies; Computer Simulation; Databases, Factual; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Monte Carlo Method; Patient Care Planning; PCSK9 Inhibitors	2017
Carotid intima media thickness in a girl with sitosterolemia carrying a homozygous mutation in the ABCG5 gene. Journal of pediatric endocrinology & metabolism : JPEM, 2017, Aug-28, Volume: 30, Issue:9 Topics: Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 5; Carotid Arteries; Carotid Intima-Media Thickness; Child, Preschool; Cholesterol, LDL; Echocardiography; Ezetimibe; Female; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Lipoproteins; Mutation; Phytosterols	2017
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Fo Journal of the American College of Cardiology, 2017, Oct-03, Volume: 70, Issue:14 Topics: Anticholesteremic Agents; Cardiology; Chemoprevention; Cholesterol, LDL; Consensus; Coronary Artery Disease; Enzyme Inhibitors; Ezetimibe; Humans; Hypercholesterolemia; Medication Therapy Management; Sequestering Agents; United States	2017
Statin and ezetimibe combination therapy: New therapeutic options for lowering Low-Density Lipoprotein Cholesterol. International journal of cardiology, 2017, 11-15, Volume: 247 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia	2017
Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer. International journal of epidemiology, 2017, 12-01, Volume: 46, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Denmark; Ezetimibe; Female; Genetic Variation; Humans; Hypercholesterolemia; Male; Membrane Proteins; Membrane Transport Proteins; Mendelian Randomization Analysis; Middle Aged; Neoplasms; Proportional Hazards Models; Risk Assessment; Risk Factors	2017
The natural history of phytosterolemia: Observations on its homeostasis. Atherosclerosis, 2018, Volume: 269 Topics: Adolescent; Adult; Age Factors; Anticholesteremic Agents; Asymptomatic Diseases; ATP Binding Cassette Transporter, Subfamily G, Member 8; Biomarkers; Canada; Child; Child, Preschool; Cholesterol; Ezetimibe; Female; Genetic Predisposition to Disease; Homeostasis; Humans; Hypercholesterolemia; Infant; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Male; Middle Aged; Mutation; Phenotype; Phytosterols; Prevalence; Puberty; Rare Diseases; Risk Factors; Sitosterols; Time Factors; Treatment Outcome; United States; Young Adult	2018
Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia. The American journal of cardiology, 2018, 05-15, Volume: 121, Issue:10 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Middle Aged; PCSK9 Inhibitors; Practice Patterns, Physicians'; Retrospective Studies	2018
Newer cholesterol-lowering agents: What you must know. The Journal of family practice, 2018, Volume: 67, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Anticholesteremic Agents; Cholesterol; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; PCSK9 Inhibitors; Proprotein Convertase 9	2018
Impact of statin-ezetimibe combination in chronic kidney disease. International journal of cardiology, 2018, 10-01, Volume: 268 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Renal Insufficiency, Chronic; Treatment Outcome	2018
[Newer evidences and recommendations in lipidology]. Orvosi hetilap, 2018, Volume: 159, Issue:32 Topics: Anticholesteremic Agents; Cholesterol, LDL; Ezetimibe; Female; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Plaque, Atherosclerotic	2018
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 2019, 06-25, Volume: 73, Issue:24 Topics: American Heart Association; Anticholesteremic Agents; Biomarkers; Cardiology; Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Medication Therapy Management; PCSK9 Inhibitors; Risk Assessment; Risk Reduction Behavior; United States	2019
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 2019, 06-25, Volume: 73, Issue:24 Topics: American Heart Association; Anticholesteremic Agents; Biomarkers; Cardiology; Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Medication Therapy Management; PCSK9 Inhibitors; Risk Assessment; Risk Reduction Behavior; United States	2019
Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease. European journal of clinical investigation, 2019, Volume: 49, Issue:2 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Aspirin; Blood Component Removal; Coronary Artery Disease; Cross-Sectional Studies; Ezetimibe; Female; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein(a); Lipoproteins, LDL; Male; Middle Aged; Platelet Aggregation Inhibitors; Young Adult	2019
A closer look at an ezetimibe discussion. The Journal of family practice, 2018, Volume: 67, Issue:11 Topics: Anticholesteremic Agents; Cholesterol; Ezetimibe; Humans; Hypercholesterolemia	2018
The important role of apolipoprotein A-II in ezetimibe driven reduction of high cholesterol diet-induced atherosclerosis. Atherosclerosis, 2019, Volume: 280 Topics: Animals; Animals, Genetically Modified; Anticholesteremic Agents; Apolipoprotein A-II; Atherosclerosis; Cholesterol; Diet, High-Fat; Endothelial Cells; Ezetimibe; Granulocytes; Hep G2 Cells; Hepatocyte Nuclear Factor 4; Hepatocytes; Humans; Hypercholesterolemia; Lipid Metabolism; Lipids; Macrophages; Microscopy, Confocal; PPAR alpha; THP-1 Cells; Zebrafish	2019
Cost-effectiveness of Evolocumab. Revista espanola de cardiologia (English ed.), 2018, Volume: 71, Issue:12 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cost-Benefit Analysis; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Proprotein Convertase 9; Spain	2018
Lipid-lowering effects of Coffea arabica pulp aqueous extract in Caco-2 cells and hypercholesterolemic rats. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2019, Volume: 52 Topics: Animals; Anticholesteremic Agents; Caco-2 Cells; Cholesterol; Coffea; Down-Regulation; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Absorption; Jejunum; Liver X Receptors; Male; Membrane Proteins; Membrane Transport Proteins; Micelles; Plant Extracts; Rats; Rats, Wistar	2019
Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis. Circulation research, 2019, Volume: 124, Issue:3 Topics: Anticholesteremic Agents; Aspirin; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Plaque, Atherosclerotic; Rivaroxaban; Thrombosis	2019
Combined Effect of Diosgenin Along with Ezetimibe or Atorvastatin on the Fate of Labelled Bile Acid and Cholesterol in Hypercholesterolemic Rats. International journal of environmental research and public health, 2019, 02-20, Volume: 16, Issue:4 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol; Diosgenin; Ezetimibe; Hypercholesterolemia; Liver; Male; Rats; Rats, Wistar	2019
Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study. BMJ open, 2019, 04-01, Volume: 9, Issue:4 Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Denmark; Diabetes Mellitus; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Ischemia; PCSK9 Inhibitors; Practice Patterns, Physicians'; Stroke	2019
Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. JAMA cardiology, 2019, 05-01, Volume: 4, Issue:5 Topics: Adult; American Heart Association; Anticholesteremic Agents; Atherosclerosis; Cardiology; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Practice Guidelines as Topic; Primary Prevention; Secondary Prevention; United States	2019
[Eligibility for the indication of PCSK9 inhibitors according to the recommendations of different scientific societies]. Medicina, 2019, Volume: 79, Issue:2 Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Argentina; Cross-Sectional Studies; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; PCSK9 Inhibitors; Practice Guidelines as Topic; Sex Factors; Societies, Scientific; Statistics, Nonparametric; Time Factors; Treatment Outcome	2019
Hypercholesterolemia Among Premature Infarcts: Time to Start the Clock of Familial Hypercholesterolemia Assessment. Journal of the American College of Cardiology, 2019, 05-21, Volume: 73, Issue:19 Topics: Ezetimibe; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Infarction; Myocardial Infarction; Proprotein Convertase 9; Young Adult	2019
Bempedoic acid and ezetimibe - better together. European journal of preventive cardiology, 2020, Volume: 27, Issue:6 Topics: Cardiovascular Diseases; Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia	2020
[Screening for hyperlipidemia in cardiovascular high-risk patients in austrian diabetes ambulances]. MMW Fortschritte der Medizin, 2012, Jun-28, Volume: 154 Suppl 2 Topics: Ambulatory Care; Anticholesteremic Agents; Austria; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Utilization; Ezetimibe; Fibric Acids; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Mass Screening; Risk Factors; Treatment Outcome; Triglycerides	2012
Bayesian inference for multivariate meta-analysis Box-Cox transformation models for individual patient data with applications to evaluation of cholesterol-lowering drugs. Statistics in medicine, 2013, Oct-15, Volume: 32, Issue:23 Topics: Adult; Azetidines; Bayes Theorem; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Markov Chains; Meta-Analysis as Topic; Models, Statistical; Monte Carlo Method; Multivariate Analysis; Triglycerides	2013
Ezetimibe decreases serum oxidized cholesterol without impairing bile acid synthesis in Japanese hypercholesterolemic patients. Atherosclerosis, 2013, Volume: 230, Issue:1 Topics: Absorption; Aged; Anthropometry; Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Body Mass Index; Case-Control Studies; Cholesterol; Diet; Ezetimibe; Female; Gas Chromatography-Mass Spectrometry; Humans; Hydroxycholesterols; Hypercholesterolemia; Intestine, Small; Japan; Life Style; Male; Middle Aged; Oxygen; Phytosterols; Sterols; Triglycerides	2013
Development of optimized supersaturable self-nanoemulsifying systems of ezetimibe: effect of polymers and efflux transporters. Expert opinion on drug delivery, 2014, Volume: 11, Issue:4 Topics: Animals; Anticholesteremic Agents; Azetidines; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Cholesterol, LDL; Disease Models, Animal; Drug Delivery Systems; Drug Stability; Emulsions; Ezetimibe; Female; Hypercholesterolemia; Intestinal Absorption; Intestine, Small; Lipids; Nanoparticles; Polymers; Rats; Rats, Sprague-Dawley; X-Ray Diffraction	2014
Use and misuse of ezetimibe: analysis of use and cost in Saskatchewan, a Canadian jurisdiction with broad access. The Canadian journal of cardiology, 2014, Volume: 30, Issue:2 Topics: Aged; Anticholesteremic Agents; Azetidines; Drug Costs; Drug Prescriptions; Drug Utilization; Ezetimibe; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Prescription Drug Misuse; Retrospective Studies; Saskatchewan	2014
Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats. Lipids in health and disease, 2014, Feb-18, Volume: 13 Topics: Animals; Azetidines; Drug Combinations; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Ezetimibe; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Proprotein Convertase 9; Quinolines; Rats; Rats, Sprague-Dawley; Serine Endopeptidases	2014
A novel mutation of ABCG5 gene in a Turkish boy with phytosterolemia presenting with macrotrombocytopenia and stomatocytosis. Pediatric blood & cancer, 2014, Volume: 61, Issue:8 Topics: Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Azetidines; Child; Ezetimibe; Hematologic Diseases; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Lipoproteins; Male; Phytosterols; Point Mutation	2014
Characterization of the pharmaceutical effect of drugs on atherosclerotic lesions in vivo using integrated fluorescence imaging and Raman spectral measurements. Analytical chemistry, 2014, Apr-15, Volume: 86, Issue:8 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Blood Vessels; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Lipid Metabolism; Lipids; Microscopy, Confocal; Pyrroles; Spectrum Analysis, Raman; Zebrafish	2014
Ezetimibe prescribing fails to keep up with evidence. JAMA, 2014, Apr-02, Volume: 311, Issue:13 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Evidence-Based Medicine; Ezetimibe; Humans; Hypercholesterolemia; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prescriptions; Randomized Controlled Trials as Topic; United States	2014
Use of targeted exome sequencing in genetic diagnosis of Chinese familial hypercholesterolemia. PloS one, 2014, Volume: 9, Issue:4 Topics: Anticholesteremic Agents; Asian People; Azetidines; Child, Preschool; China; DNA Mutational Analysis; Drug Therapy, Combination; Exome; Ezetimibe; Genotype; Humans; Hypercholesterolemia; Male; Mutation; Pedigree; Phenotype; Simvastatin; Treatment Outcome	2014
Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genetics and molecular research : GMR, 2014, Apr-03, Volume: 13, Issue:2 Topics: Aged; Atorvastatin; Azetidines; C-Reactive Protein; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cholesterol, LDL; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles	2014
The influence of ezetimibe on classical and alternative activation pathways of monocytes/macrophages isolated from patients with hypercholesterolemia. Naunyn-Schmiedeberg's archives of pharmacology, 2014, Volume: 387, Issue:8 Topics: Anticholesteremic Agents; Arginase; Azetidines; Cell Survival; Cells, Cultured; Ezetimibe; Female; Humans; Hypercholesterolemia; Interleukin-1beta; Lectins, C-Type; Lipopolysaccharides; Macrophages; Male; Mannose Receptor; Mannose-Binding Lectins; Middle Aged; Monocytes; Nitric Oxide; Nitric Oxide Synthase Type II; Receptors, Cell Surface	2014
The effect of ezetimibe on adipose tissue hormones in patients with isolated hypercholesterolemia. Pharmacological reports : PR, 2014, Volume: 66, Issue:3 Topics: Adiponectin; Adipose Tissue; Anticholesteremic Agents; Apolipoproteins; Azetidines; Biomarkers; C-Reactive Protein; Case-Control Studies; Cholesterol; Cholesterol, LDL; Ezetimibe; Fatty Acids, Nonesterified; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Tumor Necrosis Factor-alpha	2014
Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo. The American journal of pathology, 2014, Volume: 184, Issue:7 Topics: Animals; Apoptosis; Azetidines; Cell Line, Tumor; Cell Proliferation; Cholesterol; Cholesterol, Dietary; Diet, High-Fat; Ezetimibe; Female; Humans; Hypercholesterolemia; Mammary Neoplasms, Experimental; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic	2014
The effect of ezetimibe on androgen production in hypercholesterolemic women with polycystic ovary syndrome. Cardiovascular therapeutics, 2014, Volume: 32, Issue:5 Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Female; Humans; Hypercholesterolemia; Insulin Resistance; Middle Aged; Polycystic Ovary Syndrome; Simvastatin; Testosterone	2014
Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010. JAMA internal medicine, 2014, Volume: 174, Issue:9 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Clinical Trials as Topic; Disease Progression; Ezetimibe; Female; Humans; Hypercholesterolemia; Insurance, Pharmaceutical Services; Male; Middle Aged; Retrospective Studies; Simvastatin; Treatment Outcome; United States	2014
20-year-old amish woman with abdominal pain, retroperitoneal mass, and hyperlipidemia. Arthritis care & research, 2015, Volume: 67, Issue:3 Topics: Abdominal Pain; Amish; Anticholesteremic Agents; Azetidines; Biopsy; Diagnosis, Differential; Ezetimibe; Female; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Phytosterols; Predictive Value of Tests; Retroperitoneal Fibrosis; Retroperitoneal Space; Tomography, X-Ray Computed; Treatment Outcome; Xanthomatosis; Young Adult	2015
Cholesterol treatment patterns and cardiovascular clinical outcomes associated with colesevelam HCl and ezetimibe. Drugs & aging, 2014, Volume: 31, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allylamine; Anticholesteremic Agents; Azetidines; Cohort Studies; Colesevelam Hydrochloride; Coronary Artery Disease; Diagnosis-Related Groups; Ezetimibe; Female; Health Services for the Aged; Humans; Hypercholesterolemia; Male; Middle Aged; Retrospective Studies; Treatment Outcome; United States	2014
The effect of short-term combined treatment with simvastatin and ezetimibe on circulating adipokine levels in patients with isolated hypercholesterolemia. Endokrynologia Polska, 2014, Volume: 65, Issue:4 Topics: Adipokines; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Simvastatin	2014
The effect of atorvastatin and atorvastatin-ezetimibe combination therapy on androgen production in hyperandrogenic women with elevated cholesterol levels. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2015, Volume: 123, Issue:2 Topics: Adult; Androgens; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hyperandrogenism; Hypercholesterolemia; Middle Aged; Pyrroles; Sex Hormone-Binding Globulin; Treatment Outcome; Young Adult	2015
Ezetimibe use remains common among medical inpatients. The American journal of medicine, 2015, Volume: 128, Issue:2 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inpatients; Middle Aged; Practice Patterns, Physicians'; Quebec	2015
Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. Atherosclerosis, 2014, Volume: 237, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrimidines; Randomized Controlled Trials as Topic; Research Design; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult	2014
Efficacy of ezetimibe is not related to NPC1L1 gene polymorphisms in a pilot study of Chilean hypercholesterolemic subjects. Molecular diagnosis & therapy, 2015, Volume: 19, Issue:1 Topics: Adult; Anticholesteremic Agents; Azetidines; Biological Transport; Chile; Cholesterol, LDL; Ezetimibe; Female; Gene Expression; Genotype; Humans; Hypercholesterolemia; Intestinal Absorption; Male; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Pilot Projects; Polymorphism, Genetic; Treatment Outcome	2015
[Low persistence of simvastatin and ezetimibe fixed combination in the lipid lowering therapy]. Orvosi hetilap, 2015, Jan-25, Volume: 156, Issue:4 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Drug Administration Schedule; Drug Combinations; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome	2015
[Which patient will now actually benefit from ezetimib?]. MMW Fortschritte der Medizin, 2014, Dec-15, Volume: 156, Issue:21-22 Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Randomized Controlled Trials as Topic	2014
Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom. Clinical therapeutics, 2015, Apr-01, Volume: 37, Issue:4 Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Drugs, Generic; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; United Kingdom	2015
Splenic extrafollicular reactions and BM plasma cells sustain IgM response associated with hypercholesterolemia. European journal of immunology, 2015, Volume: 45, Issue:5 Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Atherosclerosis; Autoantibodies; Azetidines; Bone Marrow Cells; Cholesterol; Ezetimibe; Hypercholesterolemia; Immunoglobulin M; Lipoproteins, LDL; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Plasma Cells; Spleen	2015
IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"? Atherosclerosis, 2015, Volume: 240, Issue:1 Topics: Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol; Clinical Trials as Topic; Down-Regulation; Drug Therapy, Combination; Evidence-Based Medicine; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Treatment Outcome	2015
Evolocumab (AMG 145) for primary hypercholesterolemia. Expert review of cardiovascular therapy, 2015, Volume: 13, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipids; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases	2015
Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease. European heart journal, 2015, Jul-01, Volume: 36, Issue:25 Topics: Aged; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Gallstones; Genetic Variation; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemia; Lipid Metabolism; Male; Membrane Proteins; Membrane Transport Proteins; Mendelian Randomization Analysis; Middle Aged; Myocardial Infarction; Risk Factors; Stroke	2015
Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2015, Volume: 15, Issue:3 Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pilot Projects; Proprotein Convertase 9; Proprotein Convertases; Prospective Studies; Serine Endopeptidases	2015
Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients. Atherosclerosis, 2015, Volume: 240, Issue:2 Topics: Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Down-Regulation; Drug Combinations; Evidence-Based Medicine; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Time Factors; Treatment Outcome	2015
[LDL cholesterol lowering therapy: no target value but personalised treatment]. Nederlands tijdschrift voor geneeskunde, 2015, Volume: 159 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin	2015
Comparison of the effects of short-term hypolipidaemic treatment on plasma adipokine levels in men and women with isolated hypercholesterolaemia. Endokrynologia Polska, 2015, Volume: 66, Issue:2 Topics: Adipokines; Adipose Tissue; Animals; Anticholesteremic Agents; C-Reactive Protein; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Rabbits; Retrospective Studies; Sex Factors; Tumor Necrosis Factor-alpha	2015
[The surprising (?) results of IMPROVE-IT]. Giornale italiano di cardiologia (2006), 2015, Volume: 16, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Congresses as Topic; Ezetimibe; Global Health; Humans; Hypercholesterolemia; Incidence; Italy; Meta-Analysis as Topic; Risk Assessment; Risk Factors; Simvastatin; Treatment Outcome; United States	2015
Associations of ApoAI and ApoB-containing lipoproteins with AngII-induced abdominal aortic aneurysms in mice. Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:8 Topics: Angiotensin II; Animals; Anticholesteremic Agents; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoproteins B; Apolipoproteins E; Azetidines; Diet, Western; Disease Models, Animal; Ezetimibe; Female; Hypercholesterolemia; Male; Mice, Inbred C57BL; Mice, Knockout; Receptors, LDL; Sex Factors	2015
Vascular and metabolic effects of ezetimibe combined with simvastatin in patients with hypercholesterolemia. International journal of cardiology, 2015, Nov-15, Volume: 199 Topics: Adiponectin; Aged; Animals; Anticholesteremic Agents; Blood Pressure; C-Reactive Protein; Drug Therapy, Combination; Ezetimibe; Fat Body; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Randomized Controlled Trials as Topic; Rats; Simvastatin; Single-Blind Method	2015
Sociodemographic and diagnostic characteristics of prescribing a second-line lipid-lowering medication: ezetimibe used as initial medication, switch from statins, or add-on medication. European journal of clinical pharmacology, 2015, Volume: 71, Issue:10 Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Anticholesteremic Agents; Comorbidity; Denmark; Drug Therapy, Combination; Drug Utilization; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Logistic Models; Male; Middle Aged; Odds Ratio; Practice Patterns, Physicians'; Sex Distribution; Socioeconomic Factors	2015
Statin-Ezetimibe Combination Therapy In Diabetic Individuals. Angiology, 2016, Volume: 67, Issue:6 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia	2016
Reply to comment on: Effects of ezetimibe/simvastatin combination on metabolic parameters by Prof. Moses S Elisaf. International journal of cardiology, 2016, Jan-01, Volume: 202 Topics: Animals; Anticholesteremic Agents; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Simvastatin	2016
Effects of ezetimibe/simvastatin combination on metabolic parameters. International journal of cardiology, 2016, Jan-01, Volume: 202 Topics: Animals; Anticholesteremic Agents; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Simvastatin	2016
Intensive LDL lowering therapy for prevention of recurrent cardiovascular events: a word of caution. European heart journal, 2016, Feb-07, Volume: 37, Issue:6 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; PCSK9 Inhibitors; Secondary Prevention; Simvastatin; Treatment Outcome	2016
Might ezetimibe be considered an expensive placebo? International journal of cardiology, 2016, Mar-15, Volume: 207 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Ezetimibe; Humans; Hypercholesterolemia; Lipids; Placebo Effect; Treatment Outcome	2016
Maximum Low-density Lipoprotein Cholesterol Lowering Capacity Achievable With Drug Combinations. When 50 Plus 20 Equals 60. Revista espanola de cardiologia (English ed.), 2016, Volume: 69, Issue:3 Topics: Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Treatment Outcome	2016
New Studies Do Not Challenge the American College of Cardiology/American Heart Association Lipid Guidelines. Annals of internal medicine, 2016, 05-17, Volume: 164, Issue:10 Topics: American Heart Association; Anticholesteremic Agents; Cardiology; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Practice Guidelines as Topic; Proprotein Convertase 9; Risk Factors; Societies, Medical; United States	2016
Age may determine the effect of hypolipidemic agents on plasma adipokine levels in patients with elevated low-density lipoprotein cholesterol levels. Endokrynologia Polska, 2016, Volume: 67, Issue:3 Topics: Adipokines; Adipose Tissue; Adult; Age Factors; Aged; C-Reactive Protein; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Retrospective Studies; Simvastatin	2016
[FIXED COMBINATION ATORVASTATIN-EZETIMIBE (ATOZET®)]. Revue medicale de Liege, 2016, Volume: 71, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Risk Factors	2016
PCSK9 Inhibitors for Statin Intolerance? JAMA, 2016, Apr-19, Volume: 315, Issue:15 Topics: Antibodies, Monoclonal; Anticholesteremic Agents; Cholesterol, LDL; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Muscular Diseases	2016
Alternatives to statins in intolerant patients do lower cholesterol, study finds. BMJ (Clinical research ed.), 2016, Apr-05, Volume: 353 Topics: Antibodies, Monoclonal; Anticholesteremic Agents; Cholesterol, LDL; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Muscular Diseases	2016
Ezetimibe-sensitive cholesterol uptake by NPC1L1 protein does not require endocytosis. Molecular biology of the cell, 2016, 06-01, Volume: 27, Issue:11 Topics: Biological Transport; Cell Line; Cholesterol; Endocytosis; Ezetimibe; Hepatocytes; Humans; Hypercholesterolemia; Intestinal Absorption; Liver; Membrane Proteins; Membrane Transport Proteins; Protein Binding; Protein Interaction Domains and Motifs; Protein Transport	2016
[ANMCO Position paper: Clinical management of hypercholesterolemia in patients with acute coronary syndrome]. Giornale italiano di cardiologia (2006), 2016, Volume: 17, Issue:6 Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Treatment Outcome	2016
Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful? Journal of the American College of Cardiology, 2016, 06-28, Volume: 67, Issue:25 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Secondary Prevention; Simvastatin	2016
Reply: Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful? Journal of the American College of Cardiology, 2016, 06-28, Volume: 67, Issue:25 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Secondary Prevention; Simvastatin	2016
A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels. Postgraduate medical journal, 2017, Volume: 93, Issue:1098 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; PCSK9 Inhibitors; Practice Patterns, Physicians'; Secondary Prevention; United Kingdom	2017
The need for a new classification of cholesterol lowering therapies. Current medical research and opinion, 2017, Volume: 33, Issue:1 Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Universities	2017
Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials. The American journal of cardiology, 2016, Dec-15, Volume: 118, Issue:12 Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Back Pain; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Comorbidity; Coronary Disease; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Influenza, Human; Middle Aged; Myocardial Infarction; Nasopharyngitis; Pruritus; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Stroke; Urinary Tract Infections	2016
Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia. The American journal of cardiology, 2016, Dec-15, Volume: 118, Issue:12 Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Comorbidity; Drug Therapy, Combination; Ezetimibe; Fasting; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperglycemia; Male; Metabolic Syndrome; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides	2016
NKT Cell Hyporesponsiveness Leads to Unrestrained Accumulation of Marginal Zone B Cells in Hypercholesterolemic Apolipoprotein E-Deficient Mice. Journal of immunology (Baltimore, Md. : 1950), 2016, 11-15, Volume: 197, Issue:10 Topics: Adoptive Transfer; Animals; Apolipoproteins E; B-Lymphocyte Subsets; B-Lymphocytes; Ezetimibe; Hypercholesterolemia; Interferon-gamma; Interleukin-4; Lymphoid Tissue; Mice; Mice, Inbred C57BL; Mice, Knockout; Natural Killer T-Cells	2016
Ezetimibe: Use, costs, and adverse events in Australia. Cardiovascular therapeutics, 2017, Volume: 35, Issue:1 Topics: Anticholesteremic Agents; Australia; Drug Costs; Drug Prescriptions; Drug Utilization Review; Drug-Related Side Effects and Adverse Reactions; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hypercholesterolemia; Pharmacoepidemiology; Practice Patterns, Physicians'; Risk Factors; Time Factors; Treatment Outcome	2017
Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection. European heart journal, 2016, Dec-21, Volume: 37, Issue:48 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Body Mass Index; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Obesity; PCSK9 Inhibitors; Testosterone	2016
The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial: a return to first principles. Clinical cardiology, 2008, Volume: 31, Issue:6 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin; Treatment Outcome	2008
Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. The American journal of cardiology, 2008, Jun-15, Volume: 101, Issue:12 Topics: Administration, Oral; Anticholesteremic Agents; Azetidines; Biological Products; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Dietary Supplements; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides	2008
Is it over for ezetimibe? Expert review of cardiovascular therapy, 2008, Volume: 6, Issue:6 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Controlled Clinical Trials as Topic; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin	2008
[Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl]. MMW Fortschritte der Medizin, 2008, Jun-05, Volume: 150, Issue:23 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Ezetimibe; Germany; Heptanoic Acids; Humans; Hypercholesterolemia; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin	2008
Achieving target cholesterol levels in diabetic patients: potency of the statin or potency of the physician? The Israel Medical Association journal : IMAJ, 2008, Volume: 10, Issue:5 Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus; Dose-Response Relationship, Drug; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Israel; Male; Middle Aged; Patient Compliance	2008
Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. Cleveland Clinic journal of medicine, 2008, Volume: 75, Issue:7 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Vessels; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin; Tunica Intima	2008
Given the ENHANCE trial results, ezetimibe is still unproven. Cleveland Clinic journal of medicine, 2008, Volume: 75, Issue:7 Topics: Azetidines; Cholesterol, LDL; Coronary Vessels; Evidence-Based Medicine; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Tunica Intima	2008
Self-nanoemulsifying granules of ezetimibe: design, optimization and evaluation. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2008, Oct-02, Volume: 35, Issue:3 Topics: Animals; Anticholesteremic Agents; Azetidines; Biological Availability; Calorimetry, Differential Scanning; Capsules; Chemistry, Pharmaceutical; Cholesterol; Crystallography, X-Ray; Disease Models, Animal; Emulsions; Ezetimibe; Hydrogen-Ion Concentration; Hypercholesterolemia; Male; Microscopy, Electron, Scanning; Nanoparticles; Oils; Rats; Rats, Sprague-Dawley; Silicon Dioxide; Solubility; Surface-Active Agents	2008
Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study. Current medical research and opinion, 2008, Volume: 24, Issue:9 Topics: Aged; Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Monitoring, Physiologic	2008
Recent news reports suggest that the cholesterol medicine Zetia doesn't work. Should I stop taking my prescription? The Johns Hopkins medical letter health after 50, 2008, Volume: 20, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Humans; Hypercholesterolemia; Treatment Outcome	2008
Ezetimibe revisited. The Medical letter on drugs and therapeutics, 2008, Aug-25, Volume: 50, Issue:1293 Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Clinical Trials as Topic; Drug Combinations; Endpoint Determination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin	2008
Ptosis, diplopia and statins: an association? European journal of neurology, 2008, Volume: 15, Issue:10 Topics: Adult; Atorvastatin; Autoantibodies; Autoimmune Diseases of the Nervous System; Azetidines; Blepharoptosis; Diabetes Complications; Diagnostic Errors; Diplopia; Eyelid Diseases; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Myasthenia Gravis; Myocardial Infarction; Pain; Pravastatin; Pyrroles; Receptors, Cholinergic; Recurrence; Strabismus	2008
Serious drug-induced liver disease secondary to ezetimibe. World journal of gastroenterology, 2008, Aug-28, Volume: 14, Issue:32 Topics: Anticholesteremic Agents; Azetidines; Chemical and Drug Induced Liver Injury; Ezetimibe; Female; Humans; Hypercholesterolemia; Middle Aged	2008
Analyses of cancer data from three ezetimibe trials. The New England journal of medicine, 2008, Sep-25, Volume: 359, Issue:13 Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Humans; Hypercholesterolemia; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Risk; Simvastatin	2008
Hypercholesterolaemia: Clarifications from adverse drug reactions agency. BMJ (Clinical research ed.), 2008, Sep-16, Volume: 337 Topics: Anticholesteremic Agents; Azetidines; England; Ezetimibe; Humans; Hypercholesterolemia; Neoplasms; Risk Factors; Simvastatin; United States; United States Food and Drug Administration	2008
After ENHANCE: the cholesterol hypothesis is alive and well. The Medical journal of Australia, 2008, Sep-15, Volume: 189, Issue:6 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Ezetimibe; Humans; Hypercholesterolemia; Randomized Controlled Trials as Topic; Simvastatin; Tunica Intima; Tunica Media; Ultrasonography	2008
Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data regis Clinical therapeutics, 2008, Volume: 30, Issue:8 Topics: Age Factors; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Markov Chains; Middle Aged; Quality of Life; Quality-Adjusted Life Years; Risk Factors; Sex Factors; United Kingdom	2008
Muddy waters: more stormy SEAS for ezetimibe. International journal of clinical practice, 2008, Volume: 62, Issue:10 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Treatment Outcome	2008
Effectiveness of thrice weekly ezetimibe. The American journal of cardiology, 2008, Nov-01, Volume: 102, Issue:9 Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, LDL; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Treatment Outcome	2008
Effect of ezetimibe on plasma cholesterol levels, cholesterol absorption, and secretion of biliary cholesterol in laboratory opossums with high and low responses to dietary cholesterol. Metabolism: clinical and experimental, 2008, Volume: 57, Issue:12 Topics: Animals; Animals, Laboratory; Anticholesteremic Agents; Azetidines; Bile; Cholesterol; Cholesterol, Dietary; Diet, Atherogenic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Ezetimibe; Gallbladder; Hypercholesterolemia; Opossums; Phenotype	2008
The ENHANCE trial. Cleveland Clinic journal of medicine, 2008, Volume: 75, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin	2008
The ENHANCE trial. Cleveland Clinic journal of medicine, 2008, Volume: 75, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin	2008
Analyses of cancer data from three ezetimibe trials. The New England journal of medicine, 2009, Jan-01, Volume: 360, Issue:1 Topics: Anticholesteremic Agents; Azetidines; Data Interpretation, Statistical; Ezetimibe; Humans; Hypercholesterolemia; Neoplasms; Randomized Controlled Trials as Topic; Risk	2009
Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. The American journal of cardiology, 2009, Feb-01, Volume: 103, Issue:3 Topics: Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Randomized Controlled Trials as Topic	2009
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. Journal of neuropathology and experimental neurology, 2009, Volume: 68, Issue:3 Topics: Animals; Atorvastatin; Azetidines; Brain; Capillary Permeability; Diet; Disease Models, Animal; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Maze Learning; Mice; Mice, Transgenic; Neurofibrillary Tangles; Pyrroles; Simvastatin; Spinal Cord; Tauopathies	2009
Ezetimibe treatment of pediatric patients with hypercholesterolemia. The Journal of pediatrics, 2009, Volume: 154, Issue:6 Topics: Adolescent; Anticholesteremic Agents; Azetidines; Child; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Female; Humans; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Male; Triglycerides	2009
Vascular lipid accumulation, lipoprotein oxidation, and macrophage lipid uptake in hypercholesterolemic zebrafish. Circulation research, 2009, Apr-24, Volume: 104, Issue:8 Topics: Age Factors; Aging; Animals; Animals, Genetically Modified; Anticholesteremic Agents; Atherosclerosis; Azetidines; Cell Line; Cholesterol, Dietary; Disease Models, Animal; Endothelium, Vascular; Ezetimibe; Female; Green Fluorescent Proteins; Humans; Hypercholesterolemia; Larva; Lipid Metabolism; Lipoproteins; Luminescent Proteins; Macrophages; Male; Mice; Microscopy, Confocal; Oxidation-Reduction; Permeability; Phospholipases A2; Time Factors; Toll-Like Receptor 4; Zebrafish	2009
The g.-762T>C polymorphism of the NPC1L1 gene is common in Chinese and contributes to a higher promoter activity and higher serum cholesterol levels. Journal of human genetics, 2009, Volume: 54, Issue:4 Topics: Asian People; Azetidines; China; Cholesterol; Demography; Ezetimibe; Female; Gene Frequency; Genotype; Hep G2 Cells; Humans; Hypercholesterolemia; Lovastatin; Male; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Polymorphism, Single Nucleotide; Promoter Regions, Genetic	2009
Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2009, Volume: 15, Issue:5 Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Triglycerides	2009
Utility of ezetimibe. The American journal of cardiology, 2009, May-01, Volume: 103, Issue:9 Topics: Anticholesteremic Agents; Azetidines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Severity of Illness Index; Simvastatin; Treatment Outcome	2009
What role for [black triangle down] colesevelam in cardiovascular prevention? Drug and therapeutics bulletin, 2009, Volume: 47, Issue:5 Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Colesevelam Hydrochloride; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Treatment Outcome	2009
Regulation of steroid 5-alpha reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin. Experimental cell research, 2009, Nov-01, Volume: 315, Issue:18 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Animals; Atorvastatin; Azetidines; Cell Line, Tumor; Ezetimibe; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Liver; Lovastatin; Male; Mice; Promoter Regions, Genetic; Prostate; Prostatic Neoplasms; Pyrroles; Sterol Regulatory Element Binding Protein 2; Transfection	2009
Premature release of data from clinical trials of ezetimibe. The New England journal of medicine, 2009, Aug-13, Volume: 361, Issue:7 Topics: Adverse Drug Reaction Reporting Systems; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Databases as Topic; Drug Approval; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Registries; Simvastatin; United States	2009
Drugs for children with hypercholesterolemia: be cautious. Journal of pediatric endocrinology & metabolism : JPEM, 2009, Volume: 22, Issue:6 Topics: Anticholesteremic Agents; Azetidines; Child; Cholesterol, LDL; Contraindications; Ezetimibe; Humans; Hypercholesterolemia; Treatment Outcome	2009
Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Current medical research and opinion, 2009, Volume: 25, Issue:10 Topics: Aged; Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Greece; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Prospective Studies; Simvastatin	2009
Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia. Lipids in health and disease, 2009, Oct-12, Volume: 8 Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies	2009
[Effectiveness of ezetimibe in improving lipid goal attainment in patients with coronary heart diseases treated with statin]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi, 2009, Volume: 30, Issue:6 Topics: Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Creatine Kinase; Diabetes Complications; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Treatment Outcome; Triglycerides	2009
Cholesterol drug lowers LDL-C levels but again fails to show clinical benefit. JAMA, 2010, Jan-20, Volume: 303, Issue:3 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Clinical Trials as Topic; Drug Approval; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Niacin; Practice Patterns, Physicians'; Risk Factors; Simvastatin; Treatment Outcome; Ultrasonography; United States; United States Food and Drug Administration	2010
Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand's factor and C-reactive protein in patients with hypercholesterolaemia. Archives of cardiovascular diseases, 2010, Volume: 103, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Biomarkers; C-Reactive Protein; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Simvastatin; Thromboplastin; Time Factors; Treatment Outcome; von Willebrand Factor	2010
Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. Journal of atherosclerosis and thrombosis, 2010, Feb-26, Volume: 17, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Albuminuria; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Case-Control Studies; Cholesterol, LDL; Deoxyguanosine; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Metabolic Diseases; Metabolic Syndrome; Middle Aged; Nitrates; Nitrites; Oxidative Stress; Tumor Necrosis Factor-alpha	2010
Ezetimibe and recent clinical trials: a look on the bright side. Expert opinion on drug safety, 2010, Volume: 9, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Niacin; Placebos; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome; Triglycerides	2010
Retrospective, observation study: Quantitative and qualitative effect of ezetimibe and HMG-CoA reductase inhibitors on LDL-cholesterol: are there disappearance thresholds for small, dense LDL and IDL? Recent patents on cardiovascular drug discovery, 2010, Volume: 5, Issue:2 Topics: Aged; Azetidines; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, IDL; Lipoproteins, LDL; Male; Middle Aged; Retrospective Studies	2010
Ezetimibe. The French authorities gradually confirm the lack of benefit. Prescrire international, 2010, Volume: 19, Issue:107 Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Humans; Hypercholesterolemia	2010
[The current debate on lowering LDL cholesterol with ezetimibe]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:36 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia	2010
Ask the doctor. I have tried all of the statin drugs to lower my cholesterol, but each one has caused severe muscle pain. Are there any non-statin medications I could try using to lower my cholesterol? Harvard heart letter : from Harvard Medical School, 2010, Volume: 20, Issue:12 Topics: Allylamine; Azetidines; Colesevelam Hydrochloride; Diet, Mediterranean; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Muscular Diseases; Niacin; Pain; Sitosterols	2010
Managing residual risk in patients receiving statin therapy. The Medical journal of Australia, 2010, Sep-20, Volume: 193, Issue:6 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin	2010
Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells. Pharmacogenomics, 2010, Volume: 11, Issue:9 Topics: Absorption; Anticholesteremic Agents; Atorvastatin; ATP-Binding Cassette Transporters; Azetidines; Biological Transport; Cholesterol; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Gene Expression; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Lipid Metabolism; Male; Middle Aged; Orphan Nuclear Receptors; Pyrroles; RNA, Messenger; Simvastatin; Up-Regulation	2010
Nanocarrier for the enhanced bioavailability of a cardiovascular agent: in vitro, pharmacodynamic, pharmacokinetic and stability assessment. International journal of pharmaceutics, 2011, Jan-17, Volume: 403, Issue:1-2 Topics: Animals; Anticholesteremic Agents; Azetidines; Biological Availability; Cardiovascular Agents; Cholesterol; Drug Carriers; Drug Stability; Drug Storage; Emulsions; Ezetimibe; Hypercholesterolemia; Microscopy, Electron, Transmission; Nanostructures; Particle Size; Rats; Rats, Wistar; Solubility; Surface Properties	2011
[On the current debate on lowering LDL cholesterol with ezetimibe]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:44 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Evidence-Based Medicine; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Randomized Controlled Trials as Topic; Simvastatin	2010
Emphasizing the burden of proof: The American College of Cardiology 2008 Expert Panel Comments on the ENHANCE Trial. Circulation. Cardiovascular quality and outcomes, 2010, Volume: 3, Issue:6 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Cardiology; Carotid Arteries; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Evidence-Based Medicine; Expert Testimony; Ezetimibe; Humans; Hypercholesterolemia; Lipoproteins, LDL; Simvastatin	2010
Ezetimibe, an inhibitor of intestinal cholesterol absorption, decreases serum level of malondialdehyde-modified low-density lipoprotein in patients with hypercholesterolemia. International journal of cardiology, 2011, Feb-03, Volume: 146, Issue:3 Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Ezetimibe; Female; Humans; Hypercholesterolemia; Intestinal Absorption; Lipoproteins, LDL; Male; Middle Aged	2011
Achieving optimal lipid goals in patients with coronary artery disease. The American journal of cardiology, 2011, Mar-15, Volume: 107, Issue:6 Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Logistic Models; Male; Practice Patterns, Physicians'; Sex Factors; Triglycerides	2011
Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. Journal of lipid research, 2011, Volume: 52, Issue:4 Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol; Cholesterol, LDL; Enzyme-Linked Immunosorbent Assay; Ezetimibe; Fluorobenzenes; Hypercholesterolemia; Mice; Mice, Inbred C57BL; Proprotein Convertase 9; Proprotein Convertases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Rosuvastatin Calcium; Serine Endopeptidases; Sulfonamides; Triglycerides	2011
Ezetimibe and low density lipoprotein subfractions: an ongoing debate. Current medical research and opinion, 2011, Volume: 27, Issue:3 Topics: Anticholesteremic Agents; Azetidines; Chemical Fractionation; Cholesterol; Cholesterol, LDL; Dissent and Disputes; Ezetimibe; Humans; Hypercholesterolemia; Lipoproteins, LDL; Particle Size; Prognosis; Simvastatin	2011
Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome; Young Adult	2011
Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids in health and disease, 2011, Feb-28, Volume: 10 Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases	2011
Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression. Journal of atherosclerosis and thrombosis, 2011, Volume: 18, Issue:8 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Caco-2 Cells; DNA; Ezetimibe; Female; Hep G2 Cells; Heptanoic Acids; Humans; Hypercholesterolemia; Leukocytes, Mononuclear; Lipids; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; RNA, Messenger; Scavenger Receptors, Class B; Simvastatin	2011
Statin-associated myasthenic weakness. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2011, Volume: 94, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Cholinesterase Inhibitors; Electromyography; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Muscle Weakness; Myasthenia Gravis; Simvastatin; Treatment Outcome	2011
[After bypass surgery nearly all lipids are in the normal range. However, Lp(a) is too high, what can be done?]. MMW Fortschritte der Medizin, 2011, May-26, Volume: 153, Issue:21 Topics: Azetidines; Cholesterol; Coronary Artery Bypass; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Lipoprotein(a); Male; Postoperative Complications; Prognosis; Reference Values; Risk Factors; Secondary Prevention; Treatment Outcome	2011
Nitroxide derivatives for imaging of hypercholesterolemia-induced kidney dysfunction and assessing the effectiveness of antilipidemic drugs. Molecular pharmaceutics, 2011, Oct-03, Volume: 8, Issue:5 Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, Dietary; Cholestyramine Resin; Contrast Media; Cyclic N-Oxides; Drug Monitoring; Ezetimibe; Gadolinium DTPA; Humans; Hypercholesterolemia; Kidney; Kinetics; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; Nitrogen Oxides; Pyrrolidines; Renal Insufficiency	2011
Do functional foods have a role in the prevention of cardiovascular disease? Circulation, 2011, Aug-02, Volume: 124, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Blood Pressure; Cholesterol, Dietary; Dietary Proteins; Ezetimibe; Female; Humans; Hypercholesterolemia; Hypertension; Lipid Metabolism; Male; Milk Proteins; Phytosterols; Soybean Proteins	2011
Retrospective study on antihyperlipidemic efficacy and safety of simvastatin, ezetimibe and their combination in Korean adults. Archives of pharmacal research, 2011, Volume: 34, Issue:8 Topics: Adult; Aged; Asian People; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Disease; Drug Combinations; Drug Synergism; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Middle Aged; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides	2011
Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress. Journal of atherosclerosis and thrombosis, 2011, Volume: 18, Issue:12 Topics: Aged; Azetidines; Case-Control Studies; Endothelium, Vascular; Ezetimibe; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Oxidative Stress	2011
[Elevated augmentation index]. Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:6 Topics: Anticholesteremic Agents; Antihypertensive Agents; Azetidines; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; Drug Costs; Drug Substitution; Evidence-Based Medicine; Ezetimibe; Female; Germany; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Propanolamines; Pulse	2012
Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia. Journal of atherosclerosis and thrombosis, 2012, Volume: 19, Issue:6 Topics: Administration, Oral; Anticholesteremic Agents; Asian People; Atherosclerosis; Azetidines; Biomarkers; Case-Control Studies; Ezetimibe; Female; Humans; Hypercholesterolemia; Inflammation; Insulin Resistance; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Liver Diseases; Male; Matrix Metalloproteinase 9; Middle Aged; Prognosis; Prospective Studies; Vascular Cell Adhesion Molecule-1	2012
[Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study]. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2011, Volume: 76, Issue:4 Topics: Aged; Algorithms; Azetidines; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Lovastatin; Male; Medication Adherence; Middle Aged; Pravastatin; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2011
Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2 diabetes patients with microalbuminuria. The Journal of international medical research, 2012, Volume: 40, Issue:2 Topics: Albumins; Albuminuria; Azetidines; Blood Pressure; Body Mass Index; Chemokine CCL2; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Ezetimibe; Female; Glycated Hemoglobin; Humans; Hypercholesterolemia; Male; Middle Aged; Triglycerides	2012
[The influence of ezetimibe and simvaststin on platelet aggregation and protein c system in patients with coronary heart disease and hypercholesterolemia]. Klinicheskaia meditsina, 2012, Volume: 90, Issue:3 Topics: Anticholesteremic Agents; Azetidines; Coronary Disease; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Platelet Aggregation; Protein C; Simvastatin	2012
Optimized self nano-emulsifying systems of ezetimibe with enhanced bioavailability potential using long chain and medium chain triglycerides. Colloids and surfaces. B, Biointerfaces, 2012, Dec-01, Volume: 100 Topics: Algorithms; Animals; Anticholesteremic Agents; Azetidines; Biological Availability; Diet, High-Fat; Drug Carriers; Drug Stability; Emulsifying Agents; Ezetimibe; Female; Glycerides; Hypercholesterolemia; Intestinal Absorption; Lipoproteins, HDL; Lipoproteins, LDL; Microscopy, Electron, Transmission; Nanoparticles; Organic Chemicals; Rats; Rats, Sprague-Dawley; Thermodynamics; Triglycerides	2012
Efficacy of ezetimibe is associated with gender and baseline lipid levels in patients with type 2 diabetes. Journal of atherosclerosis and thrombosis, 2012, Volume: 19, Issue:9 Topics: Aged; Azetidines; Body Mass Index; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Ezetimibe; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Sex Factors; Triglycerides	2012
Meta-analysis methods and models with applications in evaluation of cholesterol-lowering drugs. Statistics in medicine, 2012, Dec-10, Volume: 31, Issue:28 Topics: Analysis of Variance; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Computer Simulation; Drug Therapy, Combination; Endpoint Determination; Evaluation Studies as Topic; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Likelihood Functions; Lipoproteins, HDL; Meta-Analysis as Topic; Multivariate Analysis; Randomized Controlled Trials as Topic; Research Design	2012
Effect of ezetimibe on insulin secretion in db/db diabetic mice. Experimental diabetes research, 2012, Volume: 2012 Topics: Animals; Anticholesteremic Agents; Azetidines; Diabetes Complications; Diabetes Mellitus, Type 2; Ezetimibe; Glucose Intolerance; Hypercholesterolemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Kinetics; Male; Mice; Mice, Congenic; Mice, Mutant Strains; Random Allocation; Specific Pathogen-Free Organisms	2012
Into the future: diversifying lipid management. Lancet (London, England), 2012, Dec-08, Volume: 380, Issue:9858 Topics: Antibodies, Monoclonal; Anticholesteremic Agents; Azetidines; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases	2012
[The SHARP study]. Giornale italiano di cardiologia (2006), 2013, Volume: 14, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Randomized Controlled Trials as Topic; Simvastatin	2013
[Lipid control in the double pack. Combined drugs to achieve the goal]. MMW Fortschritte der Medizin, 2002, Jun-06, Volume: 144, Issue:23 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia	2002
[Ezetimib. A new cholesterol absorption inhibitor]. Medizinische Monatsschrift fur Pharmazeuten, 2002, Volume: 25, Issue:7 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, Dietary; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Absorption	2002
[Statins plus cholesterol resorption inhibitor. LDL goal values attainable]. MMW Fortschritte der Medizin, 2002, Sep-19, Volume: 144, Issue:38 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Simvastatin; Treatment Outcome	2002
Ezetimibe in hypercholesterolaemia. International journal of clinical practice, 2002, Volume: 56, Issue:8 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Treatment Outcome	2002
Atherosclerosis: cell biology and lipoproteins: cholesterol absorption inhibitors: gateway therapy for hypercholesterolaemia. Current opinion in lipidology, 2002, Volume: 13, Issue:6 Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Azetidines; Cholesterol; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Lipoproteins	2002
[Ezetimib plus statin combination. A strong duo]. MMW Fortschritte der Medizin, 2002, Nov-28, Volume: 144, Issue:48 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Risk Factors; Simvastatin	2002
[Cholesterol resorption inhibition prevents high statin doses. Lipid lowering in double-pack]. MMW Fortschritte der Medizin, 2002, Nov-28, Volume: 144, Issue:48 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Placebos; Randomized Controlled Trials as Topic; Risk Factors	2002
[Lowering cholesterol becomes easier. Combining instead of increasing dosage]. MMW Fortschritte der Medizin, 2003, Jan-23, Volume: 145, Issue:3-4 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin	2003
Combined lipid lowering drug therapy for the effective treatment of hypercholesterolaemia. European heart journal, 2003, Volume: 24, Issue:8 Topics: Azetidines; Cholesterol; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Hypolipidemic Agents; Intestinal Absorption	2003
Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats. British journal of pharmacology, 2003, Volume: 138, Issue:8 Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Dose-Response Relationship, Drug; Ezetimibe; Hypercholesterolemia; Intestinal Absorption; Liver; Male; Rats; Rats, Sprague-Dawley	2003
New lipid-lowering combo proves successful. Circulation, 2003, May-20, Volume: 107, Issue:19 Topics: Atorvastatin; Attitude to Health; Azetidines; Drug Synergism; Drug Therapy, Combination; Europe; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Stroke; Treatment Outcome	2003
Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia. Journal of the American College of Cardiology, 2003, Jul-16, Volume: 42, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin; Treatment Outcome	2003
Ezetimibe for hypercholesterolemia. American family physician, 2003, Oct-15, Volume: 68, Issue:8 Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Humans; Hypercholesterolemia	2003
[Ezetimib as combination partner in hypercholesteremia. Lowering LDL beyond the effect of statins]. MMW Fortschritte der Medizin, 2003, Apr-17, Volume: 145, Issue:16 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia	2003
Therapy and clinical trials: ezetimibe. Current opinion in lipidology, 2003, Volume: 14, Issue:6 Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Arteriosclerosis; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Mice; Mice, Knockout; Triglycerides	2003
Ezetimibe: a new addition to lipid-lowering therapy. International journal of clinical practice, 2003, Volume: 57, Issue:8 Topics: Anticholesteremic Agents; Azetidines; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia	2003
Effectiveness of ezetimibe in clinical practice. The American journal of cardiology, 2004, Mar-01, Volume: 93, Issue:5 Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Outpatient Clinics, Hospital; Retrospective Studies; Treatment Outcome; Triglycerides	2004
Stenosis and the drug-eluting stent. Circulation, 2004, Mar-23, Volume: 109, Issue:11 Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Azetidines; Cardiology; Coronary Restenosis; Diabetes Complications; Ezetimibe; Humans; Hypercholesterolemia; Myocardial Infarction; Myocardial Ischemia; Perindopril; Radionuclide Imaging; Randomized Controlled Trials as Topic; Stents	2004
Homozygous hypercholesterolaemia and ezetimibe: a case report. Acta paediatrica (Oslo, Norway : 1992), 2004, Volume: 93, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Child; Cholesterol, LDL; Ezetimibe; Female; Homozygote; Humans; Hypercholesterolemia; LDL-Receptor Related Proteins; Point Mutation; Receptors, LDL	2004
On call. I'm a 63-year-old man with arthritis but no other conditions. My only medicines were Naprosyn and vitamins until my last annual checkup, when my cholesterol was high. My doctor gave me Zocor, which helped. But I developed muscle aches, so he swit Harvard men's health watch, 2004, Volume: 8, Issue:9 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Male; Middle Aged; Reference Values; Simvastatin	2004
[Ezetimibe (Ezetrol)]. Revue medicale de Liege, 2004, Volume: 59, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Phytosterols; Treatment Outcome	2004
[Recommended LDL value far lower. How does one achieve this goal?]. MMW Fortschritte der Medizin, 2004, Mar-25, Volume: 146, Issue:13 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Reference Values	2004
Safety and tolerability of ezetimibe. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2004,Spring, Volume: 11, Issue:1 Topics: Azetidines; Drug Tolerance; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia	2004
[New combination therapy. Up to 60% lower LDL cholesterol level]. MMW Fortschritte der Medizin, 2004, May-06, Volume: 146, Issue:19 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Drug Combinations; Drug Synergism; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin	2004
Vytorin: a combination of ezetimibe and simvastatin. The Medical letter on drugs and therapeutics, 2004, Sep-13, Volume: 46, Issue:1191 Topics: Azetidines; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hypercholesterolemia; Simvastatin; Treatment Outcome	2004
Ezetimibe--a new cholesterol-lowering drug. Drug and therapeutics bulletin, 2004, Volume: 42, Issue:9 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Costs; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Randomized Controlled Trials as Topic; Treatment Outcome	2004
Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. The American journal of cardiology, 2004, Sep-15, Volume: 94, Issue:6 Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Colesevelam Hydrochloride; Colestipol; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Treatment Outcome	2004
[Ezetimib--a new possibility for combined therapy in hypercholesterolemia]. Vnitrni lekarstvi, 2004, Volume: 50, Issue:8 Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia	2004
Effect of high plant sterol-enriched diet and cholesterol absorption inhibitor, SCH 58235, on plant sterol absorption and plasma concentrations in hypercholesterolemic wild-type Kyoto rats. Metabolism: clinical and experimental, 2005, Volume: 54, Issue:1 Topics: Animals; Azetidines; Cholesterol; Diet; Ezetimibe; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Intestinal Absorption; Male; Phytosterols; Rats; Rats, Inbred WKY; Rats, Wistar; Species Specificity	2005
[Target values are more often attainable. Almost doubly so many patients with values under 100mg/dl]. MMW Fortschritte der Medizin, 2004, Oct-28, Volume: 146, Issue:44 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Randomized Controlled Trials as Topic; Reference Values; Simvastatin; Time Factors	2004
Lipid-lowering drugs. Nursing older people, 2004, Volume: 16, Issue:9 Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Ezetimibe; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Risk Factors; Treatment Outcome	2004
Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men. Journal of women's health (2002), 2004, Volume: 13, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sex Factors; Simvastatin; Time Factors; Treatment Outcome; Women's Health	2004
Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia. PharmacoEconomics, 2004, Volume: 22 Suppl 3 Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Coronary Disease; Cost Control; Cost-Benefit Analysis; Disease Progression; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Models, Economic; Reproducibility of Results; Time Factors	2004
Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway. PharmacoEconomics, 2004, Volume: 22 Suppl 3 Topics: Anticholesteremic Agents; Azetidines; Coronary Disease; Cost-Benefit Analysis; Decision Support Techniques; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Ezetimibe; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Norway; Risk Factors; Spain	2004
[Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?]. MMW Fortschritte der Medizin, 2004, Dec-16, Volume: 146, Issue:51-52 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Cost Control; Drug Costs; Ezetimibe; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance Coverage; Male; Middle Aged; National Health Programs; Pyrroles; Simvastatin	2004
[New therapeutic alternative to aggressive statin treatment]. Ugeskrift for laeger, 2005, Jan-10, Volume: 167, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Humans; Hypercholesterolemia	2005
[Ezetimibe]. Revue de l'infirmiere, 2005, Issue:109 Topics: Anticholesteremic Agents; Azetidines; Drug Monitoring; Ezetimibe; Humans; Hypercholesterolemia; Nurse's Role; Patient Education as Topic; Patient Selection; Treatment Outcome	2005
Getting there: statin plus ezetimibe for low-density lipoprotein cholesterol goals. Mayo Clinic proceedings, 2005, Volume: 80, Issue:5 Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Practice Guidelines as Topic	2005
Development and validation of a reversed-phase HPLC method for the determination of ezetimibe in pharmaceutical dosage forms. Journal of pharmaceutical and biomedical analysis, 2005, Sep-15, Volume: 39, Issue:3-4 Topics: Acetonitriles; Anticholesteremic Agents; Azetidines; Calibration; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Industry; Drug Stability; Enterocytes; Ezetimibe; Heptanes; Hydrogen-Ion Concentration; Hypercholesterolemia; Models, Chemical; Pharmaceutical Preparations; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonic Acids; Tablets; Temperature; Time Factors; Ultraviolet Rays	2005
The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Current medical research and opinion, 2005, Volume: 21, Issue:6 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Consensus; Ezetimibe; Humans; Hypercholesterolemia; Practice Guidelines as Topic; United Kingdom	2005
[Lowering LDL cholesterol frequently does not adhere to guidelines. Also regard intestinal cholesterol source]. MMW Fortschritte der Medizin, 2005, Jun-09, Volume: 147, Issue:23 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Guideline Adherence; Humans; Hypercholesterolemia; Intestinal Mucosa; Intestines; Liver; Reference Values; Simvastatin	2005
[Ezetimib and simvastatin. Cooperation at receptors of cholesterol metabolism]. MMW Fortschritte der Medizin, 2005, Jul-07, Volume: 147, Issue:27-28 Topics: Adult; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Hypolipidemic Agents; Multicenter Studies as Topic; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome	2005
[Goal in hypercholesterolemia: lowering LDL cholesterol level by 50%]. MMW Fortschritte der Medizin, 2005, Jul-07, Volume: 147, Issue:27-28 Topics: Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Simvastatin	2005
NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids in health and disease, 2005, Aug-12, Volume: 4 Topics: Adult; Aged; Azetidines; Cholesterol, LDL; Ezetimibe; Female; Gene Frequency; Genetic Variation; Haplotypes; Humans; Hypercholesterolemia; Male; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Polymorphism, Single Nucleotide; Proteins	2005
Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Annals of clinical biochemistry, 2005, Volume: 42, Issue:Pt 5 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Hepatitis, Autoimmune; Heptanoic Acids; Humans; Hypercholesterolemia; Liver Function Tests; Middle Aged; Pyrroles	2005
Therapy and clinical trials. Current opinion in lipidology, 2005, Volume: 16, Issue:6 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Clinical Trials as Topic; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin	2005
[Ezetimibe--pharmacokinetics and therapeutics]. Arquivos brasileiros de cardiologia, 2005, Volume: 85 Suppl 5 Topics: Anticholesteremic Agents; Azetidines; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia	2005
Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia. Arteriosclerosis, thrombosis, and vascular biology, 2006, Volume: 26, Issue:5 Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Lipoproteins; Lipoproteins, IDL; Lipoproteins, VLDL; Male; Middle Aged	2006
Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Transplantation, 2006, Mar-15, Volume: 81, Issue:5 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Resistance; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Transplantation; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Triglycerides	2006
Selective compensatory induction of hepatic HMG-CoA reductase in response to inhibition of cholesterol absorption. Experimental biology and medicine (Maywood, N.J.), 2006, Volume: 231, Issue:5 Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, Dietary; Diabetes Mellitus, Type 1; Enzyme Induction; Ezetimibe; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Liver; Male; Rats; Rats, Sprague-Dawley; Receptors, LDL; Thyroid Hormones; Thyroidectomy; Transcription, Genetic	2006
Drug utilization of ezetimibe in rehabilitation centres: registry analysis of factors influencing prescription and effectiveness of treatment. Current medical research and opinion, 2006, Volume: 22, Issue:4 Topics: Aged; Anticholesteremic Agents; Azetidines; Drug Utilization Review; Ezetimibe; Female; Germany; Humans; Hypercholesterolemia; Male; Middle Aged; Practice Patterns, Physicians'; Registries; Rehabilitation Centers; Treatment Outcome	2006
Lower cholesterol without statins. Options are available. Mayo Clinic health letter (English ed.), 2006, Volume: 24, Issue:5 Topics: Allylamine; Azetidines; Cholesterol, LDL; Cholinergic Antagonists; Colesevelam Hydrochloride; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Phytosterols	2006
Severe hepatic side effects of ezetimibe. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2006, Volume: 4, Issue:7 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Liver Diseases; Male; Middle Aged; Pyrroles; Transaminases	2006
Total and low-density lipoprotein cholesterol responses to ezetimibe in clinical practice. International journal of clinical practice, 2006, Volume: 60, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Medical Audit; Middle Aged; Retrospective Studies; Treatment Outcome	2006
Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. PharmacoEconomics, 2006, Volume: 24, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles	2006
[Horse and rider]. Medizinische Monatsschrift fur Pharmazeuten, 2006, Volume: 29, Issue:10 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Heart Diseases; Humans; Hypercholesterolemia; Risk Factors	2006
Intensive lipid-lowering therapy: obvious benefits, possible risks. The Israel Medical Association journal : IMAJ, 2006, Volume: 8, Issue:12 Topics: Aged, 80 and over; Azetidines; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Muscular Diseases	2006
Treatment of hypercholesterolemia with ezetimibe in cardiac transplant recipients. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2007, Volume: 26, Issue:3 Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Ezetimibe; Female; Heart Transplantation; Humans; Hypercholesterolemia; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Muscular Diseases; Pain	2007
Lipid-lowering therapy--benefits and risks. The Israel Medical Association journal : IMAJ, 2007, Volume: 9, Issue:2 Topics: Azetidines; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Muscular Diseases; Risk Factors	2007
Lipid-lowering therapy--benefits and risks. The Israel Medical Association journal : IMAJ, 2007, Volume: 9, Issue:2 Topics: Aged, 80 and over; Azetidines; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Muscular Diseases; Risk Factors	2007
[Synthesis plus absorption inhibitors are useful for high risk patients]. Medizinische Monatsschrift fur Pharmazeuten, 2007, Volume: 30, Issue:3 Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Absorption; Risk	2007
[Molecular diagnosis and combined lipid lowering therapy of heterozygous familial hypercholesterolemia. Report of one case]. Revista medica de Chile, 2007, Volume: 135, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Female; Heterozygote; Humans; Hypercholesterolemia; LDL-Receptor Related Proteins; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Prognosis; Simvastatin	2007
Age-induced hypercholesterolemia in the rat relates to reduced elimination but not increased intestinal absorption of cholesterol. American journal of physiology. Endocrinology and metabolism, 2007, Volume: 293, Issue:3 Topics: Aging; Animals; Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cholesterol; Ezetimibe; Growth Hormone; Hypercholesterolemia; Intestinal Absorption; Male; Rats; Rats, Wistar; Treatment Outcome	2007
Therapy and clinical trials. Current opinion in lipidology, 2007, Volume: 18, Issue:4 Topics: Acquired Immunodeficiency Syndrome; Atherosclerosis; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Hypercholesterolemia; Metabolic Syndrome; Models, Biological; Obesity; Risk Factors	2007
[Statin and absorption inhibitor work synergistically. More risk patient reach LDL cholesterol goal value]. MMW Fortschritte der Medizin, 2007, Apr-26, Volume: 149, Issue:17 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Infant, Newborn; Practice Guidelines as Topic; Simvastatin; Treatment Outcome	2007
Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Current medical research and opinion, 2007, Volume: 23, Issue:9 Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Retrospective Studies	2007
Ezetimibe in search of receptor(s)--still a never-ending challenge in cholesterol absorption and transport. Biochimica et biophysica acta, 2007, Volume: 1771, Issue:9 Topics: Animals; Anticholesteremic Agents; Azetidines; Biological Transport; Cell Line; Cell Membrane; Ezetimibe; Humans; Hypercholesterolemia; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Transport Vesicles	2007
[Type 1 diabetes: what are the alternatives for lowering cholesterol levels with statins?]. Deutsche medizinische Wochenschrift (1946), 2007, Volume: 132, Issue:44 Topics: Anticholesteremic Agents; Azetidines; Diabetes Mellitus, Type 1; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Rhabdomyolysis	2007
Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice. Atherosclerosis, 2008, Volume: 198, Issue:1 Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Azetidines; Bile Acids and Salts; Body Weight; Cardiomegaly; Cholesterol; Coronary Artery Disease; Cyclic N-Oxides; Disease Models, Animal; Eating; Ezetimibe; Female; Fibrosis; Hypercholesterolemia; Intestinal Absorption; Life Expectancy; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Scavenger Receptors, Class B; Survival Rate; Triglycerides; Tropanes	2008
Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. British journal of clinical pharmacology, 2008, Volume: 65, Issue:5 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Azetidines; Case-Control Studies; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipid Peroxidation; Male; Middle Aged; Oxidative Stress; Platelet Aggregation; Simvastatin; Treatment Outcome	2008
Help for your cholesterol when statins won't do. If you are one of the many, but also one of the few... Harvard men's health watch, 2005, Volume: 9, Issue:8 Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Style; Male; Niacin	2005
Enhanced LDL-C reduction: lower is better. Does it matter how? International journal of clinical practice, 2008, Volume: 62, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia	2008
Lipid-lowering study raises issues of therapy's value. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Apr-01, Volume: 65, Issue:7 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin	2008
Use of ezetimibe in the United States and Canada. The New England journal of medicine, 2008, Apr-24, Volume: 358, Issue:17 Topics: Anticholesteremic Agents; Azetidines; Canada; Cholesterol, LDL; Cohort Studies; Drug Utilization; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Practice Patterns, Physicians'; United States	2008
Dramatically increased intestinal absorption of cholesterol following hypophysectomy is normalized by thyroid hormone. Gastroenterology, 2008, Volume: 134, Issue:4 Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Azetidines; Cholesterol; Cholesterol, Dietary; Cortisone; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 7; Disease Models, Animal; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Gas Chromatography-Mass Spectrometry; Gene Expression; Hypercholesterolemia; Hypophysectomy; Hypopituitarism; Injections, Subcutaneous; Intestinal Absorption; Lipoproteins; Liver; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Steroid Hydroxylases; Thyroxine; Treatment Outcome	2008
Is Zetia a 'do nothing' drug? Current topics in medicinal chemistry, 2008, Volume: 8, Issue:5 Topics: Azetidines; Clinical Trials as Topic; Ezetimibe; Humans; Hypercholesterolemia; Hypolipidemic Agents; Molecular Structure	2008
Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia: NICE technology appraisal guidance. Heart (British Cardiac Society), 2008, Volume: 94, Issue:5 Topics: Adult; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; Female; Heterozygote; Humans; Hypercholesterolemia; Lipids; Male; Practice Guidelines as Topic; Technology Assessment, Biomedical; Treatment Outcome	2008
Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia. Heart (British Cardiac Society), 2008, Volume: 94, Issue:5 Topics: Adult; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Ezetimibe; Female; Heterozygote; Humans; Hypercholesterolemia; Lipids; Male; Practice Guidelines as Topic; Technology Assessment, Biomedical; Treatment Outcome	2008
Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care. Current medical research and opinion, 2008, Volume: 24, Issue:6 Topics: Aged; Ambulatory Care; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Ezetimibe; Female; Forecasting; Humans; Hypercholesterolemia; Male; Middle Aged; Primary Health Care; Prospective Studies; Risk Assessment; Simvastatin; Treatment Outcome	2008
Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients. AIDS patient care and STDs, 2008, Volume: 22, Issue:6 Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Azetidines; Cholesterol, LDL; Drug Administration Schedule; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypercholesterolemia; Lopinavir; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Pyrroles; Ritonavir; Treatment Outcome	2008
Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice. Atherosclerosis, 2009, Volume: 202, Issue:1 Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Arteriosclerosis; Azetidines; Blood Pressure; Endothelium, Vascular; Ezetimibe; Female; Hypercholesterolemia; Inflammation; Lipids; Male; Mice; Mice, Knockout; Nitric Oxide Synthase Type III	2009
ENHANCE and ACCORD: controversy over surrogate end points. Current cardiology reports, 2008, Volume: 10, Issue:3 Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Clinical Trials as Topic; Clinical Trials, Phase IV as Topic; Endpoint Determination; Ezetimibe; Glycated Hemoglobin; Humans; Hypercholesterolemia; Research Design; Simvastatin	2008
The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. European journal of pharmacology, 2001, Mar-09, Volume: 415, Issue:1 Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol Esters; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Ezetimibe; Female; Hypercholesterolemia; Macaca fascicularis; Macaca mulatta; Male; Time Factors; Triglycerides	2001
Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Diabetes, 2001, Volume: 50, Issue:6 Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cricetinae; Ezetimibe; Hypercholesterolemia; Hyperinsulinism; Hyperlipidemias; Hypertriglyceridemia; Liver; Mesocricetus; Obesity; Triglycerides	2001
Ezetimibe (Schering-Plough). Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:3 Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Azetidines; Bile; Cholesterol; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Down-Regulation; Drug Combinations; Drug Evaluation, Preclinical; Drug Therapy, Combination; Drugs, Investigational; Ezetimibe; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Intestinal Mucosa; Intestines; Molecular Structure; Simvastatin	2001
The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Metabolism: clinical and experimental, 2001, Volume: 50, Issue:10 Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, Dietary; Dogs; Drug Combinations; Drug Synergism; Ezetimibe; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Lovastatin; Male; Pravastatin; Simvastatin; Time Factors	2001
[Statins remain the standard. New methods for lipid lowering therapy]. MMW Fortschritte der Medizin, 2001, Oct-18, Volume: 143, Issue:42 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia	2001